Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Lung Cancer

  Free Subscription


Articles published in Lung Cancer

Retrieve available abstracts of 940 articles:
HTML format



Single Articles


    March 2021
  1. BISSONNETTE JP, Sun A, Grills IS, Almahariq MF, et al
    Non-small cell lung cancer stage migration as a function of wait times from diagnostic imaging: A pooled analysis from five international centres.
    Lung Cancer. 2021;155:136-143.
    PubMed     Abstract available


  2. FURUKAWA R, Inoue H, Yoneshima Y, Tsutsumi H, et al
    Cytotoxic chemotherapeutic agents and the EGFR-TKI osimertinib induce calreticulin exposure in non-small cell lung cancer.
    Lung Cancer. 2021;155:144-150.
    PubMed     Abstract available


  3. EPAILLARD N, Benitez JC, Gorria T, Fabre E, et al
    Pleural effusion is a negative prognostic factor for immunotherapy in patients with non-small cell lung cancer (NSCLC): The pluie study.
    Lung Cancer. 2021;155:114-119.
    PubMed     Abstract available


  4. TASAKA Y, Honda T, Nishiyama N, Tsutsui T, et al
    Non-inferior clinical outcomes of immune checkpoint inhibitors in non-small cell lung cancer patients with interstitial lung disease.
    Lung Cancer. 2021;155:120-126.
    PubMed     Abstract available


  5. EVERS J, de Jaeger K, Hendriks LEL, van der Sangen M, et al
    Trends and variations in treatment of stage I-III non-small cell lung cancer from 2008 to 2018: A nationwide population-based study from the Netherlands.
    Lung Cancer. 2021;155:103-113.
    PubMed     Abstract available


  6. TAO J, Jatoi A, Crawford J, Lam WWT, et al
    Role of dietary carbohydrates on risk of lung cancer.
    Lung Cancer. 2021;155:87-93.
    PubMed     Abstract available


  7. YUN JK, Lee GD, Choi S, Kim HR, et al
    The addition of radiotherapy to adjuvant chemotherapy has a combinatorial effect in pN2 non-small cell lung cancer only with extranodal invasion or multiple N2 metastasis.
    Lung Cancer. 2021;155:94-102.
    PubMed     Abstract available


  8. PARK K, Chang GC, Curigliano G, Lim WT, et al
    Phase I results of S49076 plus gefitinib in patients with EGFR TKI-resistant non-small cell lung cancer harbouring MET/AXL dysregulation.
    Lung Cancer. 2021;155:127-135.
    PubMed     Abstract available


  9. AREDO JV, Purington N, Su L, Luo SJ, et al
    Metabolomic profiling for second primary lung cancer: A pilot case-control study.
    Lung Cancer. 2021;155:61-67.
    PubMed     Abstract available


  10. DAMHUS CS, Quentin JG, Malmqvist J, Siersma V, et al
    Psychosocial consequences of a three-month follow-up after receiving an abnormal lung cancer CT-screening result: A longitudinal survey.
    Lung Cancer. 2021;155:46-52.
    PubMed     Abstract available


  11. YOH K, Seto T, Satouchi M, Nishio M, et al
    Final survival results for the LURET phase II study of vandetanib in previously treated patients with RET-rearranged advanced non-small cell lung cancer.
    Lung Cancer. 2021;155:40-45.
    PubMed     Abstract available


  12. LIU J, Itchins M, Nagrial A, Cooper WA, et al
    Relationship between PD-L1 expression and outcome in EGFR-mutant lung cancer patients treated with EGFR tyrosine kinase inhibitors.
    Lung Cancer. 2021;155:28-33.
    PubMed     Abstract available


  13. WANG W, Xu C, Chen H, Jia J, et al
    Genomic alterations and clinical outcomes in patients with lung adenocarcinoma with transformation to small cell lung cancer after treatment with EGFR tyrosine kinase inhibitors: A multicenter retrospective study.
    Lung Cancer. 2021;155:20-27.
    PubMed     Abstract available


  14. GARCIA CAMPELO MR, Lin HM, Zhu Y, Perol M, et al
    Health-related quality of life in the randomized phase III trial of brigatinib vs crizotinib in advanced ALK inhibitor-naive ALK+non-small cell lung cancer (ALTA-1L).
    Lung Cancer. 2021;155:68-77.
    PubMed     Abstract available


  15. HASSAN A, Latif MT, Soo CI, Faisal AH, et al
    Corrigendum to "Short communication: Diagnosis of lung cancer increases during the annual southeast Asian haze periods" [Lung Cancer 113 (2017) 1-3].
    Lung Cancer. 2021 Mar 4. pii: S0169-5002(21)00084.
    PubMed    


  16. MORENO V, Garrido P, Papadopoulos KP, De Miguel Luken MJ, et al
    Tolerability and antitumor activity of cemiplimab, a human monoclonal anti-PD-1, as monotherapy in patients with pretreated non-small cell lung cancer (NSCLC): Data from the Phase 1 NSCLC expansion cohort.
    Lung Cancer. 2021;155:151-155.
    PubMed     Abstract available


  17. ATTILI I, Tarantino P, Passaro A, Stati V, et al
    Strategies to overcome resistance to immune checkpoint blockade in lung cancer.
    Lung Cancer. 2021;154:151-160.
    PubMed     Abstract available


  18. MORAES FY, Mansouri A, Dasgupta A, Ramotar M, et al
    Impact of EGFR mutation on outcomes following SRS for brain metastases in non-small cell lung cancer.
    Lung Cancer. 2021;155:34-39.
    PubMed     Abstract available


  19. KUNIMASA K
    A reply to "Cardiac dysfunction due to Osimertinib".
    Lung Cancer. 2021;153:195.
    PubMed    


  20. BOMMART S, Pujol JL, Coffy A, Daures JP, et al
    Authors reply to letter to the editor by Dr Degens et al.
    Lung Cancer. 2021;153:185.
    PubMed    


  21. ANAND K
    Cardiac dysfunction due to Osimertinib.
    Lung Cancer. 2021;153:193-194.
    PubMed    


    February 2021
  22. LIU G, Brenner H, Chen C, Christiani D, et al
    A reply to "Lung cancer outcomes: Are BMI and race clinically relevant?"
    Lung Cancer. 2021 Feb 26. pii: S0169-5002(21)00079.
    PubMed    


  23. WONG SK, Alex D, Bosdet I, Hughesman C, et al
    MET exon 14 skipping mutation positive non-small cell lung cancer: Response to systemic therapy.
    Lung Cancer. 2021;154:142-145.
    PubMed     Abstract available


  24. CHENG Y, Mok TS, Zhou X, Lu S, et al
    Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 trial (ARCHER 1050).
    Lung Cancer. 2021;154:176-185.
    PubMed     Abstract available


  25. FOURDRAIN A, Epailly J, Blanchard C, Georges O, et al
    Lymphatic drainage of lung cancer follows an intersegmental pathway within the visceral pleura.
    Lung Cancer. 2021;154:118-123.
    PubMed     Abstract available


  26. KOK PS, Lee K, Lord S, Yang JC, et al
    Clinical utility of plasma EGFR mutation detection with quantitative PCR in advanced lung cancer: A meta-analysis.
    Lung Cancer. 2021;154:113-117.
    PubMed     Abstract available


  27. KERR KM, Bibeau F, Thunnissen E, Botling J, et al
    The evolving landscape of biomarker testing for non-small cell lung cancer in Europe.
    Lung Cancer. 2021;154:161-175.
    PubMed     Abstract available


  28. MAO K, Liu F, Liu X, Khuri FR, et al
    Corrigendum to "Re-expression of LKB1 in LKB1-mutant EKVX cells leads to resistance to paclitaxel through the up-regulation of MDR1 expression" [Lung Cancer 88/2 (2015) 131-138].
    Lung Cancer. 2021 Feb 19. pii: S0169-5002(21)00073.
    PubMed    


  29. GARON EB, Aerts J, Kim JS, Muehlenbein CE, et al
    Safety of pemetrexed plus platinum in combination with pembrolizumab for metastatic nonsquamous non-small cell lung cancer: A post hoc analysis of KEYNOTE-189.
    Lung Cancer. 2021;155:53-60.
    PubMed     Abstract available


  30. OHARA S, Suda K, Fujino T, Hamada A, et al
    Dose-dependence in acquisition of drug tolerant phenotype and high RYK expression as a mechanism of osimertinib tolerance in lung cancer.
    Lung Cancer. 2021;154:84-91.
    PubMed     Abstract available


  31. LIU F, Liu Y, Liu X, Mao K, et al
    Corrigendum to "Inhibition of IGF1R enhances 2-deoxyglucose in the treatment of non-small cell lung cancer" [Lung Cancer 123 (2018) 36-43].
    Lung Cancer. 2021 Feb 18. pii: S0169-5002(21)00072.
    PubMed    


  32. CHENG H, Zou Y, Shah CD, Fan N, et al
    First-in-human study of inhaled Azacitidine in patients with advanced non-small cell lung cancer.
    Lung Cancer. 2021;154:99-104.
    PubMed     Abstract available


  33. AHMED Z, Kennedy K, Subramanian J
    The role for chemotherapy in 80 years and older patients with metastatic non-small cell lung cancer: A National cancer database analysis.
    Lung Cancer. 2021;154:62-68.
    PubMed     Abstract available


  34. CHEN X, Muhammad KG, Madeeha C, Fu W, et al
    Calculated indices of volatile organic compounds (VOCs) in exhalation for lung cancer screening and early detection.
    Lung Cancer. 2021 Feb 14. pii: S0169-5002(21)00065.
    PubMed     Abstract available


  35. SEBASTIAN M, Eberhardt WEE, Hoffknecht P, Metzenmacher M, et al
    KRAS G12C-mutated advanced non-small cell lung cancer: A real-world cohort from the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315).
    Lung Cancer. 2021;154:51-61.
    PubMed     Abstract available


  36. HENG WS, Pore M, Meijer C, Hiltermann TJN, et al
    A unique small cell lung carcinoma disease progression model shows progressive accumulation of cancer stem cell properties and CD44 as a potential diagnostic marker.
    Lung Cancer. 2021;154:13-22.
    PubMed     Abstract available


  37. SPAGGIARI L, Bertolaccini L, Facciolo F, Gallina FT, et al
    A risk stratification scheme for synchronous oligometastatic non-small cell lung cancer developed by a multicentre analysis.
    Lung Cancer. 2021;154:29-35.
    PubMed     Abstract available


  38. LAMOTE K, Van den Heuvel MM
    Where the nose is going to help the eye: Sniffing lung cancer.
    Lung Cancer. 2021 Feb 10. pii: S0169-5002(21)00063.
    PubMed    


  39. PALLARI E, Eriksson M, Billhult A, Billhult T, et al
    Lung cancer research and its citation on clinical practice guidelines.
    Lung Cancer. 2021;154:44-50.
    PubMed     Abstract available


  40. WANG S, Chen H, Zhong J, Qin H, et al
    Corrigendum to "Comparative study of EGFR mutations detected in malignant pleural effusion, plasma and tumor tissue in patients with adenocarcinoma of the lung" [Lung Cancer 135 (2019) 116-122].
    Lung Cancer. 2021 Feb 2. pii: S0169-5002(21)00014.
    PubMed    


    January 2021
  41. HEUVELMANS MA, van Ooijen PMA, Ather S, Silva CF, et al
    Lung cancer prediction by Deep Learning to identify benign lung nodules.
    Lung Cancer. 2021;154:1-4.
    PubMed     Abstract available


  42. ZOU Y, Wang Y, Jiang Z, Zhou Y, et al
    Breath profile as composite biomarkers for lung cancer diagnosis.
    Lung Cancer. 2021 Jan 30. pii: S0169-5002(21)00038.
    PubMed     Abstract available


  43. GOMES F, Faivre-Finn C, Mistry H, Bezjak A, et al
    Safety of G-CSF with concurrent chemo-radiotherapy in limited-stage small cell lung cancer - Secondary analysis of the randomised phase 3 CONVERT trial.
    Lung Cancer. 2021;153:165-170.
    PubMed     Abstract available


  44. FRIEDES C, Chakrabarti T, Olson S, Prichett L, et al
    Association of severe lymphopenia and disease progression in unresectable locally advanced non-small cell lung cancer treated with definitive chemoradiation and immunotherapy.
    Lung Cancer. 2021;154:36-43.
    PubMed     Abstract available


  45. EICHHORN F, Klotz LV, Kriegsmann M, Bischoff H, et al
    Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer: First clinical experience.
    Lung Cancer. 2021;153:150-157.
    PubMed     Abstract available


  46. CHU X, Zhao J, Zhou J, Zhou F, et al
    Erratum to "Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors" [Lung Cancer 150 (2020
    Lung Cancer. 2021 Jan 15. pii: S0169-5002(21)00015.
    PubMed    


  47. HASHEMI S, Fransen MF, Niemeijer A, Ben Taleb N, et al
    Surprising impact of stromal TIL's on immunotherapy efficacy in a real-world lung cancer study.
    Lung Cancer. 2021;153:81-89.
    PubMed     Abstract available


  48. ZHOU J, Yu X, Hou L, Zhao J, et al
    Epidermal growth factor receptor tyrosine kinase inhibitor remodels tumor microenvironment by upregulating LAG-3 in advanced non-small-cell lung cancer.
    Lung Cancer. 2021;153:143-149.
    PubMed     Abstract available


  49. TAKAGI H, Zhao S, Muto S, Yokouchi H, et al
    Delta-like 1 homolog (DLK1) as a possible therapeutic target and its application to radioimmunotherapy using (125)I-labelled anti-DLK1 antibody in lung cancer models (HOT1801 and FIGHT004).
    Lung Cancer. 2021;153:134-142.
    PubMed     Abstract available


  50. CHEN D, Kang P, Tao S, Li Q, et al
    Cost-effectiveness evaluation of robotic-assisted thoracoscopic surgery versus open thoracotomy and video-assisted thoracoscopic surgery for operable non-small cell lung cancer.
    Lung Cancer. 2021;153:99-107.
    PubMed     Abstract available


  51. OHTAKI Y, Shimizu K, Suzuki H, Suzuki K, et al
    Salvage surgery for non-small cell lung cancer after tyrosine kinase inhibitor treatment.
    Lung Cancer. 2021;153:108-116.
    PubMed     Abstract available


  52. IKEDA T, Kadota K, Yoshida C, Ishikawa R, et al
    The epithelial-mesenchymal transition phenotype is associated with the frequency of tumor spread through air spaces (STAS) and a High risk of recurrence after resection of lung carcinoma.
    Lung Cancer. 2021;153:49-55.
    PubMed     Abstract available


  53. PROVENCIO M, Majem M, Guirado M, Massuti B, et al
    Phase II clinical trial with metronomic oral vinorelbine and tri-weekly cisplatin as induction therapy, subsequently concomitant with radiotherapy (RT) in patients with locally advanced, unresectable, non-small cell lung cancer (NSCLC). Analysis of su
    Lung Cancer. 2021;153:25-34.
    PubMed     Abstract available


  54. SANDFELD-PAULSEN B, Aggerholm-Pedersen N, Winther-Larsen A
    Hyponatremia in lung cancer: Incidence and prognostic value in a Danish population-based cohort study.
    Lung Cancer. 2021;153:42-48.
    PubMed     Abstract available


  55. LI Z, Lin Y, Chi X, Xu M, et al
    Appearance of an ALK mutation conferring resistance to crizotinib in non-small cell lung cancer harboring oncogenic ROS1 fusion.
    Lung Cancer. 2021 Jan 8. pii: S0169-5002(21)00007.
    PubMed    


  56. BRACKEN-CLARKE D, Kapoor D, Baird AM, Buchanan PJ, et al
    Vaping and lung cancer - A review of current data and recommendations.
    Lung Cancer. 2021;153:11-20.
    PubMed     Abstract available


  57. YANG ZY, Liu ZY, Mu CY, Jiang JH, et al
    Letter: Exploring the accuracy of biopsy in diagnosis of pulmonary sarcomatoid carcinoma.
    Lung Cancer. 2021;151:97.
    PubMed    


    December 2020
  58. DURHAM DD, Croswell JM, Marcus PM
    Do competing causes of mortality contribute to overdiagnosis in lung cancer screening?
    Lung Cancer. 2020;153:21-24.
    PubMed     Abstract available


  59. ABBAR B, De Castelbajac V, Gougis P, Assoun S, et al
    Definitions, outcomes, and management of hyperprogression in patients with non-small-cell lung cancer treated with immune checkpoint inhibitors.
    Lung Cancer. 2020;152:109-118.
    PubMed     Abstract available


  60. LOBEFARO R, Viscardi G, Di Liello R, Massa G, et al
    Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers.
    Lung Cancer. 2020;152:165-173.
    PubMed     Abstract available


  61. RONDEN MI, Bahce I, Hashemi SMS, Dickhoff C, et al
    Factors influencing multi-disciplinary tumor board recommendations in stage III non-small cell lung cancer.
    Lung Cancer. 2020;152:149-156.
    PubMed     Abstract available


  62. BRAILLON A
    Lung cancer outcomes: Are BMI and race clinically relevant?
    Lung Cancer. 2020 Dec 23. pii: S0169-5002(20)30749.
    PubMed    


  63. SHIBATA Y, Matsumoto S, Yoh K, Goto K, et al
    Evaluation of variant frequency in SARS-CoV-2 infection-related genes utilizing lung cancer genomic database.
    Lung Cancer. 2020 Dec 23. pii: S0169-5002(20)30733.
    PubMed    


  64. CASIRAGHI M, Sedda G, Del Signore E, Piperno G, et al
    Surgery for small cell lung cancer: When and how.
    Lung Cancer. 2020;152:71-77.
    PubMed     Abstract available


  65. MATSUURA Y, Ichinose J, Nakao M, Ninomiya H, et al
    Outcomes of nodal upstaging comparing video-assisted thoracoscopic surgery versus open thoracotomy for lung cancer.
    Lung Cancer. 2020;152:78-85.
    PubMed     Abstract available


  66. DE MARINIS F, Laktionov KK, Poltoratskiy A, Egorova I, et al
    Afatinib in EGFR TKI-naive patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: Interim analysis of a Phase 3b study.
    Lung Cancer. 2020;152:127-134.
    PubMed     Abstract available


  67. THOMAS PA, Couderc AL, Boulate D, Greillier L, et al
    Early-stage non-small cell lung cancer beyond life expectancy: Still not too old for surgery?
    Lung Cancer. 2020;152:86-93.
    PubMed     Abstract available


  68. PENG W, Pu X, Jiang M, Wang J, et al
    Dacomitinib induces objective responses in metastatic brain lesions of patients with EGFR-mutant non-small-cell lung cancer: A brief report.
    Lung Cancer. 2020;152:66-70.
    PubMed     Abstract available


  69. YANG X, Man J, Chen H, Zhang T, et al
    Temporal trends of the lung cancer mortality attributable to smoking from 1990 to 2017: A global, regional and national analysis.
    Lung Cancer. 2020;152:49-57.
    PubMed     Abstract available


  70. TAKAMORI S, Takada K, Shimokawa M, Matsubara T, et al
    Clinical utility of pretreatment Glasgow prognostic score in non-small-cell lung cancer patients treated with immune checkpoint inhibitors.
    Lung Cancer. 2020;152:27-33.
    PubMed     Abstract available


  71. JIANG M, Fares AF, Shepshelovich D, Yang P, et al
    The relationship between body-mass index and overall survival in non-small cell lung cancer by sex, smoking status, and race: A pooled analysis of 20,937 International lung Cancer consortium (ILCCO) patients.
    Lung Cancer. 2020;152:58-65.
    PubMed     Abstract available


  72. YANG GJ, Li J, Xu HY, Sun Y, et al
    Osimertinib for Chinese advanced non-small cell lung cancer patients harboring diverse EGFR exon 20 insertion mutations.
    Lung Cancer. 2020;152:39-48.
    PubMed     Abstract available


  73. VIGARIOS E, Rabeau A, Mazieres J, Sibaud V, et al
    Stomatitis associated with osimertinib in advanced lung cancer treatment: Characterization and implications for management.
    Lung Cancer. 2020 Dec 4. pii: S0169-5002(20)30714.
    PubMed    


  74. MOLDAVER D, Hurry M, Evans WK, Cheema PK, et al
    A reply to "Correspondence Re: Development, validation and results from the impact of treatment evolution in non-small cell lung cancer (iTEN) model".
    Lung Cancer. 2020 Dec 2. pii: S0169-5002(20)30691.
    PubMed    


  75. MI J, Xu Q, Lizaso A, Zhang Y, et al
    A reply to "MET-mutant cancer and immune checkpoint inhibitors: A large database analysis".
    Lung Cancer. 2020;150:259-260.
    PubMed    


  76. LIU L, Xu Q, Lizaso A, Zhang Y, et al
    A reply to "ROS1-mutant cancer and immune checkpoint inhibitors: A large database analysis".
    Lung Cancer. 2020;150:254-255.
    PubMed    


  77. LI X, Wang R, Wang L
    MET-mutant cancer and immune checkpoint inhibitors: A large database analysis.
    Lung Cancer. 2020;150:256-258.
    PubMed    


  78. LI X, Wang L, Yu J
    ROS1-mutant cancer and immune checkpoint inhibitors: A large database analysis.
    Lung Cancer. 2020;150:252-253.
    PubMed    


    November 2020
  79. ELFVING H, Brostrom E, Moens LNJ, Almlof J, et al
    Evaluation of NTRK immunohistochemistry as a screening method for NTRK gene fusion detection in non-small cell lung cancer.
    Lung Cancer. 2020;151:53-59.
    PubMed     Abstract available


  80. MCCANN B, Muhr R, O'Rourke N, Milroy R, et al
    ADVANCE-1: An adapted collaborative benchmarking approach in centre-based lung cancer care.
    Lung Cancer. 2020;151:44-52.
    PubMed     Abstract available


  81. LU S, Wang J, Cheng Y, Mok T, et al
    Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078).
    Lung Cancer. 2020;152:7-14.
    PubMed     Abstract available


  82. GARON EB, Kim JS, Govindan R
    Pemetrexed maintenance with or without pembrolizumab in non-squamous non-small cell lung cancer: A cross-trial comparison of KEYNOTE-189 versus PARAMOUNT, PRONOUNCE, and JVBL.
    Lung Cancer. 2020;151:25-29.
    PubMed     Abstract available


  83. YAMAMOTO N, Seto T, Nishio M, Goto K, et al
    Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: Survival follow-up results of the randomized JO25567 study.
    Lung Cancer. 2020;151:20-24.
    PubMed     Abstract available


  84. ARAKAWA S, Yoshida T, Shirasawa M, Takayanagi D, et al
    RB1 loss induced small cell lung cancer transformation as acquired resistance to pembrolizumab in an advanced NSCLC patient.
    Lung Cancer. 2020 Nov 20. pii: S0169-5002(20)30690.
    PubMed    


  85. LEE Y, Joo J, Lee YJ, Lee EK, et al
    Randomized phase II study of platinum-based chemotherapy plus controlled diet with or without metformin in patients with advanced non-small cell lung cancer.
    Lung Cancer. 2020;151:8-15.
    PubMed     Abstract available


  86. SONI S, Rastogi A, Prasad KT, Behera D, et al
    Thyroid dysfunction in non-small cell lung cancer patients treated with epidermal growth factor receptor and anaplastic lymphoma kinase inhibitors: Results of a prospective cohort.
    Lung Cancer. 2020;151:16-19.
    PubMed     Abstract available


  87. TSITSIAS T, Okiror L, Veres L, King J, et al
    New N1/N2 classification and lobe specific lymphatic drainage: Impact on survival in patients with non-small cell lung cancer treated with surgery.
    Lung Cancer. 2020 Nov 16. pii: S0169-5002(20)30680.
    PubMed     Abstract available


  88. WAKUDA K, Yabe M, Kodama H, Nishioka N, et al
    Efficacy of pembrolizumab in patients with brain metastasis caused by previously untreated non-small cell lung cancer with high tumor PD-L1 expression.
    Lung Cancer. 2020 Nov 15. pii: S0169-5002(20)30684.
    PubMed     Abstract available


  89. WANG M, Zhang D, Wang G, Xia J, et al
    HER2 amplification as a potential mechanism of acquired resistance to afatinib in an advanced non-small-cell lung cancer patient.
    Lung Cancer. 2020 Nov 13. pii: S0169-5002(20)30679.
    PubMed    


  90. JOOSTEN PJM, Dickhoff C, van der Noort V, Klomp HM, et al
    Is pneumonectomy justifiable for patients with a locoregional recurrence or persistent disease after curative intent chemoradiotherapy for locally advanced non-small cell lung cancer?
    Lung Cancer. 2020;150:209-215.
    PubMed     Abstract available


  91. ZHOU Y, Wang B, Qu J, Yu F, et al
    Survival outcomes and symptomatic central nervous system (CNS) metastasis in EGFR-mutant advanced non-small cell lung cancer without baseline CNS metastasis: Osimertinib vs. first-generation EGFR tyrosine kinase inhibitors.
    Lung Cancer. 2020;150:178-185.
    PubMed     Abstract available


  92. VICKERS AJ, Frese K, Galvin M, Carter M, et al
    Brief report on the clinical characteristics of patients whose samples generate small cell lung cancer circulating tumour cell derived explants.
    Lung Cancer. 2020;150:216-220.
    PubMed     Abstract available


  93. GASSA A, Fassunke J, Schueten S, Kuhlmann L, et al
    Detection of circulating tumor DNA by digital droplet PCR in resectable lung cancer as a predictive tool for recurrence.
    Lung Cancer. 2020 Nov 5. pii: S0169-5002(20)30670.
    PubMed     Abstract available


  94. WU YL, Shi Y, Tan DSW, Xiaoqing L, et al
    Phase 1/2 study of ceritinib in Chinese patients with advanced anaplastic lymphoma kinase-rearranged non-small cell lung cancer previously treated with crizotinib: Results from ASCEND-6.
    Lung Cancer. 2020;150:240-246.
    PubMed     Abstract available


  95. LI JJN, Karim K, Sung M, Le LW, et al
    Tobacco exposure and immunotherapy response in PD-L1 positive lung cancer patients.
    Lung Cancer. 2020;150:159-163.
    PubMed     Abstract available


  96. BISHNOI R, Shah C, Blaes A, Bian J, et al
    Cardiovascular toxicity in patients treated with immunotherapy for metastatic non-small cell lung cancer: A SEER-medicare study: CVD outcomes with the use of ICI in mNSCLC.
    Lung Cancer. 2020;150:172-177.
    PubMed     Abstract available


  97. GRIESINGER F, Eberhardt W, Nusch A, Reiser M, et al
    Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315).
    Lung Cancer. 2020 Nov 2. pii: S0169-5002(20)30663.
    PubMed     Abstract available


    October 2020
  98. YUN JK, Park I, Kim HR, Choi YS, et al
    Long-term outcomes of video-assisted thoracoscopic lobectomy for clinical N1 non-small cell lung cancer: A propensity score-weighted comparison with open thoracotomy.
    Lung Cancer. 2020;150:201-208.
    PubMed     Abstract available


  99. BERSANELLI M, Buti S, Giannarelli D, Leonetti A, et al
    Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study.
    Lung Cancer. 2020;150:123-131.
    PubMed     Abstract available


  100. FAEHLING M, Schumann C, Christopoulos P, Hoffknecht P, et al
    Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC): Real-world data on survival and safety from the German expanded-access program (EAP).
    Lung Cancer. 2020;150:114-122.
    PubMed     Abstract available


  101. ZENG C, Gao Y, Xiong J, Lu J, et al
    Tumor-infiltrating CD8(+) T cells in ALK-positive lung cancer are functionally impaired despite the absence of PD-L1 on tumor cells.
    Lung Cancer. 2020;150:139-144.
    PubMed     Abstract available


  102. YOTSUKURA M, Asamura H, Suzuki S, Asakura K, et al
    Corrigendum to "Prognostic impact of cancer-associated active fibroblasts and invasive architectural patterns on early-stage lung adenocarcinoma" [Lung Cancer 145 (2020) 158-166].
    Lung Cancer. 2020 Oct 13. pii: S0169-5002(20)30639.
    PubMed    


  103. SUBBIAH V, Paz-Ares L, Besse B, Moreno V, et al
    Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment.
    Lung Cancer. 2020;150:90-96.
    PubMed     Abstract available


  104. WANG L, Ruan M, Lei B, Yan H, et al
    The potential of (18)F-FDG PET/CT in predicting PDL1 expression status in pulmonary lesions of untreated stage IIIB-IV non-small-cell lung cancer.
    Lung Cancer. 2020;150:44-52.
    PubMed     Abstract available


  105. ZENG J, Mao WM, Chen QX, Luo TB, et al
    Quality of life with adjuvant gefitinib versus vinorelbine plus cisplatin in patients with completely resected stage II-IIIA (N1-N2) EGFR-mutant non-small-cell lung cancer: Results from the ADJUVANT (CTONG1104) study.
    Lung Cancer. 2020;150:164-171.
    PubMed     Abstract available


  106. GARCIA-CAMPELO R, Arrieta O, Massuti B, Rodriguez-Abreu D, et al
    Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL).
    Lung Cancer. 2020;150:62-69.
    PubMed     Abstract available


  107. INAGAKI Y, Tamiya A
    Comment on: 'Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer'.
    Lung Cancer. 2020;148:179-180.
    PubMed    


    September 2020
  108. SHAO D, Cheng Y, Yuan ZS, Jiang BY, et al
    Value of interim (18)F-FDG PET/CT for predicting progression-free survival in stage B/IV EGFR-mutant non-small-cell lung cancer patients with EGFR-TKI therapy.
    Lung Cancer. 2020;149:137-143.
    PubMed     Abstract available


  109. TAO H, Shi L, Zhou A, Li H, et al
    Distribution of EML4-ALK fusion variants and clinical outcomes in patients with resected non-small cell lung cancer.
    Lung Cancer. 2020;149:154-161.
    PubMed     Abstract available


  110. ZHANG L, Yip R, Jirapatnakul A, Li M, et al
    Lung cancer screening intervals based on cancer risk.
    Lung Cancer. 2020;149:113-119.
    PubMed     Abstract available


  111. TAKEDA-MIYATA N, Konishi E, Tanaka T, Shimomura M, et al
    Prognostic significance of spread through air spaces in pulmonary metastases from colorectal cancer.
    Lung Cancer. 2020;149:61-67.
    PubMed     Abstract available


  112. FUKUMOTO K, Mori S, Shintani Y, Okami J, et al
    Impact of the preoperative body mass index on the postoperative outcomes in patients with completely resected non-small cell lung cancer: A retrospective analysis of 16,503 cases in a Japanese Lung Cancer Registry Study.
    Lung Cancer. 2020;149:120-129.
    PubMed     Abstract available


  113. GOLDMAN JW, Garassino MC, Chen Y, Ozguroglu M, et al
    Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study.
    Lung Cancer. 2020;149:46-52.
    PubMed     Abstract available


  114. REISSIG TM, Sara L, Ting S, Reis H, et al
    ERK phosphorylation as a marker of RAS activity and its prognostic value in non-small cell lung cancer.
    Lung Cancer. 2020;149:10-16.
    PubMed     Abstract available


  115. LIU X, Hong L, Nilsson M, Hubert SM, et al
    Concurrent use of aspirin with osimertinib is associated with improved survival in advanced EGFR-mutant non-small cell lung cancer.
    Lung Cancer. 2020;149:33-40.
    PubMed     Abstract available


  116. LI J, Wang Y, Zhang B, Xu J, et al
    Characteristics and response to crizotinib in lung cancer patients with MET amplification detected by next-generation sequencing.
    Lung Cancer. 2020;149:17-22.
    PubMed     Abstract available


  117. ALBORELLI I, Bratic Hench I, Chijioke O, Prince SS, et al
    Robust assessment of tumor mutational burden in cytological specimens from lung cancer patients.
    Lung Cancer. 2020;149:84-89.
    PubMed     Abstract available


  118. VOONG KR, Naidoo J
    Radiation pneumonitis after definitive chemoradiation and durvalumab for non-small cell lung cancer.
    Lung Cancer. 2020 Sep 5. pii: S0169-5002(20)30596.
    PubMed    


  119. BERGHMANS T, Lievens Y, Aapro M, Baird AM, et al
    European Cancer Organisation Essential Requirements for Quality Cancer Care (ERQCC): Lung cancer.
    Lung Cancer. 2020;150:221-239.
    PubMed     Abstract available


    August 2020
  120. BAUM P, Diers J, Haag J, Klotz L, et al
    Nationwide effect of high procedure volume in lung cancer surgery on in-house mortality in Germany.
    Lung Cancer. 2020;149:78-83.
    PubMed     Abstract available


  121. CHU X, Zhao J, Zhou J, Zhou F, et al
    Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors.
    Lung Cancer. 2020;150:76-82.
    PubMed     Abstract available


  122. CHRISTOPOULOS P, Kirchner M, Roeper J, Saalfeld F, et al
    Risk stratification of EGFR(+) lung cancer diagnosed with panel-based next-generation sequencing.
    Lung Cancer. 2020;148:105-112.
    PubMed     Abstract available


  123. SUDA K, Murakami I, Obata K, Sakai K, et al
    Spatial heterogeneity of acquired resistance mechanisms to 1st/2nd generation EGFR tyrosine kinase inhibitors in lung cancer.
    Lung Cancer. 2020;148:100-104.
    PubMed     Abstract available


  124. ISMAIL RK, Schramel FMNH, van Dartel M, Hilarius DL, et al
    The Dutch Lung Cancer Audit: Nationwide quality of care evaluation of lung cancer patients.
    Lung Cancer. 2020;149:68-77.
    PubMed     Abstract available


  125. ANG L, Chan CPY, Yau WP, Seow WJ, et al
    Association between family history of lung cancer and lung cancer risk: a systematic review and meta-analysis.
    Lung Cancer. 2020;148:129-137.
    PubMed     Abstract available


  126. YAMAMOTO M, Serizawa T, Sato Y, Higuchi Y, et al
    Stereotactic radiosurgery for brain metastases: A retrospective cohort study comparing treatment results between two lung cancer patient age groups, 75 years or older vs 65-74 years.
    Lung Cancer. 2020;149:103-112.
    PubMed     Abstract available


  127. VAN VEGGEL B, de Langen AJ
    A reply to "Comment on: 'Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer".
    Lung Cancer. 2020 Aug 8. pii: S0169-5002(20)30555.
    PubMed    


  128. RECK M, Syrigos K, Miliauskas S, Zochbauer-Muller S, et al
    Non-interventional LUME-BioNIS study of nintedanib plus docetaxel after chemotherapy in adenocarcinoma non-small cell lung cancer: A subgroup analysis in patients with prior immunotherapy.
    Lung Cancer. 2020;148:159-165.
    PubMed     Abstract available


  129. WADDLE MR, Ko SJ, May J, Kaleem T, et al
    Improving identification of candidates for lung cancer screening in a high risk population.
    Lung Cancer. 2020;148:79-85.
    PubMed     Abstract available


  130. MADISON R, Schrock AB, Castellanos E, Gregg JP, et al
    Retrospective analysis of real-world data to determine clinical outcomes of patients with advanced non-small cell lung cancer following cell-free circulating tumor DNA genomic profiling.
    Lung Cancer. 2020;148:69-78.
    PubMed     Abstract available


  131. SURYAVANSHI M, Jaipuria J, Panigrahi MK, Goyal N, et al
    CSF cell-free DNA EGFR testing using DdPCR holds promise over conventional modalities for diagnosing leptomeningeal involvement in patients with non-small cell lung cancer.
    Lung Cancer. 2020;148:33-39.
    PubMed     Abstract available


  132. MARCHIONI A, Andrisani D, Tonelli R, Piro R, et al
    Integrated intErventional bronchoscopy in the treatment of locally adVanced non-small lung cancER with central Malignant airway Obstructions: a multicentric REtrospective study (EVERMORE).
    Lung Cancer. 2020;148:40-47.
    PubMed     Abstract available


  133. CHANG HL, Wei PJ, Wu KL, Huang HL, et al
    Checkpoint inhibitor pneumonitis mimicking COVID-19 infection during the COVID-19 pandemic.
    Lung Cancer. 2020;146:376-377.
    PubMed    


  134. WANG K, Liu Y, Hu T, Liu Y, et al
    The treatment and outcome of a pulmonary sarcomatoid carcinoma patient infected with SARS-CoV-2.
    Lung Cancer. 2020;146:373-375.
    PubMed    


    July 2020
  135. BARTLETT EC, Kemp SV, Ridge CA, Desai SR, et al
    Baseline Results of the West London lung cancer screening pilot study - Impact of mobile scanners and dual risk model utilisation.
    Lung Cancer. 2020;148:12-19.
    PubMed     Abstract available


  136. ROJO F, Corassa M, Mavroudis D, Oz AB, et al
    International real-world study of DLL3 expression in patients with small cell lung cancer.
    Lung Cancer. 2020;147:237-243.
    PubMed     Abstract available


  137. YOUNG K, Jiang H, Marquez M, Yeung J, et al
    Retrospective study of the incidence and outcomes from lung cancer in solid organ transplant recipients.
    Lung Cancer. 2020;147:214-220.
    PubMed     Abstract available


  138. VAD-NIELSEN J, Meldgaard P, Sorensen BS, Nielsen AL, et al
    Cell-free Chromatin Immunoprecipitation (cfChIP) from blood plasma can determine gene-expression in tumors from non-small-cell lung cancer patients.
    Lung Cancer. 2020;147:244-251.
    PubMed     Abstract available


  139. YANG G, Xu H, Yang L, Xu F, et al
    Apatinib in combination with pemetrexed-platinum chemotherapy for chemo-naive non-squamous non-small cell lung cancer: a phase II clinical study.
    Lung Cancer. 2020;147:229-236.
    PubMed     Abstract available


  140. ZHENG J, Cao H, Li Y, Rao C, et al
    Effectiveness and prognostic factors of first-line crizotinib treatment in patients with ROS1-rearranged non-small cell lung cancer: A multicenter retrospective study.
    Lung Cancer. 2020;147:130-136.
    PubMed     Abstract available


  141. FAN Y, Chen J, Zhou C, Wang H, et al
    Afatinib in patients with advanced non-small cell lung cancer harboring HER2 mutations, previously treated with chemotherapy: A phase II trial.
    Lung Cancer. 2020;147:209-213.
    PubMed     Abstract available


  142. VARLOTTO JM, Voland R, DeCamp MM, Rava P, et al
    The rates of second lung cancers and the survival of surgically-resected second primary lung cancers in patients undergoing resection of an initial primary lung cancer.
    Lung Cancer. 2020;147:115-122.
    PubMed     Abstract available


  143. BEN DORI S, Aizic A, Sabo E, Hershkovitz D, et al
    Spatial heterogeneity of PD-L1 expression and the risk for misclassification of PD-L1 immunohistochemistry in non-small cell lung cancer.
    Lung Cancer. 2020;147:91-98.
    PubMed     Abstract available


  144. SVEDBERG A, Bjorn N, Sigurgeirsson B, Pradhananga S, et al
    Genetic association of gemcitabine/carboplatin-induced leukopenia and neutropenia in non-small cell lung cancer patients using whole-exome sequencing.
    Lung Cancer. 2020;147:106-114.
    PubMed     Abstract available


  145. TOUMAZIS I, Bastani M, Han SS, Plevritis SK, et al
    Risk-Based lung cancer screening: A systematic review.
    Lung Cancer. 2020;147:154-186.
    PubMed     Abstract available


  146. JIA XH, Xu H, Geng LY, Jiao M, et al
    Efficacy and safety of neoadjuvant immunotherapy in resectable nonsmall cell lung cancer: A meta-analysis.
    Lung Cancer. 2020;147:143-153.
    PubMed     Abstract available


  147. SUH JW, Jeong YH, Cho A, Kim DJ, et al
    Corrigendum to "Stepwise flowchart for decision making on sublobar resection through the estimation of spread through air space in early stage lung cancer" [Lung Cancer 142 (2020) 28-33].
    Lung Cancer. 2020 Jul 8. pii: S0169-5002(20)30485.
    PubMed    


  148. SUN C, Anraku M, Kawahara T, Karasaki T, et al
    Prognostic significance of low pectoralis muscle mass on preoperative chest computed tomography in localized non-small cell lung cancer after curative-intent surgery.
    Lung Cancer. 2020;147:71-76.
    PubMed     Abstract available


  149. HAENTSCHEL M, Boeckeler M, Ehab A, Wagner R, et al
    A reply to "A modern approach to Advanced Non-Small Cell Lung Cancer: Minimally-invasive procedures and in parallel multiple DNA/RNA high-throughput sequencing".
    Lung Cancer. 2020 Jul 3. pii: S0169-5002(20)30515.
    PubMed    


  150. REMON J, Nadal E, Domine M, Ruffinelli J, et al
    Malignant pleural mesothelioma: Treatment patterns and outcomes from the Spanish Lung Cancer Group.
    Lung Cancer. 2020;147:83-90.
    PubMed     Abstract available


  151. WANG Q, Li X, Ren S, Su C, et al
    HOTAIR induces EGFR-TKIs resistance in non-small cell lung cancer through epithelial-mesenchymal transition.
    Lung Cancer. 2020;147:99-105.
    PubMed     Abstract available


  152. DI NOIA V, D'Aveni A, Squadroni M, Beretta GD, et al
    Immune checkpoint inhibitors in SARS-CoV-2 infected cancer patients: the spark that ignites the fire?
    Lung Cancer. 2020;145:208-210.
    PubMed    


  153. CHEN H, Louie AV
    High risk, same reward?
    Lung Cancer. 2020;145:221.
    PubMed    


  154. BALDINI E, Tibaldi C
    A reply to "Immune related adverse events and response to immunotherapy: focus on corticosteroids."
    Lung Cancer. 2020;145:226.
    PubMed    


  155. INDINI A, Rijavec E, Grossi F
    Immune related adverse events and response to immunotherapy: Focus on corticosteroids.
    Lung Cancer. 2020;145:225.
    PubMed    


    June 2020
  156. CORSINI EM, Wang Q, Tran HT, Mitchell KG, et al
    Peripheral cytokines are not influenced by the type of surgical approach for non-small cell lung cancer by four weeks postoperatively.
    Lung Cancer. 2020;146:303-309.
    PubMed     Abstract available


  157. CUI W, Franchini F, Alexander M, Officer A, et al
    Real world outcomes in KRAS G12C mutation positive non-small cell lung cancer.
    Lung Cancer. 2020;146:310-317.
    PubMed     Abstract available


  158. SUNG JH, Brown MC, Perez-Cosio A, Pratt L, et al
    Acceptability and accuracy of patient-reported outcome measures (PROMs) for surveillance of breathlessness in routine lung cancer care: A mixed-method study.
    Lung Cancer. 2020;147:1-11.
    PubMed     Abstract available


  159. GACHECHILADZE M, Skarda J, Skanderova D, Uberall I, et al
    Prognostic value of tumor-infiltrating lymphocytes (TILs) and their association with PD-L1 expression and DNA repair protein RAD51 in patients with resected non-small cell lung carcinoma.
    Lung Cancer. 2020;147:30-38.
    PubMed     Abstract available


  160. CHEN C, Wang W, Yu Z, Tian S, et al
    Combination of computed tomography-guided iodine-125 brachytherapy and bronchial arterial chemoembolization for locally advanced stage III non-small cell lung cancer after failure of concurrent chemoradiotherapy.
    Lung Cancer. 2020;146:290-296.
    PubMed     Abstract available


  161. SOMMER MS, Vibe-Petersen J, Staerkind MB, Langer SW, et al
    Early initiated postoperative rehabilitation enhances quality of life in patients with operable lung cancer: Secondary outcomes from a randomized trial.
    Lung Cancer. 2020;146:285-289.
    PubMed     Abstract available


  162. LU S, Chen G, Sun Y, Sun S, et al
    A Phase III, randomized, double-blind, placebo-controlled, multicenter study of fruquintinib in Chinese patients with advanced nonsquamous non-small-cell lung cancer - The FALUCA study.
    Lung Cancer. 2020;146:252-262.
    PubMed     Abstract available


  163. HURKMANS DP, Tamminga M, van Es B, Peters T, et al
    Molecular data show conserved DNA locations distinguishing lung cancer subtypes and regulation of immune genes.
    Lung Cancer. 2020;146:341-349.
    PubMed     Abstract available


  164. CHEN LN, Spivack J, Cao T, Saqi A, et al
    Characteristics and outcomes of lung cancer in solid organ transplant recipients.
    Lung Cancer. 2020;146:297-302.
    PubMed     Abstract available


  165. WANG Z, Zhao J, Ma Z, Cui J, et al
    A Phase 2 Study of Tislelizumab in Combination With Platinum-Based Chemotherapy as First-line Treatment for Advanced Lung Cancer in Chinese Patients.
    Lung Cancer. 2020;147:259-268.
    PubMed     Abstract available


  166. KOBAYASHI K, Soejima K, Fukunaga K, Shintani Y, et al
    Key prognostic factors for EGFR-mutated non-adenocarcinoma lung cancer patients in the Japanese Joint Committee of Lung Cancer Registry Database.
    Lung Cancer. 2020;146:236-243.
    PubMed     Abstract available


  167. WANG W, Cheng G, Zhang G, Song Z, et al
    Evaluation of a new diagnostic immunohistochemistry approach for ROS1 rearrangement in non-small cell lung cancer.
    Lung Cancer. 2020;146:224-229.
    PubMed     Abstract available


  168. GAGNE A, Orain M, Ionescu D, Tsao MS, et al
    Comprehensive assessment of PD-L1 immunohistochemistry on paired tissue and cytology specimens from non-small cell lung cancer.
    Lung Cancer. 2020;146:276-284.
    PubMed     Abstract available


  169. NICOSIA L, Di Muzio J, Agolli L, Alongi F, et al
    What is the role of reirradiation in the management of locoregionally relapsed non small-cell lung cancer?
    Lung Cancer. 2020;146:263-275.
    PubMed     Abstract available


  170. HUANG M, Insinga RP, Burke T, Zhang Y, et al
    In response to She et al., "Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater".
    Lung Cancer. 2020 Jun 17. pii: S0169-5002(20)30489.
    PubMed    


  171. LEI Y, Feng H, Qiang H, Shang Z, et al
    Clinical characteristics and prognostic factors of surgically resected combined small cell lung cancer: a retrospective study.
    Lung Cancer. 2020;146:244-251.
    PubMed     Abstract available


  172. LU M, Hu C, Wu F, Shu L, et al
    MiR-320a is associated with cisplatin resistance in lung adenocarcinoma and its clinical value in non-small cell lung cancer: A comprehensive analysis based on microarray data.
    Lung Cancer. 2020;147:193-197.
    PubMed     Abstract available


  173. STAHEL RA, Curioni-Fontecedro A, Rohrmann S, Dafni U, et al
    Survival outcome of non-small cell lung cancer patients: Comparing results between the database of the Comprehensive Cancer Center Zurich and the Epidemiological Cancer Registry Zurich and Zug.
    Lung Cancer. 2020;146:217-223.
    PubMed     Abstract available


  174. IGAWA S, Naoki K, Shintani Y, Sekine I, et al
    Survival and prognostic factors in elderly patients receiving second-line chemotherapy for relapsed small-cell lung cancer: Results from the Japanese Joint Committee of Lung Cancer Registry.
    Lung Cancer. 2020;146:160-164.
    PubMed     Abstract available


  175. MENG P, Koopman B, Kok K, Ter Elst A, et al
    Combined osimertinib, dabrafenib and trametinib treatment for advanced non-small-cell lung cancer patients with an osimertinib-induced BRAF V600E mutation.
    Lung Cancer. 2020 Jun 4. pii: S0169-5002(20)30472.
    PubMed     Abstract available


  176. FORNACON-WOOD I, Faivre-Finn C, O'Connor JPB, Price GJ, et al
    Radiomics as a personalized medicine tool in lung cancer: Separating the hope from the hype.
    Lung Cancer. 2020;146:197-208.
    PubMed     Abstract available


  177. CHEN D, Chen C, Chen Y
    Letter to the editor concerning 'Stepwise flowchart for decision making on sublobar resection through the estimation of spread through air space in early stage lung cancer'.
    Lung Cancer. 2020;144:92.
    PubMed    


    May 2020
  178. JUNG HA, Sun JM, Lee SH, Ahn JS, et al
    Ten-year patient journey of stage III non-small cell lung cancer patients: A single-center, observational, retrospective study in Korea (Realtime autOmatically updated data warehOuse in healTh care; UNIVERSE-ROOT study).
    Lung Cancer. 2020;146:112-119.
    PubMed     Abstract available


  179. JUNG HA, Noh JM, Sun JM, Lee SH, et al
    Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer.
    Lung Cancer. 2020;146:23-29.
    PubMed     Abstract available


  180. ITO M, Kanda S, Yoshida T, Okuma Y, et al
    Eltrombopag olamine for refractory immune-related thrombocytopenia induced by pembrolizumab in a non-small cell lung cancer patient.
    Lung Cancer. 2020 May 30. pii: S0169-5002(20)30439.
    PubMed     Abstract available


  181. ROGADO J, Pangua C, Serrano-Montero G, Obispo B, et al
    Covid-19 and lung cancer: A greater fatality rate?
    Lung Cancer. 2020;146:19-22.
    PubMed     Abstract available


  182. YANG YM, Jang Y, Lee SH, Kang B, et al
    AXL/MET dual inhibitor, CB469, has activity in non-small cell lung cancer with acquired resistance to EGFR TKI with AXL or MET activation.
    Lung Cancer. 2020;146:70-77.
    PubMed     Abstract available


  183. ZHENG J, Zhu Y, Sun K, Shen Q, et al
    Investigation on the prognostic impact of concurrent genomic alterations in crizotinib-treated EML4-ALK-rearranged advanced non-small cell lung cancer patients.
    Lung Cancer. 2020;146:209-216.
    PubMed     Abstract available


  184. HAN J, Tian K, Yang J, Gong Y, et al
    Durvalumab vs placebo consolidation therapy after chemoradiotherapy in stage III non-small-cell lung cancer: An updated PACIFIC trial-based cost-effectiveness analysis.
    Lung Cancer. 2020;146:42-49.
    PubMed     Abstract available


  185. RECK M, Luft A, Bondarenko I, Shevnia S, et al
    A phase III, randomized, double-blind, multicenter study to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB8 (proposed bevacizumab biosimilar) and reference bevacizumab in patients with metastatic or recurrent nonsquamous
    Lung Cancer. 2020;146:12-18.
    PubMed     Abstract available


  186. LIAO Z, Rivin Del Campo E, Salem A, Pang Q, et al
    Optimizing lung cancer radiation treatment worldwide in COVID-19 outbreak.
    Lung Cancer. 2020;146:230-235.
    PubMed     Abstract available


  187. TESSEMA M, Tassew DD, Yingling CM, Do K, et al
    Identification of novel epigenetic abnormalities as sputum biomarkers for lung cancer risk among smokers and COPD patients.
    Lung Cancer. 2020;146:189-196.
    PubMed     Abstract available


  188. IKEMATSU Y, Tanaka K, Toyokawa G, Ijichi K, et al
    NEUROD1 is highly expressed in extensive-disease small cell lung cancer and promotes tumor cell migration.
    Lung Cancer. 2020;146:97-104.
    PubMed     Abstract available


  189. LEAL JL, Peters G, Szaumkessel M, Leong T, et al
    NTRK and ALK rearrangements in malignant pleural mesothelioma, pulmonary neuroendocrine tumours and non-small cell lung cancer.
    Lung Cancer. 2020;146:154-159.
    PubMed     Abstract available


  190. ZHAO D, Mambetsariev I, Li H, Chen C, et al
    Association of molecular characteristics with survival in advanced non-small cell lung cancer patients treated with checkpoint inhibitors.
    Lung Cancer. 2020;146:174-181.
    PubMed     Abstract available


  191. LAM ACL, Aggarwal R, Cheung S, Stewart EL, et al
    Predictors of participant nonadherence in lung cancer screening programs: a systematic review and meta-analysis.
    Lung Cancer. 2020;146:134-144.
    PubMed     Abstract available


  192. SHI R, Filho SNM, Li M, Fares A, et al
    BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer.
    Lung Cancer. 2020;146:78-85.
    PubMed     Abstract available


  193. SHARPNACK MF, Cho JH, Johnson TS, Otterson GA, et al
    Clinical and Molecular Correlates of Tumor Mutation Burden in Non-Small Cell Lung Cancer.
    Lung Cancer. 2020;146:36-41.
    PubMed     Abstract available


  194. CHAN GH, Gwee YX, Low JL, Huang Y, et al
    Immune checkpoint inhibition for non-small cell lung cancer in patients with pulmonary tuberculosis or Hepatitis B: Experience from a single Asian centre.
    Lung Cancer. 2020;146:145-153.
    PubMed     Abstract available


  195. MCFARLAND DC
    A comment on "Newly diagnosed patients with advanced non-small cell lung cancer: A clinical description of those with moderate to severe depressive symptoms".
    Lung Cancer. 2020 May 20. pii: S0169-5002(20)30429.
    PubMed    


  196. ZENKE Y, Niho S, Umemura S, Ishihara M, et al
    Phase I/II study of carboplatin plus weekly nab-paclitaxel in patients aged >/=75 years with squamous-cell lung cancer: TORG1322.
    Lung Cancer. 2020;146:182-188.
    PubMed     Abstract available


  197. CRENGLE S
    Comment on: Jaine et al Cost-effectiveness of a low-dose computed tomography screening programme for lung cancer in New Zealand. Lung Cancer 2018, 124, 233-240. 2018/10/01. DOI: 10.1016/j.lungcan.2018.08.004.
    Lung Cancer. 2020 May 16. pii: S0169-5002(20)30377.
    PubMed    


  198. YUN JK, Lee GD, Choi S, Kim HR, et al
    Comparison of prognostic impact of lymphovascular invasion in stage IA non-small cell lung cancer after lobectomy versus sublobar resection: A propensity score-matched analysis.
    Lung Cancer. 2020;146:105-111.
    PubMed     Abstract available


  199. ROSSI G, Caruso D, Nosseir S, Banchelli I, et al
    A modern approach to advanced Non-Small Cell Lung Cancer: minimally-invasive procedures and in parallel multiple DNA/RNA high-throughput sequencing.
    Lung Cancer. 2020 May 14. pii: S0169-5002(20)30430.
    PubMed    


  200. SUN F, Franks K, Murray L, Lilley J, et al
    Cardiovascular mortality and morbidity following radical radiotherapy for lung cancer: Is cardiovascular death under-reported?
    Lung Cancer. 2020;146:1-5.
    PubMed     Abstract available


  201. MORGENSZTERN D, Johnson M, Rudin CM, Rossi M, et al
    SC-002 in patients with relapsed or refractory small cell lung cancer and large cell neuroendocrine carcinoma: Phase 1 study.
    Lung Cancer. 2020;145:126-131.
    PubMed     Abstract available


  202. ISAKA T, Ito H, Nakayama H, Yokose T, et al
    Effect of epidermal growth factor receptor mutation on early-stage non-small cell lung cancer according to the 8th TNM classification.
    Lung Cancer. 2020;145:111-118.
    PubMed     Abstract available


  203. BEAGAN JJ, Bach S, van Boerdonk RA, van Dijk E, et al
    Circulating tumor DNA analysis of EGFR-mutant non-small cell lung cancer patients receiving osimertinib following previous tyrosine kinase inhibitor treatment.
    Lung Cancer. 2020;145:173-180.
    PubMed     Abstract available


  204. QUIST M, Langer SW, Lillelund C, Winther L, et al
    Effects of an exercise intervention for patients with advanced inoperable lung cancer undergoing chemotherapy: A randomized clinical trial.
    Lung Cancer. 2020;145:76-82.
    PubMed     Abstract available


  205. DALL'OLIO FG, Maggio I, Massucci M, Mollica V, et al
    ECOG performance status >/=2 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors-A systematic review and meta-analysis of real world data.
    Lung Cancer. 2020;145:95-104.
    PubMed     Abstract available


  206. ROSSI D
    Metronomic oral vinorelbine and lung cancer therapy during the COVID 19 pandemic: A single-center experience.
    Lung Cancer. 2020;145:83-84.
    PubMed     Abstract available


  207. DREVET G, Duruisseaux M, Lafitte C, Derberne M, et al
    A reply to "A comment on "Lung cancer surgical treatment after solid organ transplantation: a single center 30-year experience".
    Lung Cancer. 2020 May 6. pii: S0169-5002(20)30406.
    PubMed    


  208. HOFMAN V, Benzaquen J, Heeke S, Lassalle S, et al
    Real-world assessment of the BRAF status in non-squamous cell lung carcinoma using VE1 immunohistochemistry: A single laboratory experience (LPCE, Nice, France).
    Lung Cancer. 2020;145:58-62.
    PubMed     Abstract available


  209. CHEN V, Iwama E, Kim IK, Giaccone G, et al
    Serum CRIPTO does not confer drug resistance against osimertinib but is an indicator of tumor burden in non-small cell lung cancer.
    Lung Cancer. 2020;145:48-57.
    PubMed     Abstract available


  210. TAKADA K, Takamori S, Yoneshima Y, Tanaka K, et al
    Serum markers associated with treatment response and survival in non-small cell lung cancer patients treated with anti-PD-1 therapy.
    Lung Cancer. 2020;145:18-26.
    PubMed     Abstract available


  211. SERENO M, Gutierrez-Gutierrez G, Sandoval C, Falagan S, et al
    A favorable outcome of pneumonia COVID 19 in an advanced lung cancer patient with severe neutropenia: Is immunosuppression a risk factor for SARS-COV2 infection?
    Lung Cancer. 2020 May 4. pii: S0169-5002(20)30399.
    PubMed    


  212. HANDRA-LUCA A
    C-Myc in mucinous colloid carcinoma of the lung.
    Lung Cancer. 2020;143:93-94.
    PubMed    


    April 2020
  213. LIN YT, Tsai TH, Wu SG, Liu YN, et al
    Complex EGFR mutations with secondary T790M mutation confer shorter osimertinib progression-free survival and overall survival in advanced non-small cell lung cancer.
    Lung Cancer. 2020;145:1-9.
    PubMed     Abstract available


  214. THOMAS R, Chen YH, Hatabu H, Mak RH, et al
    Radiographic patterns of symptomatic radiation pneumonitis in lung cancer patients: Imaging predictors for clinical severity and outcome.
    Lung Cancer. 2020;145:132-139.
    PubMed     Abstract available


  215. DENG J, Zhao M, Wang T, She Y, et al
    A modified T categorization for part-solid lesions in Chinese patients with clinical stage I Non-small cell lung cancer.
    Lung Cancer. 2020;145:33-39.
    PubMed     Abstract available


  216. SOLOMON BJ, Kim EE, Winter M, Monti K, et al
    Ophthalmological assessment of crizotinib in advanced non-small-cell lung cancer.
    Lung Cancer. 2020;145:167-172.
    PubMed     Abstract available


  217. SCHEFFLER M, Holzem A, Kron A, Nogova L, et al
    Co-occurrence of targetable mutations in Non-small cell lung cancer (NSCLC) patients harboring MAP2K1 mutations.
    Lung Cancer. 2020;144:40-48.
    PubMed     Abstract available


  218. LIU B, Henschke CI, Flores RM, Taioli E, et al
    Serum cotinine verification of self-reported smoking status among adults eligible for lung cancer screening in the 1999-2018 National Health and Nutrition Examination Survey.
    Lung Cancer. 2020;144:49-56.
    PubMed     Abstract available


  219. POPAT S, Grohe C, Corral J, Reck M, et al
    Anti-angiogenic agents in the age of resistance to immune checkpoint inhibitors: Do they have a role in non-oncogene-addicted non-small cell lung cancer?
    Lung Cancer. 2020;144:76-84.
    PubMed     Abstract available


  220. DE RUITER JC, Heineman DJ, Daniels JM, van Diessen JN, et al
    The role of surgery for stage I non-small cell lung cancer in octogenarians in the era of stereotactic body radiotherapy in the Netherlands.
    Lung Cancer. 2020;144:64-70.
    PubMed     Abstract available


  221. BREADNER D, Blanchette P, Shanmuganathan S, Boldt RG, et al
    Efficacy and safety of ALK inhibitors in ALK-rearranged non-small cell lung cancer: A systematic review and meta-analysis.
    Lung Cancer. 2020;144:57-63.
    PubMed     Abstract available


  222. JAINE R, Kvizhinadze G, Nair N, Blakely T, et al
    Cost-effectiveness of a low-dose computed tomography screening programme for lung cancer in New Zealand.
    Lung Cancer. 2020 Apr 18. pii: S0169-5002(20)30337.
    PubMed     Abstract available


  223. GOFFIN JR
    Correspondence Re: Development, validation and results from the impact of treatment evolution in non-small cell lung cancer (iTEN) model.
    Lung Cancer. 2020 Apr 4. pii: S0169-5002(20)30351.
    PubMed    


  224. ESCOIN-PEREZ C, Blasco S, Juan-Vidal O
    Immune checkpoint inhibitors in special populations. A focus on advanced lung cancer patients.
    Lung Cancer. 2020;144:1-9.
    PubMed     Abstract available


  225. THAI AA, Stuart E, Te Marvelde L, Milne RL, et al
    Reply to the letter-to-the editor "Hospital volume and the case for centralisation of surgical services".
    Lung Cancer. 2020;142:140-141.
    PubMed    


  226. STIRLING R, Stenger M, Zalcberg J
    Comment on: 'Hospital lung surgery volume and patient outcomes'.
    Lung Cancer. 2020;142:138-139.
    PubMed    


    March 2020
  227. FRUH M, Panje CM, Reck M, Blackhall F, et al
    Choice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) - A decision-making analysis amongst European lung cancer experts.
    Lung Cancer. 2020;146:6-11.
    PubMed     Abstract available


  228. VERONESI G, Navone N, Novellis P, Dieci E, et al
    Favorable incremental cost-effectiveness ratio for lung cancer screening in Italy.
    Lung Cancer. 2020;143:73-79.
    PubMed     Abstract available


  229. BOYSEN FYNBOE EBERT E, McCulloch T, Holmskov Hansen K, Linnet H, et al
    Clearing of circulating tumour DNA predicts clinical response to osimertinib in EGFR mutated lung cancer patients.
    Lung Cancer. 2020;143:67-72.
    PubMed     Abstract available


  230. KARAYAMA M, Yoshizawa N, Sugiyama M, Mori K, et al
    Intravoxel incoherent motion magnetic resonance imaging for predicting the long-term efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer.
    Lung Cancer. 2020;143:47-54.
    PubMed     Abstract available


  231. MA L, Zhang Q, Dong Y, Li H, et al
    SPECC1L-ALK: A novel gene fusion response to ALK inhibitors in non-small cell lung cancer.
    Lung Cancer. 2020 Mar 18. pii: S0169-5002(20)30347.
    PubMed    


  232. YANG G, Li J, Xu H, Yang Y, et al
    EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study.
    Lung Cancer. 2020 Mar 18. pii: S0169-5002(20)30344.
    PubMed     Abstract available


  233. SANCHIS-BORJA M, Ricordel C, Chiappa AM, Hureaux J, et al
    Encephalitis related to immunotherapy for lung cancer: Analysis of a multicenter cohort.
    Lung Cancer. 2020;143:36-39.
    PubMed     Abstract available


  234. EIDE IJZ, Helland A, Ekman S, Mellemgaard A, et al
    Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study).
    Lung Cancer. 2020;143:27-35.
    PubMed     Abstract available


  235. PETERS S, Shaw AT, Besse B, Felip E, et al
    Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer.
    Lung Cancer. 2020;144:10-19.
    PubMed     Abstract available


  236. SHEINSON D, Wong WB, Wu N, Mansfield AS, et al
    Impact of delaying initiation of anaplastic lymphoma kinase inhibitor treatment on survival in patients with advanced non-small-cell lung cancer.
    Lung Cancer. 2020;143:86-92.
    PubMed     Abstract available


  237. ROCH B, Coffy A, Jean-Baptiste S, Palaysi E, et al
    Cachexia - sarcopenia as a determinant of disease control rate and survival in non-small lung cancer patients receiving immune-checkpoint inhibitors.
    Lung Cancer. 2020;143:19-26.
    PubMed     Abstract available


  238. ITO M, Miyata Y, Tsutani Y, Ito H, et al
    Positive EGFR mutation status is a risk of recurrence in pN0-1 lung adenocarcinoma when combined with pathological stage and histological subtype: A retrospective multi-center analysis.
    Lung Cancer. 2020;141:107-113.
    PubMed     Abstract available


  239. GOSNEY JR, Boothman AM, Ratcliffe M, Kerr KM, et al
    Cytology for PD-L1 testing: A systematic review.
    Lung Cancer. 2020;141:101-106.
    PubMed     Abstract available


  240. LI C, Shen Y, Hu F, Chu T, et al
    Micropapillary pattern is associated with the development of brain metastases and the reduction of survival time in EGFR-mutation lung adenocarcinoma patients with surgery.
    Lung Cancer. 2020;141:72-77.
    PubMed     Abstract available


  241. ZHAO J, Lin G, Zhuo M, Fan Z, et al
    Next-generation sequencing based mutation profiling reveals heterogeneity of clinical response and resistance to osimertinib.
    Lung Cancer. 2020;141:114-118.
    PubMed     Abstract available


    February 2020
  242. TANG Y, Xia B, Xie R, Xu X, et al
    Erratum to "Timing in combination with radiotherapy and patterns of disease progression in non-small cell lung cancer treated with EGFR-TKI" [Lung Cancer, 140 (February) (2020) 65-70].
    Lung Cancer. 2020 Feb 27. pii: S0169-5002(20)30278.
    PubMed    


  243. KHORRAMI M, Bera K, Leo P, Vaidya P, et al
    Stable and discriminating radiomic predictor of recurrence in early stage non-small cell lung cancer: Multi-site study.
    Lung Cancer. 2020;142:90-97.
    PubMed     Abstract available


  244. HIRPARA DH, Gupta V, Davis LE, Zhao H, et al
    Severe symptoms persist for Up to one year after diagnosis of stage I-III lung cancer: An analysis of province-wide patient reported outcomes.
    Lung Cancer. 2020;142:80-89.
    PubMed     Abstract available


  245. CORRAO G, Marvaso G, Ferrara R, Lo Russo G, et al
    Stereotatic radiotherapy in metastatic non-small cell lung cancer: Combining immunotherapy and radiotherapy with a focus on liver metastases.
    Lung Cancer. 2020;142:70-79.
    PubMed     Abstract available


  246. THEELEN WS, de Jong MC, Baas P
    Synergizing systemic responses by combining immunotherapy with radiotherapy in metastatic non-small cell lung cancer: The potential of the abscopal effect.
    Lung Cancer. 2020;142:106-113.
    PubMed     Abstract available


  247. PERTEJO-FERNANDEZ A, Ricciuti B, Hammond SP, Marty FM, et al
    Safety and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer and hepatitis B or hepatitis C infection.
    Lung Cancer. 2020 Feb 24. pii: S0169-5002(20)30310.
    PubMed     Abstract available


  248. CHEN K, Cheng G, Zhang F, Zhu G, et al
    PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy.
    Lung Cancer. 2020;142:98-105.
    PubMed     Abstract available


  249. BESSE B, Garrido P, Cortot AB, Johnson M, et al
    Efficacy and safety of necitumumab and pembrolizumab combination therapy in patients with Stage IV non-small cell lung cancer.
    Lung Cancer. 2020;142:63-69.
    PubMed     Abstract available


  250. BOUSEMA JE, Heineman DJ, Dijkgraaf MGW, Annema JT, et al
    Adherence to the mediastinal staging guideline and unforeseen N2 disease in patients with resectable non-small cell lung cancer: Nationwide results from the Dutch Lung Cancer Audit - Surgery.
    Lung Cancer. 2020;142:51-58.
    PubMed     Abstract available


  251. FINKE I, Behrens G, Schwettmann L, Gerken M, et al
    Socioeconomic differences and lung cancer survival in Germany: Investigation based on population-based clinical cancer registration.
    Lung Cancer. 2020;142:1-8.
    PubMed     Abstract available


  252. WANG F, Qin J, Xie F, Wu Q, et al
    Transformation of EML4-ALK fusion-positive adenocarcinoma into squamous cell carcinoma in association with acquired resistance to crizotinib.
    Lung Cancer. 2020;140:118-120.
    PubMed    


  253. LAM WS, Creaney J, Chen FK, Chin WL, et al
    A phase II trial of single oral FGF inhibitor, AZD4547, as second or third line therapy in malignant pleural mesothelioma.
    Lung Cancer. 2020;140:87-92.
    PubMed     Abstract available


  254. WU H, Dong S, Li X, Shi L, et al
    Clinical utility of dual-energy CT used as an add-on to 18F FDG PET/CT in the preoperative staging of resectable NSCLC with suspected single osteolytic metastases.
    Lung Cancer. 2020;140:80-86.
    PubMed     Abstract available


  255. REALE ML, Chiari R, Tiseo M, Vitiello F, et al
    Be-TeaM: An Italian real-world observational study on second-line therapy for EGFR-mutated NSCLC patients.
    Lung Cancer. 2020;140:71-79.
    PubMed     Abstract available


  256. BALDINI E, Lunghi A, Cortesi E, Turci D, et al
    Immune-related adverse events correlate with clinical outcomes in NSCLC patients treated with nivolumab: The Italian NSCLC expanded access program.
    Lung Cancer. 2020;140:59-64.
    PubMed     Abstract available


  257. GIBERT J, Clave S, Hardy-Werbin M, Taus A, et al
    Concomitant genomic alterations in KRAS mutant advanced lung adenocarcinoma.
    Lung Cancer. 2020;140:42-45.
    PubMed     Abstract available


  258. SANDS JM, Nguyen T, Shivdasani P, Sacher AG, et al
    Next-generation sequencing informs diagnosis and identifies unexpected therapeutic targets in lung squamous cell carcinomas.
    Lung Cancer. 2020;140:35-41.
    PubMed     Abstract available


  259. EDAHIRO R, Shiroyama T, Hijiki S, Nojima S, et al
    Severe myocarditis with slight lymphocytic infiltration after nivolumab treatment.
    Lung Cancer. 2020;140:116-117.
    PubMed    


  260. SHOJI S, Watanabe S, Takamura K, Umezu H, et al
    First-line osimertinib treatment in patients with lung squamous cell carcinoma harboring active epidermal growth factor receptor mutations.
    Lung Cancer. 2020;140:113-115.
    PubMed    


    January 2020
  261. ALEXANDER M, Pavlakis N, John T, O'Connell R, et al
    A multicenter study of thromboembolic events among patients diagnosed with ROS1-rearranged non-small cell lung cancer.
    Lung Cancer. 2020;142:34-40.
    PubMed     Abstract available


  262. ZHUANG H, Jiang W, Cheng W, Qian K, et al
    Corrigendum to "Down-regulation of HSP27 sensitizes TRAIL-resistant tumor cell to TRAIL-induced apoptosis" [Lung Cancer 68 (1) (2010) 27-38].
    Lung Cancer. 2020 Jan 16. pii: S0169-5002(20)30003.
    PubMed    


  263. WOLFF HB, Alberts L, van der Linden N, Bongers ML, et al
    Cost-effectiveness of stereotactic body radiation therapy versus video assisted thoracic surgery in medically operable stage I non-small cell lung cancer: A modeling study.
    Lung Cancer. 2020;141:89-96.
    PubMed     Abstract available


  264. JOHNSON AM, Johnson A, Hines RB, Mohammadi R, et al
    Neighborhood context and non-small cell lung cancer outcomes in Florida non-elderly patients by race/ethnicity.
    Lung Cancer. 2020;142:20-27.
    PubMed     Abstract available


  265. RICE SJ, Liu X, Hyland V, Liu Z, et al
    Mutations in genes connected with the TCF7L2 transcription factor are associated with a poor prognosis in non-small cell lung cancer.
    Lung Cancer. 2020;141:97-100.
    PubMed     Abstract available


  266. ZENG L, Xiao L, Jiang W, Yang H, et al
    Investigation of efficacy and acquired resistance for EGFR-TKI plus bevacizumab as first-line treatment in patients with EGFR sensitive mutant non-small cell lung cancer in a Real world population.
    Lung Cancer. 2020;141:82-88.
    PubMed     Abstract available


  267. SERRA P, Centeno C, Sanz-Santos J, Torky M, et al
    Is it necessary to sample the contralateral nodal stations by EBUS-TBNA in patients with lung cancer and clinical N0 / N1 on PET-CT?
    Lung Cancer. 2020;142:9-12.
    PubMed     Abstract available


  268. JONES GS, Elimian K, Baldwin DR, Hubbard RB, et al
    A systematic review of survival following anti-cancer treatment for small cell lung cancer.
    Lung Cancer. 2020;141:44-55.
    PubMed     Abstract available


  269. NIHO S, Yoshida T, Akimoto T, Sakamaki K, et al
    Randomized phase II study of chemoradiotherapy with cisplatin + S-1 versus cisplatin + pemetrexed for locally advanced non-squamous non-small cell lung cancer: SPECTRA study.
    Lung Cancer. 2020;141:64-71.
    PubMed     Abstract available


  270. YOSHIMURA K, Inoue Y, Tsuchiya K, Karayama M, et al
    Elucidation of the relationships of MET protein expression and gene copy number status with PD-L1 expression and the immune microenvironment in non-small cell lung cancer.
    Lung Cancer. 2020;141:21-31.
    PubMed     Abstract available


  271. NAGASAKA M, Lehman A, Chlebowski R, Haynes BM, et al
    COPD and lung cancer incidence in the Women's Health Initiative Observational Study: A brief report.
    Lung Cancer. 2020;141:78-81.
    PubMed     Abstract available


  272. HAENTSCHEL M, Boeckeler M, Ehab A, Wagner R, et al
    Cryobiopsy increases the EGFR detection rate in non-small cell lung cancer.
    Lung Cancer. 2020;141:56-63.
    PubMed     Abstract available


  273. CAO X, Ganti AK, Stinchcombe T, Wong ML, et al
    Predicting risk of chemotherapy-induced severe neutropenia: A pooled analysis in individual patients data with advanced lung cancer.
    Lung Cancer. 2020;141:14-20.
    PubMed     Abstract available


  274. BUGLIONE M, Jereczek-Fossa BA, Bonu ML, Franceschini D, et al
    Radiosurgery and fractionated stereotactic radiotherapy in oligometastatic/oligoprogressive non-small cell lung cancer patients: Results of a multi-institutional series of 198 patients treated with "curative" intent.
    Lung Cancer. 2020;141:1-8.
    PubMed     Abstract available


  275. ZHOU F, Zhao W, Chen X, Zhang J, et al
    Response to the combination of dabrafenib, trametinib and osimertinib in a patient with EGFR-mutant NSCLC harboring an acquired BRAF(V600E) mutation.
    Lung Cancer. 2020;139:219-220.
    PubMed    


  276. ZELTSMAN M, Dozier J, Vaghjiani RG, Poch A, et al
    Decreasing use of epidural analgesia with increasing minimally invasive lobectomy: Impact on postoperative morbidity.
    Lung Cancer. 2020;139:68-72.
    PubMed     Abstract available


  277. PINSKY P, Gierada DS
    Long-term cancer risk associated with lung nodules observed on low-dose screening CT scans.
    Lung Cancer. 2020;139:179-184.
    PubMed     Abstract available


  278. MIYAKE N, Ochi N, Yamane H, Fukazawa T, et al
    Targeting ROR1 in combination with pemetrexed in malignant mesothelioma cells.
    Lung Cancer. 2020;139:170-178.
    PubMed     Abstract available


  279. WIESWEG M, Herold T, Metzenmacher M, Eberhardt WE, et al
    Clinical response to crizotinib and emergence of resistance in lung adenocarcinoma harboring a MET c-Cbl binding site mutation.
    Lung Cancer. 2020;139:165-168.
    PubMed     Abstract available


  280. YANG S, Mao S, Li X, Zhao C, et al
    Uncommon EGFR mutations associate with lower incidence of T790M mutation after EGFR-TKI treatment in patients with advanced NSCLC.
    Lung Cancer. 2020;139:133-139.
    PubMed     Abstract available


  281. STOCKHAMMER P, Ploenes T, Theegarten D, Schuler M, et al
    Detection of TGF-beta in pleural effusions for diagnosis and prognostic stratification of malignant pleural mesothelioma.
    Lung Cancer. 2020;139:124-132.
    PubMed     Abstract available


  282. ZHANG JT, Li Y, Yan LX, Zhu ZF, et al
    Disparity in clinical outcomes between pure and combined pulmonary large-cell neuroendocrine carcinoma: A multi-center retrospective study.
    Lung Cancer. 2020;139:118-123.
    PubMed     Abstract available


  283. WANG B, Tang Y, Chen Y, Hamal P, et al
    Joint use of the radiomics method and frozen sections should be considered in the prediction of the final classification of peripheral lung adenocarcinoma manifesting as ground-glass nodules.
    Lung Cancer. 2020;139:103-110.
    PubMed     Abstract available


  284. CHEN X, Pang Z, Wang Y, Bie F, et al
    The role of surgery for atypical bronchopulmonary carcinoid tumor: Development and validation of a model based on Surveillance, Epidemiology, and End Results (SEER) database.
    Lung Cancer. 2020;139:94-102.
    PubMed     Abstract available


  285. SOUSA AC, Silveira C, Janeiro A, Malveiro S, et al
    Detection of rare and novel EGFR mutations in NSCLC patients: Implications for treatment-decision.
    Lung Cancer. 2020;139:35-40.
    PubMed     Abstract available


  286. CARACENI A, Lo Dico S, Zecca E, Brunelli C, et al
    Outpatient palliative care and thoracic medical oncology: Referral criteria and clinical care pathways.
    Lung Cancer. 2020;139:13-17.
    PubMed     Abstract available


  287. RIBEIRO MFSA, Alessi JVM, Oliveira LJC, Gongora ABL, et al
    Alectinib activity in chemotherapy-refractory metastatic RET-rearranged non-small cell lung carcinomas: A case series.
    Lung Cancer. 2020;139:9-12.
    PubMed     Abstract available


    December 2019
  288. GIAJ LEVRA M, Cotte FE, Corre R, Calvet C, et al
    Immunotherapy rechallenge after nivolumab treatment in advanced non-small cell lung cancer in the real-world setting: A national data base analysis.
    Lung Cancer. 2019;140:99-106.
    PubMed     Abstract available


  289. EBERT EBF, McCulloch T, Hansen KH, Linnet H, et al
    Clearing of circulating tumour DNA predicts clinical response to first line tyrosine kinase inhibitors in advanced epidermal growth factor receptor mutated non-small cell lung cancer.
    Lung Cancer. 2019;141:37-43.
    PubMed     Abstract available


  290. SMIT HJM, Aerts J, van den Heuvel M, Hiltermann TJN, et al
    Effects of checkpoint inhibitors in advanced non-small cell lung cancer at population level from the National Immunotherapy Registry.
    Lung Cancer. 2019;140:107-112.
    PubMed     Abstract available


  291. VAN VEGGEL B, Madeira R Santos JFV, Hashemi SMS, Paats MS, et al
    Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer.
    Lung Cancer. 2019;141:9-13.
    PubMed     Abstract available


  292. TOFFART AC, Asfari S, Mc Leer A, Reymond E, et al
    Percutaneous CT-guided biopsy of lytic bone lesions in patients clinically suspected of lung cancer: Diagnostic performances for pathological diagnosis and molecular testing.
    Lung Cancer. 2019;140:93-98.
    PubMed     Abstract available


  293. TANG Y, Xia B, Xu X, Zhang M, et al
    Timing in combination with radiotherapy and patterns of disease progression in non-small cell lung cancer treated with EGFR-TKI.
    Lung Cancer. 2019;140:65-70.
    PubMed     Abstract available


  294. NACHIRA D, Meacci E, Congedo MT, Chiappetta M, et al
    Upstaging, centrality and survival in early stage non-small cell lung cancer video-assisted surgery: Lymph nodal upstaging in lung cancer surgery: is it really a surgical technique problem?
    Lung Cancer. 2019 Dec 18. pii: S0169-5002(19)30774.
    PubMed    


  295. GROSU HB, Manzanera A, Shivakumar S, Sun S, et al
    Survival disparities following surgery among patients with different histological types of non-small cell lung cancer.
    Lung Cancer. 2019;140:55-58.
    PubMed     Abstract available


  296. HELMINEN O, Valo J, Andersen H, Lautamaki A, et al
    Real-world guideline-based treatment of lung cancer improves short- and long-term outcomes and resection rate: A population-based study.
    Lung Cancer. 2019;140:1-7.
    PubMed     Abstract available


    November 2019
  297. KUBOTA K, Kunitoh H, Seto T, Shimada N, et al
    Randomized phase II trial of adjuvant chemotherapy with docetaxel plus cisplatin versus paclitaxel plus carboplatin in patients with completely resected non-small cell lung cancer: TORG 0503.
    Lung Cancer. 2019;141:32-36.
    PubMed     Abstract available


  298. BLOM EF, Ten Haaf K, de Koning HJ
    Trends in lung cancer risk and screening eligibility affect overdiagnosis estimates.
    Lung Cancer. 2019;139:200-206.
    PubMed     Abstract available


  299. NAKAGAWA K, Hida T, Nokihara H, Morise M, et al
    Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer.
    Lung Cancer. 2019;139:195-199.
    PubMed     Abstract available


  300. NARTEY Y, Stewart I, Khakwani A, Beattie V, et al
    Is the English Cancer Patient Experience Survey representative? A comparative analysis with the National Lung Cancer Audit.
    Lung Cancer. 2019;140:27-34.
    PubMed     Abstract available


  301. SHIN SH, Jeong BH, Jhun BW, Yoo H, et al
    The utility of endosonography for mediastinal staging of non-small cell lung cancer in patients with radiological N0 disease.
    Lung Cancer. 2019;139:151-156.
    PubMed     Abstract available


  302. TAN AC, Lai GGY, Tan GS, Poon SY, et al
    Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.
    Lung Cancer. 2019;139:207-215.
    PubMed     Abstract available


  303. HASHIMOTO K, Kaira K, Kawasaki T, Yamaguchi O, et al
    Psuedoprogression mimicking hyperprogressive disease after pembrolizumab treatment in a patient with lung cancer.
    Lung Cancer. 2019 Nov 25. pii: S0169-5002(19)30744.
    PubMed    


  304. ANDERSEN BL, Valentine TR, Lo SB, Carbone DP, et al
    Newly diagnosed patients with advanced non-small cell lung cancer: A clinical description of those with moderate to severe depressive symptoms.
    Lung Cancer. 2019 Nov 21. pii: S0169-5002(19)30729.
    PubMed     Abstract available


  305. MORITA R, Okishio K, Shimizu J, Saito H, et al
    Real-world effectiveness and safety of nivolumab in patients with non-small cell lung cancer: A multicenter retrospective observational study in Japan.
    Lung Cancer. 2019;140:8-18.
    PubMed     Abstract available


  306. ICHIHARA E, Harada D, Inoue K, Sato K, et al
    The impact of body mass index on the efficacy of anti-PD-1/PD-L1 antibodies in patients with non-small cell lung cancer.
    Lung Cancer. 2019;139:140-145.
    PubMed     Abstract available


  307. PRUIS MA, Geurts-Giele WRR, von der TJH, Meijssen IC, et al
    Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer.
    Lung Cancer. 2019;140:46-54.
    PubMed     Abstract available


  308. BEAU-FALLER M, Pencreach E, Leduc C, Blons H, et al
    Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): Results of the
    Lung Cancer. 2019;140:19-26.
    PubMed     Abstract available


  309. TENDLER S, Holmqvist M, Wagenius G, Lewensohn R, et al
    Educational level, management and outcomes in small-cell lung cancer (SCLC): A population-based cohort study.
    Lung Cancer. 2019;139:111-117.
    PubMed     Abstract available


  310. GIAJ-LEVRA N, Giaj Levra M, Berghmans T, Novello S, et al
    Oligometastatic non-small cell lung cancer (NSCLC): Does number of metastasis matter?
    Lung Cancer. 2019 Nov 13. pii: S0169-5002(19)30719.
    PubMed    


  311. CONG M, Feng H, Ren JL, Xu Q, et al
    Development of a predictive radiomics model for lymph node metastases in pre-surgical CT-based stage IA non-small cell lung cancer.
    Lung Cancer. 2019;139:73-79.
    PubMed     Abstract available


  312. LI T, Zhang F, Wu Z, Cui L, et al
    PLEKHM2-ALK: A novel fusion in small-cell lung cancer and durable response to ALK inhibitors.
    Lung Cancer. 2019;139:146-150.
    PubMed     Abstract available


  313. GERBER DE, Camidge DR, Morgensztern D, Cetnar J, et al
    Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer.
    Lung Cancer. 2019;139:60-67.
    PubMed     Abstract available


  314. TAKEDA M, Sakai K, Hayashi H, Tanaka K, et al
    Impact of coexisting gene mutations in EGFR-mutated non-small cell lung cancer before treatment on EGFR T790M mutation status after EGFR-TKIs.
    Lung Cancer. 2019;139:28-34.
    PubMed     Abstract available


  315. GHIMIRE B, Maroni R, Vulkan D, Shah Z, et al
    Erratum to "Evaluation of a health service adopting proactive approach to reduce high risk of lung cancer: The Liverpool Healthy Lung Programme" [Lung Cancer 134 (August) (2019) 66-71].
    Lung Cancer. 2019 Nov 2. pii: S0169-5002(19)30677.
    PubMed    


  316. MATSUMOTO Y, Sawa K, Fukui M, Oyanagi J, et al
    Predictive impact of low-frequency pretreatment T790M mutation in patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors.
    Lung Cancer. 2019;139:80-88.
    PubMed     Abstract available


  317. BALATA H, Traverse-Healy L, Blandin-Knight S, Armitage C, et al
    Attending community-based lung cancer screening influences smoking behaviour in deprived populations.
    Lung Cancer. 2019;139:41-46.
    PubMed     Abstract available


    October 2019
  318. REALE ML, De Luca E, Lombardi P, Marandino L, et al
    Quality of life analysis in lung cancer: A systematic review of phase III trials published between 2012 and 2018.
    Lung Cancer. 2019;139:47-54.
    PubMed     Abstract available


  319. ZHANG D, Zhang Y, Huang Y, Kong L, et al
    Hyper-progressive disease in a patient with advanced non-small cell lung cancer on immune checkpoint inhibitor therapy: A case report and literature review.
    Lung Cancer. 2019;139:18-21.
    PubMed     Abstract available


  320. DREVET G, Duruisseaux M, Maury JM, Benjamin R, et al
    Lung cancer surgical treatment after solid organ transplantation: A single center 30-year experience.
    Lung Cancer. 2019;139:55-59.
    PubMed     Abstract available


  321. KATAOKA Y, Yamamoto Y, Otsuki T, Kaku S, et al
    Corrigendum to "External validation of prognostic indices for overall survival of malignant pleural mesothelioma" [Lung Cancer 113 (November) (2017) 88-92].
    Lung Cancer. 2019 Oct 23. pii: S0169-5002(19)30678.
    PubMed    


  322. MOLDAVER D, Hurry M, Evans WK, Cheema PK, et al
    Development, validation and results from the impact of treatment evolution in non-small cell lung cancer (iTEN) model.
    Lung Cancer. 2019;139:185-194.
    PubMed     Abstract available


  323. EICHHORN F, Klotz LV, Muley T, Kobinger S, et al
    Prognostic relevance of regional lymph-node distribution in patients with N1-positive non-small cell lung cancer: A retrospective single-center analysis.
    Lung Cancer. 2019;138:95-101.
    PubMed     Abstract available


  324. THOMPSON JC, Hwang WT, Davis C, Deshpande C, et al
    Gene signatures of tumor inflammation and epithelial-to-mesenchymal transition (EMT) predict responses to immune checkpoint blockade in lung cancer with high accuracy.
    Lung Cancer. 2019;139:1-8.
    PubMed     Abstract available


  325. TSUKITA Y, Inoue A, Sugawara S, Kuyama S, et al
    Phase II study of S-1 in patients with previously-treated invasive thymoma and thymic carcinoma: North Japan lung cancer study group trial 1203.
    Lung Cancer. 2019;139:89-93.
    PubMed     Abstract available


  326. SHE L, Hu H, Liao M, Xia X, et al
    Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater.
    Lung Cancer. 2019;138:88-94.
    PubMed     Abstract available


  327. PULITI D, Mascalchi M, Carozzi FM, Carrozzi L, et al
    Decreased cardiovascular mortality in the ITALUNG lung cancer screening trial: Analysis of underlying factors.
    Lung Cancer. 2019;138:72-78.
    PubMed     Abstract available


  328. OU SI, Gadgeel SM, Barlesi F, Yang JC, et al
    Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer.
    Lung Cancer. 2019;139:22-27.
    PubMed     Abstract available


  329. NAITO T, Udagawa H, Umemura S, Sakai T, et al
    Non-small cell lung cancer with loss of expression of the SWI/SNF complex is associated with aggressive clinicopathological features, PD-L1-positive status, and high tumor mutation burden.
    Lung Cancer. 2019;138:35-42.
    PubMed     Abstract available


  330. PEROL M, Pavlakis N, Levchenko E, Platania M, et al
    Patient-reported outcomes from the randomized phase III ALEX study of alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer.
    Lung Cancer. 2019;138:79-87.
    PubMed     Abstract available


  331. KHORRAMI M, Jain P, Bera K, Alilou M, et al
    Corrigendum to "Predicting pathologic response to neoadjuvant chemoradiation in resectable stage III non-small cell lung cancer patients using computed tomography radiomic features" [Lung Cancer 135 (September) (2019) 1-9].
    Lung Cancer. 2019;136:156.
    PubMed    


  332. BAR J, Ofek E, Barshack I, Gottfried T, et al
    Transformation to small cell lung cancer as a mechanism of resistance to immunotherapy in non-small cell lung cancer.
    Lung Cancer. 2019;138:109-115.
    PubMed     Abstract available


    September 2019
  333. ASAHINA H, Oizumi S, Takamura K, Harada T, et al
    A prospective phase II study of carboplatin and nab-paclitaxel in patients with advanced non-small cell lung cancer and concomitant interstitial lung disease (HOT1302).
    Lung Cancer. 2019;138:65-71.
    PubMed     Abstract available


  334. MEHLMAN C, Cadranel J, Rousseau-Bussac G, Lacave R, et al
    Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: A multicentric retrospective French study.
    Lung Cancer. 2019;137:149-156.
    PubMed     Abstract available


  335. STAMATIS G, Leschber G, Schwarz B, Brintrup DL, et al
    Perioperative course and quality of life in a prospective randomized multicenter phase III trial, comparing standard lobectomy versus anatomical segmentectomy in patients with non-small cell lung cancer up to 2cm, stage IA (7th edition of TNM staging
    Lung Cancer. 2019;138:19-26.
    PubMed     Abstract available


  336. PARK SY, Byun GE, Lee CY, Lee JG, et al
    Clinical implications of uncertain resection in scenarios of metastasis of the highest or most distant mediastinal lymph node station following surgical treatment of non-small-cell lung cancer.
    Lung Cancer. 2019;138:1-5.
    PubMed     Abstract available


  337. GELATTI ACZ, Drilon A, Santini FC
    Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
    Lung Cancer. 2019;137:113-122.
    PubMed     Abstract available


  338. TERAMOTO K, Igarashi T, Kataoka Y, Ishida M, et al
    Clinical significance of PD-L1-positive cancer-associated fibroblasts in pN0M0 non-small cell lung cancer.
    Lung Cancer. 2019;137:56-63.
    PubMed     Abstract available


  339. YOSHIMURA A, Yamada T, Miyagawa-Hayashino A, Sonobe Y, et al
    Comparing three different anti-PD-L1 antibodies for immunohistochemical evaluation of small cell lung cancer.
    Lung Cancer. 2019;137:108-112.
    PubMed     Abstract available


  340. AGER BJ, Wells SM, Gruhl JD, Stoddard GJ, et al
    Stereotactic body radiotherapy versus percutaneous local tumor ablation for early-stage non-small cell lung cancer.
    Lung Cancer. 2019;138:6-12.
    PubMed     Abstract available


  341. KADOURI L, Rottenberg Y, Zick A, Hamburger T, et al
    Homologous recombination in lung cancer, germline and somatic mutations, clinical and phenotype characterization.
    Lung Cancer. 2019;137:48-51.
    PubMed     Abstract available


  342. GALLI G, De Toma A, Pagani F, Randon G, et al
    Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer.
    Lung Cancer. 2019;137:38-42.
    PubMed     Abstract available


  343. GUIBERT N, Jones G, Beeler JF, Plagnol V, et al
    Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer.
    Lung Cancer. 2019;137:1-6.
    PubMed     Abstract available


  344. BODOR JN, Feliciano JL, Edelman MJ
    Corrigendum to "Outcomes of patients with disease recurrence after treatment for locally advanced non-small cell lung cancer detected by routine follow-up CT scans versus a symptom driven evaluation" [Lung Cancer 135 (September) (2019) 16-20].
    Lung Cancer. 2019 Sep 5. pii: S0169-5002(19)30616.
    PubMed    


  345. LAN S, Li H, Liu Y, Ma L, et al
    Erratum to "Somatic mutation of LRP1B is associated with tumor mutational burden in patients with lung cancer" [Lung Cancer 132 (June) (2019) 154-156].
    Lung Cancer. 2019 Sep 4. pii: S0169-5002(19)30622.
    PubMed    


  346. BESSE B, Barlesi F, Demedts I, Fuentes Pradera J, et al
    A phase 1b study of necitumumab in combination with abemaciclib in patients with stage IV non-small cell lung cancer.
    Lung Cancer. 2019;137:136-143.
    PubMed     Abstract available


  347. FRASER I, Lefresne S, Regan J, Berthelet E, et al
    Palliative thoracic radiotherapy near the end of life in lung cancer: A population-based analysis.
    Lung Cancer. 2019;135:97-103.
    PubMed     Abstract available


  348. HOJBJERG JA, Ebert EBF, Clement MS, Winther-Larsen A, et al
    Circulating miR-30b and miR-30c predict erlotinib response in EGFR-mutated non-small cell lung cancer patients.
    Lung Cancer. 2019;135:92-96.
    PubMed     Abstract available


  349. CAPIZZI E, Dall'Olio FG, Gruppioni E, Sperandi F, et al
    Clinical significance of ROS1 5' deletions in non-small cell lung cancer.
    Lung Cancer. 2019;135:88-91.
    PubMed     Abstract available


  350. HOPKINS RJ, Ko J, Gamble GD, Young RP, et al
    Airflow limitation and survival after surgery for non-small cell lung cancer: Results from a systematic review and lung cancer screening trial (NLST-ACRIN sub-study).
    Lung Cancer. 2019;135:80-87.
    PubMed     Abstract available


  351. KIM DW, Lee DH, Han JY, Lee J, et al
    Safety, tolerability, and anti-tumor activity of olmutinib in non-small cell lung cancer with T790M mutation: A single arm, open label, phase 1/2 trial.
    Lung Cancer. 2019;135:66-72.
    PubMed     Abstract available


  352. GUO J, Wang X, Wang Y, Wang L, et al
    A promising role of interferon regulatory factor 5 as an early warning biomarker for the development of human non-small cell lung cancer.
    Lung Cancer. 2019;135:47-55.
    PubMed     Abstract available


  353. MESSARITAKIS I, Nikolaou M, Koinis F, Politaki E, et al
    Characterization of DLL3-positive circulating tumor cells (CTCs) in patients with small cell lung cancer (SCLC) and evaluation of their clinical relevance during front-line treatment.
    Lung Cancer. 2019;135:33-39.
    PubMed     Abstract available


  354. CADHAM CJ, Jayasekera JC, Advani SM, Fallon SJ, et al
    Smoking cessation interventions for potential use in the lung cancer screening setting: A systematic review and meta-analysis.
    Lung Cancer. 2019;135:205-216.
    PubMed     Abstract available


  355. GRIESINGER F, Korol EE, Kayaniyil S, Varol N, et al
    Efficacy and safety of first-line carboplatin-versus cisplatin-based chemotherapy for non-small cell lung cancer: A meta-analysis.
    Lung Cancer. 2019;135:196-204.
    PubMed     Abstract available


  356. NOSAKI K, Saka H, Hosomi Y, Baas P, et al
    Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies.
    Lung Cancer. 2019;135:188-195.
    PubMed     Abstract available


  357. HEINEMAN DJ, Hoeijmakers F, Beck N, Dickhoff C, et al
    Impact of health care organization on surgical lung cancer care.
    Lung Cancer. 2019;135:181-187.
    PubMed     Abstract available


  358. YOKOYAMA T, Yoshioka H, Fujimoto D, Demura Y, et al
    A phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small-cell lung cancer (KTORG1402).
    Lung Cancer. 2019;135:175-180.
    PubMed     Abstract available


  359. ISLA D, De Las Penas R, Insa A, Marse R, et al
    Oral vinorelbine versus etoposide with cisplatin and chemo-radiation as treatment in patients with stage III non-small cell lung cancer: A randomized phase II (RENO study).
    Lung Cancer. 2019;135:161-168.
    PubMed     Abstract available


  360. BODOR JN, Feliciano JL, Edelman MJ
    Outcomes of patients with disease recurrence after treatment for locally advanced non-small cell lung cancer detected by routine follow-up CT scans versus a symptom driven evaluation.
    Lung Cancer. 2019;135:16-20.
    PubMed     Abstract available


  361. ALCARAZ J, Carrasco JL, Millares L, Luis IC, et al
    Stromal markers of activated tumor associated fibroblasts predict poor survival and are associated with necrosis in non-small cell lung cancer.
    Lung Cancer. 2019;135:151-160.
    PubMed     Abstract available


  362. UDAGAWA H, Akamatsu H, Tanaka K, Takeda M, et al
    Phase I safety and pharmacokinetics study of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small cell lung cancer.
    Lung Cancer. 2019;135:145-150.
    PubMed     Abstract available


  363. ZHANG L, Pu D, Liu D, Wang Y, et al
    Identification and validation of novel circulating biomarkers for early diagnosis of lung cancer.
    Lung Cancer. 2019;135:130-137.
    PubMed     Abstract available


  364. RUDNICKA J, Kowalkowski T, Buszewski B
    Searching for selected VOCs in human breath samples as potential markers of lung cancer.
    Lung Cancer. 2019;135:123-129.
    PubMed     Abstract available


  365. NOOR ZS, Goldman JW, Lawler WE, Telivala B, et al
    Luminespib plus pemetrexed in patients with non-squamous non-small cell lung cancer.
    Lung Cancer. 2019;135:104-109.
    PubMed     Abstract available


  366. KHORRAMI M, Jain P, Bera K, Alilou M, et al
    Predicting pathologic response to neoadjuvant chemoradiation in resectable stage III non-small cell lung cancer patients using computed tomography radiomic features.
    Lung Cancer. 2019;135:1-9.
    PubMed     Abstract available


    August 2019
  367. SUMITOMO R, Hirai T, Fujita M, Murakami H, et al
    PD-L1 expression on tumor-infiltrating immune cells is highly associated with M2 TAM and aggressive malignant potential in patients with resected non-small cell lung cancer.
    Lung Cancer. 2019;136:136-144.
    PubMed     Abstract available


  368. KIM YJ, Keam B, Ock CY, Song S, et al
    A phase II study of pembrolizumab and paclitaxel in patients with relapsed or refractory small-cell lung cancer.
    Lung Cancer. 2019;136:122-128.
    PubMed     Abstract available


  369. BHANDARI S, Tripathi P, Pham D, Pinkston C, et al
    Performance of community-based lung cancer screening program in a Histoplasma endemic region.
    Lung Cancer. 2019;136:102-104.
    PubMed     Abstract available


  370. AREDO JV, Padda SK, Kunder CA, Han SS, et al
    Response to comment on "Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes".
    Lung Cancer. 2019 Aug 26. pii: S0169-5002(19)30621.
    PubMed    


  371. ZHOU K, Jiang C, Li Q
    Cost-effectiveness analysis of pembrolizumab monotherapy and chemotherapy in the non-small-cell lung cancer with different PD-L1 tumor proportion scores.
    Lung Cancer. 2019;136:98-101.
    PubMed     Abstract available


  372. WANG H, Agulnik J, Kasymjanova G, Fiset PO, et al
    Erratum to "The metastatic site does not influence PD-L1 expression in advanced non-small cell lung carcinoma" [Lung Cancer 132 (June) (2019) 36-38].
    Lung Cancer. 2019 Aug 24. pii: S0169-5002(19)30617.
    PubMed    


  373. YOON DW, Shin DW, Cho JH, Yang JH, et al
    Increased risk of coronary heart disease and stroke in lung cancer survivors: A Korean nationwide study of 20,458 patients.
    Lung Cancer. 2019;136:115-121.
    PubMed     Abstract available


  374. OU SI, Cui J, Schrock AB, Goldberg ME, et al
    Erratum to "Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/G and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib" [Lung Cancer, 108 (June 2017) 228-
    Lung Cancer. 2019 Aug 22. pii: S0169-5002(19)30614.
    PubMed    


  375. TAY RY, Heigener D, Reck M, Califano R, et al
    Immune checkpoint blockade in small cell lung cancer.
    Lung Cancer. 2019;137:31-37.
    PubMed     Abstract available


  376. MAYMANI H, Hess K, Groisberg R, Hong DS, et al
    Corrigendum to "Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials" [Lung Cancer 120 (June) (2018) 137-141].
    Lung Cancer. 2019 Aug 21. pii: S0169-5002(19)30618.
    PubMed    


  377. JIN J, Gan Y, Liu H, Wang Z, et al
    Diminishing microbiome richness and distinction in the lower respiratory tract of lung cancer patients: A multiple comparative study design with independent validation.
    Lung Cancer. 2019;136:129-135.
    PubMed     Abstract available


  378. HE Y, Jia K, Dziadziuszko R, Zhao S, et al
    Galectin-9 in non-small cell lung cancer.
    Lung Cancer. 2019;136:80-85.
    PubMed     Abstract available


  379. SHOJI F, Takeoka H, Kozuma Y, Toyokawa G, et al
    Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
    Lung Cancer. 2019;136:45-51.
    PubMed     Abstract available


  380. GAUVAIN C, Vauleon E, Chouaid C, Le Rhun E, et al
    Erratum to "Intracerebral efficacy and tolerance of nivolumab in non-small-cell lung cancer patients with brain metastases" [Lung Cancer 116 (February 2018) 62-66].
    Lung Cancer. 2019 Aug 14. pii: S0169-5002(18)30595.
    PubMed    


  381. MORGENSZTERN D, Karaseva N, Felip E, Delgado I, et al
    An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancer.
    Lung Cancer. 2019;136:74-79.
    PubMed     Abstract available


  382. VILLARUZ LC, Cobo M, Syrigos K, Mavroudis D, et al
    A phase II study of nab-paclitaxel and carboplatin chemotherapy plus necitumumab in the first-line treatment of patients with stage IV squamous non-small cell lung cancer.
    Lung Cancer. 2019;136:52-56.
    PubMed     Abstract available


  383. DESCOURT R, Perol M, Rousseau-Bussac G, Planchard D, et al
    Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study).
    Lung Cancer. 2019;136:109-114.
    PubMed     Abstract available


  384. LEE GJ, Lee H, Woo IS, Kim T, et al
    Erratum to "High expression level of SOX2 is significantly associated with shorter survival in patients with thymic epithelial tumors" [Lung Cancer 132 (June) (2019) 9-16].
    Lung Cancer. 2019 Aug 13. pii: S0169-5002(19)30554.
    PubMed    


  385. LEVY A, Hendriks LEL, Le Pechoux C, Falk S, et al
    Current management of limited-stage SCLC and CONVERT trial impact: Results of the EORTC Lung Cancer Group survey.
    Lung Cancer. 2019;136:145-147.
    PubMed     Abstract available


  386. MURTHY V, Katzman DP, Tsay JJ, Bessich JL, et al
    Tumor-draining lymph nodes demonstrate a suppressive immunophenotype in patients with non-small cell lung cancer assessed by endobronchial ultrasound-guided transbronchial needle aspiration: A pilot study.
    Lung Cancer. 2019;137:94-99.
    PubMed     Abstract available


  387. WEN J, Chen J, Fan M
    Comment on the article titled "Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes".
    Lung Cancer. 2019 Aug 12. pii: S0169-5002(19)30568.
    PubMed    


  388. RAJADURAI P, Cheah PL, How SH, Liam CK, et al
    Molecular testing for advanced non-small cell lung cancer in Malaysia: Consensus statement from the College of Pathologists, Academy of Medicine Malaysia, the Malaysian Thoracic Society, and the Malaysian Oncological Society.
    Lung Cancer. 2019;136:65-73.
    PubMed     Abstract available


  389. CHENG H, Li XJ, Wang XJ, Chen ZW, et al
    A meta-analysis of adjuvant EGFR-TKIs for patients with resected non-small cell lung cancer.
    Lung Cancer. 2019;137:7-13.
    PubMed     Abstract available


  390. MAISONNEUVE P, Iavicoli S, Veronesi G
    Response to comment on: "Low-dose computed tomography screening for lung cancer in people with workplace exposure to asbestos".
    Lung Cancer. 2019 Aug 4. pii: S0169-5002(19)30574.
    PubMed    


  391. TANG W, Li X, Xie X, Sun X, et al
    EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations.
    Lung Cancer. 2019;136:6-14.
    PubMed     Abstract available


  392. HARAGAN A, Field JK, Davies MPA, Escriu C, et al
    Heterogeneity of PD-L1 expression in non-small cell lung cancer: Implications for specimen sampling in predicting treatment response.
    Lung Cancer. 2019;134:79-84.
    PubMed     Abstract available


  393. ZUGAZAGOITIA J, Gomez-Rueda A, Jantus-Lewintre E, Isla D, et al
    Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance.
    Lung Cancer. 2019;134:72-78.
    PubMed     Abstract available


  394. GHIMIRE B, Maroni R, Vulkan D, Shah Z, et al
    Evaluation of a health service adopting proactive approach to reduce high risk of lung cancer: The Liverpool Healthy Lung Programme.
    Lung Cancer. 2019;134:66-71.
    PubMed     Abstract available


  395. BOUSEMA JE, van Dorp M, Hoeijmakers F, Huijbregts IA, et al
    Guideline adherence of mediastinal staging of non-small cell lung cancer: A multicentre retrospective analysis.
    Lung Cancer. 2019;134:52-58.
    PubMed     Abstract available


  396. HELLYER JA, Stehr H, Das M, Padda SK, et al
    Impact of KEAP1/NFE2L2/CUL3 mutations on duration of response to EGFR tyrosine kinase inhibitors in EGFR mutated non-small cell lung cancer.
    Lung Cancer. 2019;134:42-45.
    PubMed     Abstract available


  397. VAN DE VEN M, Retel VP, Koffijberg H, van Harten WH, et al
    Variation in the time to treatment for stage III and IV non-small cell lung cancer patients for hospitals in the Netherlands.
    Lung Cancer. 2019;134:34-41.
    PubMed     Abstract available


  398. MELOSKY B, Juergens R, McLeod D, Leighl N, et al
    Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer.
    Lung Cancer. 2019;134:259-267.
    PubMed     Abstract available


  399. BOADA M, Guzman R, Montesinos M, Libreros A, et al
    UPSTAGING, CENTRALITY AND SURVIVAL IN EARLY STAGE NON-SMALL CELL LUNG CANCER VIDEO-ASSISTED SURGERY.
    Lung Cancer. 2019;134:254-258.
    PubMed     Abstract available


  400. BALATA H, Evison M, Sharman A, Crosbie P, et al
    CT screening for lung cancer: Are we ready to implement in Europe?
    Lung Cancer. 2019;134:25-33.
    PubMed     Abstract available


  401. ACKERMANN CJ, Reck M, Paz-Ares L, Barlesi F, et al
    First-line immune checkpoint blockade for advanced non-small-cell lung cancer: Travelling at the speed of light.
    Lung Cancer. 2019;134:245-253.
    PubMed     Abstract available


  402. VANNITAMBY A, Hendry S, Irving L, Steinfort D, et al
    Novel multiplex droplet digital PCR assay for scoring PD-L1 in non-small cell lung cancer biopsy specimens.
    Lung Cancer. 2019;134:233-237.
    PubMed     Abstract available


  403. FRANCAVIGLIA I, Magliacane G, Lazzari C, Grassini G, et al
    Identification and monitoring of somatic mutations in circulating cell-free tumor DNA in lung cancer patients.
    Lung Cancer. 2019;134:225-232.
    PubMed     Abstract available


  404. LIU Z, Liang H, Lin J, Cai X, et al
    The incidence of lymph node metastasis in patients with different oncogenic driver mutations among T1 non-small-cell lung cancer.
    Lung Cancer. 2019;134:218-224.
    PubMed     Abstract available


  405. CAPELLETTO E, Migliorino MR, Morabito A, Chiari R, et al
    Final results of the SENECA (SEcond line NintEdanib in non-small cell lung CAncer) trial.
    Lung Cancer. 2019;134:210-217.
    PubMed     Abstract available


  406. YOSHIMURA K, Inoue Y, Karayama M, Tsuchiya K, et al
    Heterogeneity analysis of PD-L1 expression and copy number status in EBUS-TBNA biopsy specimens of non-small cell lung cancer: Comparative assessment of primary and metastatic sites.
    Lung Cancer. 2019;134:202-209.
    PubMed     Abstract available


  407. DING PN, Becker TM, Bray VJ, Chua W, et al
    The predictive and prognostic significance of liquid biopsy in advanced epidermal growth factor receptor-mutated non-small cell lung cancer: A prospective study.
    Lung Cancer. 2019;134:187-193.
    PubMed     Abstract available


  408. KASAHARA N, Kaira K, Yamaguchi K, Masubuchi H, et al
    Fluorodeoxyglucose uptake is associated with low tumor-infiltrating lymphocyte levels in patients with small cell lung cancer.
    Lung Cancer. 2019;134:180-186.
    PubMed     Abstract available


  409. DIETEL M, Savelov N, Salanova R, Micke P, et al
    Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non-small-cell lung cancer: The global, multicenter EXPRESS study.
    Lung Cancer. 2019;134:174-179.
    PubMed     Abstract available


  410. OWEN DH, Williams TM, Bertino EM, Mo X, et al
    Homologous recombination and DNA repair mutations in patients treated with carboplatin and nab-paclitaxel for metastatic non-small cell lung cancer.
    Lung Cancer. 2019;134:167-173.
    PubMed     Abstract available


  411. TAN KS
    Misclassification of the actual causes of death and its impact on analysis: A case study in non-small cell lung cancer.
    Lung Cancer. 2019;134:16-24.
    PubMed     Abstract available


  412. HYUN MH, Lee ES, Eo JS, Kim S, et al
    Clinical implications of circulating cell-free DNA quantification and metabolic tumor burden in advanced non-small cell lung cancer.
    Lung Cancer. 2019;134:158-166.
    PubMed     Abstract available


  413. KIM H, Goo JM, Paeng JC, Kim YT, et al
    Evaluation of maximum standardized uptake value at fluorine-18 fluorodeoxyglucose positron emission tomography as a complementary T factor in the eighth edition of lung cancer stage classification.
    Lung Cancer. 2019;134:151-157.
    PubMed     Abstract available


  414. MANJUNATH Y, Upparahalli SV, Suvilesh KN, Avella DM, et al
    Circulating tumor cell clusters are a potential biomarker for detection of non-small cell lung cancer.
    Lung Cancer. 2019;134:147-150.
    PubMed     Abstract available


  415. GIBSON AJW, Li H, D'Silva A, Elegbede AA, et al
    Factors associated with early mortality in non-small cell lung cancer patients following systemic anti-cancer therapy: A 10 year population-based study.
    Lung Cancer. 2019;134:141-146.
    PubMed     Abstract available


  416. DAFNI U, Tsourti Z, Vervita K, Peters S, et al
    Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis.
    Lung Cancer. 2019;134:127-140.
    PubMed     Abstract available


  417. SANTO A, Pilotto S, Galetta D, Grossi F, et al
    Maintenance with lanreotide in small-cell lung cancer expressing somatostatine receptors: A multicenter, randomized, phase 3 trial.
    Lung Cancer. 2019;134:121-126.
    PubMed     Abstract available


  418. ZHANG B, Niu X, Zhang Q, Wang C, et al
    Circulating tumor DNA detection is correlated to histologic types in patients with early-stage non-small-cell lung cancer.
    Lung Cancer. 2019;134:108-116.
    PubMed     Abstract available


  419. NAKAMURA H, Sugano M, Miyashita T, Hashimoto H, et al
    Organoid culture containing cancer cells and stromal cells reveals that podoplanin-positive cancer-associated fibroblasts enhance proliferation of lung cancer cells.
    Lung Cancer. 2019;134:100-107.
    PubMed     Abstract available


  420. HAYASHI H, Iihara H, Hirose C, Fukuda Y, et al
    Effects of pharmacokinetics-related genetic polymorphisms on the side effect profile of afatinib in patients with non-small cell lung cancer.
    Lung Cancer. 2019;134:1-6.
    PubMed     Abstract available


  421. MAISONNEUVE P, Rampinelli C, Bertolotti R, Misotti A, et al
    Corrigendum to "Low-dose computed tomography screening for lung cancer in people with workplace exposure to asbestos" [Lung Cancer, 131 (May) (2019) 23-30].
    Lung Cancer. 2019;134:279.
    PubMed    


  422. CHOE EA, Cha YJ, Kim JH, Pyo KH, et al
    Dynamic changes in PD-L1 expression and CD8(+) T cell infiltration in non-small cell lung cancer following chemoradiation therapy.
    Lung Cancer. 2019;136:30-36.
    PubMed     Abstract available


  423. WANG G, Ionescu DN, Lee CH, Hiruki T, et al
    PD-L1 testing on the EBUS-FNA cytology specimens of non-small cell lung cancer.
    Lung Cancer. 2019;136:1-5.
    PubMed     Abstract available


    July 2019
  424. GRONDAHL V, Binderup T, Langer SW, Petersen RH, et al
    Erratum to "Characteristics of 252 patients with bronchopulmonary neuroendocrine tumours treated at the Copenhagen NET Centre of Excellence" [Lung Cancer 132 (June) (2019) 141-149].
    Lung Cancer. 2019 Jul 31. pii: S0169-5002(19)30561.
    PubMed    


  425. BARBONE F, Barbiero F, Fasola G
    Correspondence regarding "Low-dose computed tomography screening for lung cancer in people with workplace exposure to asbestos".
    Lung Cancer. 2019 Jul 27. pii: S0169-5002(19)30564.
    PubMed    


  426. WANG X, Leader JK, Wang R, Wilson D, et al
    Erratum to "Vasculature surrounding a nodule: A novel lung cancer biomarker" [Lung Cancer 114 (December) (2017) 38-43].
    Lung Cancer. 2019 Jul 26. pii: S0169-5002(19)30560.
    PubMed    


  427. SUBRAMANIAN J, Fernandes AW, Laliberte F, Pavilack M, et al
    The rate of occurrence, healthcare resource use and costs of adverse events among metastatic non-small cell lung cancer patients treated with first- and second-generation epidermal growth factor receptor tyrosine kinase inhibitors.
    Lung Cancer. 2019;138:131-138.
    PubMed     Abstract available


  428. STEFFENS CC, Elender C, Hutzschenreuter U, Dille S, et al
    Corrigendum to "Treatment and outcome of 432 patients with extensive-stage small cell lung cancer in first, second and third line - Results from the prospective German TLK cohort study" [Lung Cancer 130 (2019) (April) 216-225].
    Lung Cancer. 2019 Jul 22. pii: S0169-5002(19)30555.
    PubMed    


  429. AWAD MM, Leonardi GC, Kravets S, Dahlberg SE, et al
    Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis.
    Lung Cancer. 2019;133:96-102.
    PubMed     Abstract available


  430. PETERS S, Felip E, Dafni U, Belka C, et al
    Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial.
    Lung Cancer. 2019;133:83-87.
    PubMed     Abstract available


  431. LI X, Zhang C, Sun Z, Yang F, et al
    Propensity-matched analysis of adjuvant chemotherapy for completely resected Stage IB non-small-cell lung cancer patients.
    Lung Cancer. 2019;133:75-82.
    PubMed     Abstract available


  432. TSAKONAS G, Botling J, Micke P, Rivard C, et al
    c-MET as a biomarker in patients with surgically resected non-small cell lung cancer.
    Lung Cancer. 2019;133:69-74.
    PubMed     Abstract available


  433. MORABITO A, Piccirillo MC, Maione P, Luciani A, et al
    Effect on quality of life of cisplatin added to single-agent chemotherapy as first-line treatment for elderly patients with advanced non-small cell lung cancer: Joint analysis of MILES-3 and MILES-4 randomised phase 3 trials.
    Lung Cancer. 2019;133:62-68.
    PubMed     Abstract available


  434. DIMOU A, Bamias A, Gogas H, Syrigos K, et al
    Inhibition of the Hedgehog pathway in lung cancer.
    Lung Cancer. 2019;133:56-61.
    PubMed     Abstract available


  435. MELOSKY B, Bradbury P, Tu D, Florescu M, et al
    Selumetinib in patients receiving standard pemetrexed and platinum-based chemotherapy for advanced or metastatic KRAS wildtype or unknown non-squamous non-small cell lung cancer: A randomized, multicenter, phase II study. Canadian Cancer Trials Group
    Lung Cancer. 2019;133:48-55.
    PubMed     Abstract available


  436. SAKIN A, Sahin S, Yasar N, Demir C, et al
    Prognostic impact of blood transfusion in patients with metastatic non-small cell lung cancer receiving chemotherapy.
    Lung Cancer. 2019;133:38-44.
    PubMed     Abstract available


  437. LOWENSTEIN M, Vijayaraghavan M, Burke NJ, Karliner L, et al
    Real-world lung cancer screening decision-making: Barriers and facilitators.
    Lung Cancer. 2019;133:32-37.
    PubMed     Abstract available


  438. AREDO JV, Padda SK, Kunder CA, Han SS, et al
    Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes.
    Lung Cancer. 2019;133:144-150.
    PubMed     Abstract available


  439. SHINDE A, Horne ZD, Li R, Glaser S, et al
    Optimal adjuvant therapy in clinically N2 non-small cell lung cancer patients undergoing neoadjuvant chemotherapy and surgery: The importance of pathological response and lymph node ratio.
    Lung Cancer. 2019;133:136-143.
    PubMed     Abstract available


  440. DEGENS JHRJ, Sanders KJC, de Jong EEC, Groen HJM, et al
    The prognostic value of early onset, CT derived loss of muscle and adipose tissue during chemotherapy in metastatic non-small cell lung cancer.
    Lung Cancer. 2019;133:130-135.
    PubMed     Abstract available


  441. ROMERO-VIELVA L, Viteri S, Moya-Horno I, Toscas JI, et al
    Salvage surgery after definitive chemo-radiotherapy for patients with Non-Small Cell Lung Cancer.
    Lung Cancer. 2019;133:117-122.
    PubMed     Abstract available


  442. KSIENSKI D, Wai ES, Croteau N, Freeman AT, et al
    Pembrolizumab for advanced nonsmall cell lung cancer: Efficacy and safety in everyday clinical practice.
    Lung Cancer. 2019;133:110-116.
    PubMed     Abstract available


  443. GAYE E, Geier M, Bore P, Guilloique M, et al
    Intra-cranial efficacy of brigatinib in an ALK-positive non-small cell lung cancer patient presenting leptomeningeal carcinomatosis.
    Lung Cancer. 2019;133:1-3.
    PubMed     Abstract available


    June 2019
  444. PARDO-CABELLO AJ, Manzano-Gamero V
    Small cell lung cancer elevates procalcitonin levels in the absence of infection.
    Lung Cancer. 2019 Jun 17. pii: S0169-5002(19)30511.
    PubMed    


  445. FUJIMOTO D, Yomota M, Sekine A, Morita M, et al
    Nivolumab for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia: A multicenter, open-label single-arm phase II trial.
    Lung Cancer. 2019 Jun 3. pii: S0169-5002(19)30494.
    PubMed     Abstract available


  446. YOO JK, Lee JM, Kang SH, Jeon SH, et al
    The novel microRNA hsa-miR-CHA1 regulates cell proliferation and apoptosis in human lung cancer by targeting XIAP.
    Lung Cancer. 2019;132:99-106.
    PubMed     Abstract available


  447. SUH CH, Kim KW, Pyo J, Hatabu H, et al
    The incidence of ALK inhibitor-related pneumonitis in advanced non-small-cell lung cancer patients: A systematic review and meta-analysis.
    Lung Cancer. 2019;132:79-86.
    PubMed     Abstract available


  448. GALLI G, Triulzi T, Proto C, Signorelli D, et al
    Association between antibiotic-immunotherapy exposure ratio and outcome in metastatic non small cell lung cancer.
    Lung Cancer. 2019;132:72-78.
    PubMed     Abstract available


  449. ASSOUN S, Theou-Anton N, Nguenang M, Cazes A, et al
    Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer.
    Lung Cancer. 2019;132:65-71.
    PubMed     Abstract available


  450. ICHIHARA E, Hotta K, Ninomiya K, Kubo T, et al
    Re-administration of osimertinib in osimertinib-acquired resistant non-small-cell lung cancer.
    Lung Cancer. 2019;132:54-58.
    PubMed     Abstract available


  451. CUI S, Ni Y, Zhao Y, Li Z, et al
    Epidermal growth factor receptor-targeted immunomagnetic liposomes for circulating tumor cell enumeration in non-small cell lung cancer treated with epidermal growth factor receptor-tyrosine kinase inhibitors.
    Lung Cancer. 2019;132:45-53.
    PubMed     Abstract available


  452. WANG H, Agulnik J, Kasymjanova G, Fiset PO, et al
    The metastatic site does not influence PD-L1 expression in advanced non-small cell lung carcinoma.
    Lung Cancer. 2019;132:36-38.
    PubMed     Abstract available


  453. PLATANIA M, Pasini F, Porcu L, Boeri M, et al
    Oral maintenance metronomic vinorelbine versus best supportive care in advanced non-small-cell lung cancer after platinum-based chemotherapy: The MA.NI.LA. multicenter, randomized, controlled, phase II trial.
    Lung Cancer. 2019;132:17-23.
    PubMed     Abstract available


  454. VAD-NIELSEN J, Gammelgaard KR, Daugaard TF, Nielsen AL, et al
    Cause-and-Effect relationship between FGFR1 expression and epithelial-mesenchymal transition in EGFR-mutated non-small cell lung cancer cells.
    Lung Cancer. 2019;132:132-140.
    PubMed     Abstract available


  455. PARK K, Bennouna J, Boyer M, Hida T, et al
    Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer.
    Lung Cancer. 2019;132:126-131.
    PubMed     Abstract available


  456. MINNITI G, Scaringi C, Lanzetta G, Anzellini D, et al
    Comparative effectiveness of multi-fraction stereotactic radiosurgery for surgically resected or intact large brain metastases from non-small-cell lung cancer (NSCLC).
    Lung Cancer. 2019;132:119-125.
    PubMed     Abstract available


  457. LIANG F, Wu C, Gu H, Zhu M, et al
    Lung cancer incidence in female rises significantly in urban sprawl of Shanghai after introduction of LDCT screening.
    Lung Cancer. 2019;132:114-118.
    PubMed     Abstract available


  458. OYANAGI J, Koh Y, Sato K, Mori K, et al
    Predictive value of serum protein levels in patients with advanced non-small cell lung cancer treated with nivolumab.
    Lung Cancer. 2019;132:107-113.
    PubMed     Abstract available


  459. FUKUDA M, Kitazaki T, Ogawara D, Ichiki M, et al
    Randomized phase II study of pemetrexed or pemetrexed plus bevacizumab for elderly patients with previously untreated non-squamous non-small cell lung cancer: Results of the Lung Oncology Group in Kyushu (LOGIK1201).
    Lung Cancer. 2019;132:1-8.
    PubMed     Abstract available


  460. SONG T, Jiang L, Lin Y
    Comment on: 'Correlation of Tumor Spread through Air Spaces and Clinicopathological Characteristics in Surgically Resected Lung Adenocarcinomas'.
    Lung Cancer. 2019;132:150.
    PubMed    


  461. HSIEH MS, Lin MW
    Response to comment on: "Correlation of Tumor Spread through Air Spaces and Clinicopathological Characteristics in Surgically Resected Lung Adenocarcinomas."
    Lung Cancer. 2019;132:151.
    PubMed    


    May 2019
  462. TAKANO N, Ariyasu R, Koyama J, Sonoda T, et al
    Improvement in the survival of patients with stage IV non-small-cell lung cancer: Experience in a single institutional 1995-2017.
    Lung Cancer. 2019;131:69-77.
    PubMed     Abstract available


  463. LIN C, Shi X, Yang S, Zhao J, et al
    Comparison of ALK detection by FISH, IHC and NGS to predict benefit from crizotinib in advanced non-small-cell lung cancer.
    Lung Cancer. 2019;131:62-68.
    PubMed     Abstract available


  464. PEROL M, Winfree KB, Cuyun Carter G, Lin Cui Z, et al
    Association of baseline symptom burden with efficacy outcomes: Exploratory analysis from the randomized phase III REVEL study in advanced non-small-cell lung cancer.
    Lung Cancer. 2019;131:6-13.
    PubMed     Abstract available


  465. SULLIVAN DR, Eden KB, Dieckmann NF, Golden SE, et al
    Understanding patients' values and preferences regarding early stage lung cancer treatment decision making.
    Lung Cancer. 2019;131:47-57.
    PubMed     Abstract available


  466. WILLEN L, Berglund A, Bergstrom S, Bergqvist M, et al
    Educational level and management and outcomes in non-small cell lung cancer. A nationwide population-based study.
    Lung Cancer. 2019;131:40-46.
    PubMed     Abstract available


  467. VAYR F, Savall F, Bigay-Game L, Soulat JM, et al
    Lung cancer survivors and employment: A systematic review.
    Lung Cancer. 2019;131:31-39.
    PubMed     Abstract available


  468. MAISONNEUVE P, Rampinelli C, Bertolotti R, Misotti A, et al
    Low-dose computed tomography screening for lung cancer in people with workplace exposure to asbestos.
    Lung Cancer. 2019;131:23-30.
    PubMed     Abstract available


  469. YAN SX, Qureshi MM, Dyer M, Truong MT, et al
    Stereotactic body radiation therapy with higher biologically effective dose is associated with improved survival in stage II non-small cell lung cancer.
    Lung Cancer. 2019;131:147-153.
    PubMed     Abstract available


  470. YIN K, Li YS, Zheng MM, Jiang BY, et al
    A molecular graded prognostic assessment (molGPA) model specific for estimating survival in lung cancer patients with leptomeningeal metastases.
    Lung Cancer. 2019;131:134-138.
    PubMed     Abstract available


  471. LATTUCA-TRUC M, Timsit JF, Levra MG, Ruckly S, et al
    Trends in response rate and survival in small-cell lung cancer patients between 1997 and 2017.
    Lung Cancer. 2019;131:122-127.
    PubMed     Abstract available


  472. YAMADA T, Ohta K, Motooka Y, Fujino K, et al
    Significance of Tsukushi in lung cancer.
    Lung Cancer. 2019;131:104-111.
    PubMed     Abstract available


  473. CHRISTENSEN NL, Dalton S, Ravn J, Christensen J, et al
    Treatment, no treatment and early death in Danish stage I lung cancer patients.
    Lung Cancer. 2019;131:1-5.
    PubMed     Abstract available


  474. GAN CT, Verschuuren E, van de Bij W, Van De Wauwer C, et al
    Comment on: Synchronous multiple non-small cell lung cancers in an allograft lung recipient.
    Lung Cancer. 2019;131:154.
    PubMed    


  475. PUJOL JL, Bommart S, Pujol P
    Response to comment on: 'Synchronous multiple non-small cell lung cancers in an allograft lung recipient'.
    Lung Cancer. 2019;131:155-156.
    PubMed    


    April 2019
  476. LAN S, Li H, Liu Y, Ma L, et al
    Somatic mutation of LRP1B is associated with tumor mutational burden in patients with lung cancer.
    Lung Cancer. 2019 Apr 28. pii: S0169-5002(19)30426.
    PubMed    


  477. FOSTER CC, Rusthoven CG, Sher DJ, Feldman L, et al
    Corrigendum to "Adjuvant chemotherapy following stereotactic body radiotherapy for early stage non-small-cell lung cancer is associated with lower overall survival: A National Cancer Database Analysis" [Lung Cancer, Volume 130 (April) (2019) 162-168].
    Lung Cancer. 2019 Apr 25. pii: S0169-5002(19)30398.
    PubMed    


  478. NISHIO M, Nakagawa K, Mitsudomi T, Yamamoto N, et al
    Corrigendum to "Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer" [Lung Cancer 121 (July) (2018) Pages 37-40].
    Lung Cancer. 2019 Apr 24. pii: S0169-5002(19)30399.
    PubMed    


  479. WATANABE S, Yoshioka H, Sakai H, Hotta K, et al
    Corrigendum to "Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: A phase 1b and randomized, open-label, multicenter, phase 2 trial in Japan" [Lu
    Lung Cancer. 2019 Apr 20. pii: S0169-5002(19)30397.
    PubMed    


  480. HARRIS EJA, Musk AW, DeKlerk N, Brims FJH, et al
    Correspondence regarding "Low-dose computed tomography screening for lung cancer in people with workplace exposure to asbestos".
    Lung Cancer. 2019 Apr 20. pii: S0169-5002(19)30417.
    PubMed    


  481. HAQUE W, Verma V, Butler EB, Teh BS, et al
    Pathologic nodal clearance and complete response following neoadjuvant chemoradiation for clinical N2 non-small cell lung cancer: Predictors and long-term outcomes.
    Lung Cancer. 2019;130:93-100.
    PubMed     Abstract available


  482. LEE K, Kim Y, Jung HA, Lee SH, et al
    Repeat biopsy procedures and T790M rates after afatinib, gefitinib, or erlotinib therapy in patients with lung cancer.
    Lung Cancer. 2019;130:87-92.
    PubMed     Abstract available


  483. JIANG T, Bai Y, Zhou F, Li W, et al
    Clinical value of neutrophil-to-lymphocyte ratio in patients with non-small-cell lung cancer treated with PD-1/PD-L1 inhibitors.
    Lung Cancer. 2019;130:76-83.
    PubMed     Abstract available


  484. ARRIETA O, Barron F, Maldonado F, Cabrera L, et al
    Radical consolidative treatment provides a clinical benefit and long-term survival in patients with synchronous oligometastatic non-small cell lung cancer: A phase II study.
    Lung Cancer. 2019;130:67-75.
    PubMed     Abstract available


  485. GUBENS MA, Sequist LV, Stevenson JP, Powell SF, et al
    Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non-small-cell lung cancer: KEYNOTE-021 cohorts D and H.
    Lung Cancer. 2019;130:59-66.
    PubMed     Abstract available


  486. LA FLEUR L, Falk-Sorqvist E, Smeds P, Berglund A, et al
    Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11.
    Lung Cancer. 2019;130:50-58.
    PubMed     Abstract available


  487. YONESHIMA Y, Tanaka K, Shiraishi Y, Hata K, et al
    Safety and efficacy of PD-1 inhibitors in non-small cell lung cancer patients positive for antinuclear antibodies.
    Lung Cancer. 2019;130:5-9.
    PubMed     Abstract available


  488. PERUMAL E, So Youn K, Sun S, Seung-Hyun J, et al
    PTEN inactivation induces epithelial-mesenchymal transition and metastasis by intranuclear translocation of beta-catenin and snail/slug in non-small cell lung carcinoma cells.
    Lung Cancer. 2019;130:25-34.
    PubMed     Abstract available


  489. STEFFENS CC, Elender C, Hutzschenreuter U, Dille S, et al
    Treatment and outcome of 432 patients with extensive-stage small cell lung cancer in first, second and third line - Results from the prospective German TLK cohort study.
    Lung Cancer. 2019;130:216-225.
    PubMed     Abstract available


  490. LUO Q, Steinberg J, O'Connell DL, Yu XQ, et al
    Lung cancer mortality in Australia in the twenty-first century: How many lives can be saved with effective tobacco control?
    Lung Cancer. 2019;130:208-215.
    PubMed     Abstract available


  491. WU YL, Zhou C, Lu S, Qin S, et al
    Erlotinib versus gemcitabine/cisplatin in Chinese patients with EGFR mutation-positive advanced non-small-cell lung cancer: Crossover extension and post-hoc analysis of the ENSURE study.
    Lung Cancer. 2019;130:18-24.
    PubMed     Abstract available


  492. CARNEIRO-LOBO TC, Scalabrini LC, Magalhaes LDS, Cardeal LB, et al
    IKKbeta targeting reduces KRAS-induced lung cancer angiogenesis in vitro and in vivo: A potential anti-angiogenic therapeutic target.
    Lung Cancer. 2019;130:169-178.
    PubMed     Abstract available


  493. FOSTER CC, Rusthoven CG, Sher DJ, Feldman L, et al
    Adjuvant chemotherapy following stereotactic body radiotherapy for early stage non-small-cell lung cancer is associated with lower overall: A National Cancer Database Analysis.
    Lung Cancer. 2019;130:162-168.
    PubMed     Abstract available


  494. SAKATA Y, Kawamura K, Ichikado K, Shingu N, et al
    The association between tumor burden and severe immune-related adverse events in non-small cell lung cancer patients responding to immune-checkpoint inhibitor treatment.
    Lung Cancer. 2019;130:159-161.
    PubMed     Abstract available


  495. BRONSERUD MM, Iachina M, Green A, Groenvold M, et al
    Patient reported outcome data as performance indicators in surgically treated lung cancer patients.
    Lung Cancer. 2019;130:143-148.
    PubMed     Abstract available


  496. COSTANTINI A, Fallet V, Corny J, Friard S, et al
    Nivolumab-refractory patients with advanced non-small-cell lung cancer.
    Lung Cancer. 2019;130:128-134.
    PubMed     Abstract available


  497. MELTZER LR, Unrod M, Simmons VN, Brandon KO, et al
    Capitalizing on a teachable moment: Development of a targeted self-help smoking cessation intervention for patients receiving lung cancer screening.
    Lung Cancer. 2019;130:121-127.
    PubMed     Abstract available


  498. GEERSE OP, Brandenbarg D, Kerstjens HAM, Berendsen AJ, et al
    The distress thermometer as a prognostic tool for one-year survival among patients with lung cancer.
    Lung Cancer. 2019;130:101-107.
    PubMed     Abstract available


  499. ZHAO S, Gao G, Li W, Li X, et al
    Antibiotics are associated with attenuated efficacy of anti-PD-1/PD-L1 therapies in Chinese patients with advanced non-small cell lung cancer.
    Lung Cancer. 2019;130:10-17.
    PubMed     Abstract available


  500. ZHOU K, Zhou J, Huang J, Zhang N, et al
    Cost-effectiveness analysis of atezolizumab plus chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer.
    Lung Cancer. 2019;130:1-4.
    PubMed     Abstract available


    March 2019
  501. HU SY, Hsieh MS, Hsu HH, Tsai TM, et al
    Corrigendum to "Correlation of tumor spread through air spaces and clinicopathological characteristics in surgically resected lung adenocarcinomas" [Lung Cancer 126 (2018) 189-193].
    Lung Cancer. 2019 Mar 13. pii: S0169-5002(19)30349.
    PubMed    


  502. ONO A, Isaka M, Serizawa M, Omae K, et al
    Corrigendum to "Genetic alterations of driver genes as independent prognostic factors for disease-free survival in patients with resected non-small cell lung cancer" [Lung Cancer 128 (2019) 152-157].
    Lung Cancer. 2019 Mar 12. pii: S0169-5002(19)30350.
    PubMed    


  503. BRAVACCINI S
    What impacts the cost-effectiveness of PD-L1 testing in non-small cell lung cancer?
    Lung Cancer. 2019 Mar 11. pii: S0169-5002(19)30355.
    PubMed     Abstract available


  504. UBERALL I, Gachechiladze M, Joerger M, Andel J, et al
    Tumor autophagy is associated with survival outcomes in patients with resected non-small cell lung cancer.
    Lung Cancer. 2019;129:85-91.
    PubMed     Abstract available


  505. MENDOZA DP, Dagogo-Jack I, Chen T, Padole A, et al
    Imaging characteristics of BRAF-mutant non-small cell lung cancer by functional class.
    Lung Cancer. 2019;129:80-84.
    PubMed     Abstract available


  506. HEILBRONER SP, Xanthopoulos EP, Buono D, Huang Y, et al
    Impact of estrogen monotherapy on survival in women with stage III-IV non-small cell lung cancer.
    Lung Cancer. 2019;129:8-15.
    PubMed     Abstract available


  507. TUNALI I, Gray JE, Qi J, Abdalah M, et al
    Novel clinical and radiomic predictors of rapid disease progression phenotypes among lung cancer patients treated with immunotherapy: An early report.
    Lung Cancer. 2019;129:75-79.
    PubMed     Abstract available


  508. ZHENG X, Zhang G, Li P, Zhang M, et al
    Mutation tracking of a patient with EGFR-mutant lung cancer harboring de novo MET amplification: Successful treatment with gefitinib and crizotinib.
    Lung Cancer. 2019;129:72-74.
    PubMed     Abstract available


  509. ANDRATSCHKE N, Kraft J, Nieder C, Tay R, et al
    Optimal management of brain metastases in oncogenic-driven non-small cell lung cancer (NSCLC).
    Lung Cancer. 2019;129:63-71.
    PubMed     Abstract available


  510. WATANABE S, Yoshioka H, Sakai H, Hotta K, et al
    Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: A phase 1b and randomized, open-label, multicenter, phase 2 trial in Japan.
    Lung Cancer. 2019;129:55-62.
    PubMed     Abstract available


  511. KOH YW, Lee SJ, Han JH, Haam S, et al
    PD-L1 protein expression in non-small-cell lung cancer and its relationship with the hypoxia-related signaling pathways: A study based on immunohistochemistry and RNA sequencing data.
    Lung Cancer. 2019;129:41-47.
    PubMed     Abstract available


  512. CRINO L, Bronte G, Bidoli P, Cravero P, et al
    Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer.
    Lung Cancer. 2019;129:35-40.
    PubMed     Abstract available


  513. GEMINE RE, Ghosal R, Collier G, Parry D, et al
    Longitudinal study to assess impact of smoking at diagnosis and quitting on 1-year survival for people with non-small cell lung cancer.
    Lung Cancer. 2019;129:1-7.
    PubMed     Abstract available


  514. LIU Y, Liu T, Li N, Wang T, et al
    Identification of a novel WNK1-ROS1 fusion in a lung adenocarcinoma sensitive to crizotinib.
    Lung Cancer. 2019;129:92-94.
    PubMed     Abstract available


  515. BO L, Li C, Pan L, Wang H, et al
    Diagnosing a solitary pulmonary nodule using multiple bronchoscopic guided technologies: A prospective randomized study.
    Lung Cancer. 2019;129:48-54.
    PubMed     Abstract available


  516. YANG B, Lee H, Um SW, Kim K, et al
    Incidence of brain metastasis in lung adenocarcinoma at initial diagnosis on the basis of stage and genetic alterations.
    Lung Cancer. 2019;129:28-34.
    PubMed     Abstract available


  517. THAI AA, Stuart E, Te Marvelde L, Milne RL, et al
    Hospital lung surgery volume and patient outcomes.
    Lung Cancer. 2019;129:22-27.
    PubMed     Abstract available


  518. ISHIDA H, Shimizu Y, Sakaguchi H, Nitanda H, et al
    Distinctive clinicopathological features of adenocarcinoma in situ and minimally invasive adenocarcinoma of the lung: A retrospective study.
    Lung Cancer. 2019;129:16-21.
    PubMed     Abstract available


  519. YAMASAKI M, Takenaka T, Matsumoto N, Asaoku H, et al
    Primary pulmonary collision tumor comprising squamous cell carcinoma and mucosa-associated lymphoid tissue lymphoma.
    Lung Cancer. 2019;129:107-109.
    PubMed    


    February 2019
  520. SHI JF, Wang L, Wu N, Li JL, et al
    Clinical characteristics and medical service utilization of lung cancer in China, 2005-2014: Overall design and results from a multicenter retrospective epidemiologic survey.
    Lung Cancer. 2019;128:91-100.
    PubMed     Abstract available


  521. HORN L, Bauml J, Forde PM, Davis KL, et al
    Real-world treatment patterns and survival of patients with BRAF V600-mutated metastatic non-small cell lung cancer.
    Lung Cancer. 2019;128:74-90.
    PubMed     Abstract available


  522. BRONSERUD MM, Iachina M, Green A, Groenvold M, et al
    Patient-reported outcomes (PROs) in lung cancer: Experiences from a nationwide feasibility study.
    Lung Cancer. 2019;128:67-73.
    PubMed     Abstract available


  523. YAN X, Wang H, Li P, Zhang G, et al
    Efficacy of first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) alone or in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC) with low-abundance mutation.
    Lung Cancer. 2019;128:6-12.
    PubMed     Abstract available


  524. NIEUWENHUIS L, van den Brandt PA
    Nut and peanut butter consumption and the risk of lung cancer and its subtypes: A prospective cohort study.
    Lung Cancer. 2019;128:57-66.
    PubMed     Abstract available


  525. HAMADA K, Irie M, Fujino Y, Hyodo M, et al
    Prognostic value of preoperative exercise capacity in patients undergoing thoracoscopic lobectomy for non-small cell lung cancer.
    Lung Cancer. 2019;128:47-52.
    PubMed     Abstract available


  526. ZAMARRON E, Prats E, Tejero E, Pardo P, et al
    Static lung hyperinflation is an independent risk factor for lung cancer in patients with chronic obstructive pulmonary disease.
    Lung Cancer. 2019;128:40-46.
    PubMed     Abstract available


  527. MIZUGAKI H, Hamada A, Shibata T, Hosoda F, et al
    Exploration of germline variants responsible for adverse events of crizotinib in anaplastic lymphoma kinase-positive non-small cell lung cancer by target-gene panel sequencing.
    Lung Cancer. 2019;128:20-25.
    PubMed     Abstract available


  528. SCHUCHERT MJ, Normolle DP, Awais O, Pennathur A, et al
    Factors influencing recurrence following anatomic lung resection for clinical stage I non-small cell lung cancer.
    Lung Cancer. 2019;128:145-151.
    PubMed     Abstract available


  529. CEDILLO JL, Bordas A, Arnalich F, Esteban-Rodriguez I, et al
    Anti-tumoral activity of the human-specific duplicated form of alpha7-nicotinic receptor subunit in tobacco-induced lung cancer progression.
    Lung Cancer. 2019;128:134-144.
    PubMed     Abstract available


  530. ABEL S, Hasan S, White R, Schumacher L, et al
    Stereotactic ablative radiotherapy (SABR) in early stage non-small cell lung cancer: Comparing survival outcomes in adenocarcinoma and squamous cell carcinoma.
    Lung Cancer. 2019;128:127-133.
    PubMed     Abstract available


  531. KOO HJ, Choi CM, Park S, Lee HN, et al
    Chest radiography surveillance for lung cancer: Results from a National Health Insurance database in South Korea.
    Lung Cancer. 2019;128:120-126.
    PubMed     Abstract available


  532. ITO K, Miura S, Sakaguchi T, Murotani K, et al
    The impact of high PD-L1 expression on the surrogate endpoints and clinical outcomes of anti-PD-1/PD-L1 antibodies in non-small cell lung cancer.
    Lung Cancer. 2019;128:113-119.
    PubMed     Abstract available


  533. GADGEEL SM, Lukas RV, Goldschmidt J, Conkling P, et al
    Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study.
    Lung Cancer. 2019;128:105-112.
    PubMed     Abstract available


  534. STEVENS C, Smith SG, Quaife SL, Vrinten C, et al
    Interest in lifestyle advice at lung cancer screening: Determinants and preferences.
    Lung Cancer. 2019;128:1-5.
    PubMed     Abstract available


  535. MAUCLET C, Duplaquet F, Pirard L, Rondelet B, et al
    Complete tumor response of a locally advanced lung large-cell neuroendocrine carcinoma after palliative thoracic radiotherapy and immunotherapy with nivolumab.
    Lung Cancer. 2019;128:53-56.
    PubMed     Abstract available


  536. ZHAO S, Li X, Zhao C, Jiang T, et al
    Loss of T790M mutation is associated with early progression to osimertinib in Chinese patients with advanced NSCLC who are harboring EGFR T790M.
    Lung Cancer. 2019;128:33-39.
    PubMed     Abstract available


  537. TAKADA K, Kohashi K, Shimokawa M, Haro A, et al
    Co-expression of IDO1 and PD-L1 in lung squamous cell carcinoma: Potential targets of novel combination therapy.
    Lung Cancer. 2019;128:26-32.
    PubMed     Abstract available


    January 2019
  538. HENDRIKS LEL, Dingemans AC
    Is it time to incorporate surgery in the treatment of stage IV non-small cell lung cancer?
    Lung Cancer. 2019 Jan 30. pii: S0169-5002(19)30297.
    PubMed    


  539. AULIAC JB, Perol M, Planchard D, Monnet I, et al
    Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation.
    Lung Cancer. 2019;127:96-102.
    PubMed     Abstract available


  540. YOON HS, Wen W, Long J, Zheng W, et al
    Association of oral health with lung cancer risk in a low-income population of African Americans and European Americans in the Southeastern United States.
    Lung Cancer. 2019;127:90-95.
    PubMed     Abstract available


  541. GU X, Zhang Q, Chu YB, Zhao YY, et al
    Cost-effectiveness of afatinib, gefitinib, erlotinib and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China.
    Lung Cancer. 2019;127:84-89.
    PubMed     Abstract available


  542. HAQUE W, Verma V, Butler EB, Teh BS, et al
    Post-treatment mortality after definitive chemoradiotherapy versus trimodality therapy for locally advanced non-small cell lung cancer.
    Lung Cancer. 2019;127:76-83.
    PubMed     Abstract available


  543. DOTSON T, Bellinger C, Su J, Hansen K, et al
    Feasibility of lung cancer RNA acquisition from a single transbronchial or transthoracic needle pass (FASTT trial).
    Lung Cancer. 2019;127:6-11.
    PubMed     Abstract available


  544. SAKAI H, Takeda M, Sakai K, Nakamura Y, et al
    Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non-small cell lung cancer negative for EGFR mutation and ALK fusion.
    Lung Cancer. 2019;127:59-65.
    PubMed     Abstract available


  545. COUTINHO AD, Shah M, Lunacsek OE, Eaddy M, et al
    Real-world treatment patterns and outcomes of patients with small cell lung cancer progressing after 2 lines of therapy.
    Lung Cancer. 2019;127:53-58.
    PubMed     Abstract available


  546. CHOUAID C, Bensimon L, Clay E, Millier A, et al
    Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France.
    Lung Cancer. 2019;127:44-52.
    PubMed     Abstract available


  547. THOMPSON JC, Fan R, Black T, Yu GH, et al
    Measurement and immunophenotyping of pleural fluid EpCAM-positive cells and clusters for the management of non-small cell lung cancer patients.
    Lung Cancer. 2019;127:25-33.
    PubMed     Abstract available


  548. YU Y, Ou Q, Wu X, Bao H, et al
    Concomitant resistance mechanisms to multiple tyrosine kinase inhibitors in ALK-positive non-small cell lung cancer.
    Lung Cancer. 2019;127:19-24.
    PubMed     Abstract available


  549. HASEGAWA H, Yasuda H, Hamamoto J, Masuzawa K, et al
    Efficacy of afatinib or osimertinib plus cetuximab combination therapy for non-small-cell lung cancer with EGFR exon 20 insertion mutations.
    Lung Cancer. 2019;127:146-152.
    PubMed     Abstract available


  550. MONSALVE AF, Hoag JR, Resio BJ, Chiu AS, et al
    Variable impact of prior cancer history on the survival of lung cancer patients.
    Lung Cancer. 2019;127:130-137.
    PubMed     Abstract available


  551. MURAWSKI M, Walter J, Schwarzkopf L
    Assessing the lung cancer comorbidome: An analysis of German claims data.
    Lung Cancer. 2019;127:122-129.
    PubMed     Abstract available


  552. PYO KH, Kim JH, Lee JM, Kim SE, et al
    Promising preclinical platform for evaluation of immuno-oncology drugs using Hu-PBL-NSG lung cancer models.
    Lung Cancer. 2019;127:112-121.
    PubMed     Abstract available


  553. WU YL, Zhao Q, Deng L, Zhang Y, et al
    Leptomeningeal metastasis after effective first-generation EGFR TKI treatment of advanced non-small cell lung cancer.
    Lung Cancer. 2019;127:1-5.
    PubMed     Abstract available


  554. SUH CH, Kim KW, Nishino M
    Reply to the comments on: Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients: Meta-analysis of incidence and risk factors of EGFR-TKI pneumonitis i
    Lung Cancer. 2019;127:168.
    PubMed    


  555. CHAPEL DB, Churg A, Santoni-Rugiu E, Tsujimura T, et al
    Molecular pathways and diagnosis in malignant mesothelioma: A review of the 14th International Conference of the International Mesothelioma Interest Group.
    Lung Cancer. 2019;127:69-75.
    PubMed     Abstract available


  556. PARK S, Han J, Sun JM
    Histologic transformation of ALK-rearranged adenocarcinoma to squamous cell carcinoma after treatment with ALK inhibitor.
    Lung Cancer. 2019;127:66-68.
    PubMed     Abstract available


  557. HSU KH, Huang YH, Tseng JS, Chen KC, et al
    High PD-L1 expression correlates with primary resistance to EGFR-TKIs in treatment naive advanced EGFR-mutant lung adenocarcinoma patients.
    Lung Cancer. 2019;127:37-43.
    PubMed     Abstract available


  558. ROMESSER PB, Bardash Y, Buonocore D, Chaft JE, et al
    Outcomes of Stage III NSCLC with occult primary vs. known primary lesions.
    Lung Cancer. 2019;127:34-36.
    PubMed     Abstract available


  559. MAZZASCHI G, Facchinetti F, Missale G, Canetti D, et al
    The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC.
    Lung Cancer. 2019;127:153-163.
    PubMed     Abstract available


  560. WU L, Dell'Anno I, Lapidot M, Sekido Y, et al
    Progress of malignant mesothelioma research in basic science: A review of the 14th international conference of the international mesothelioma interest group (iMig2018).
    Lung Cancer. 2019;127:138-145.
    PubMed     Abstract available


  561. ROCA E, Pozzari M, Vermi W, Tovazzi V, et al
    Outcome of EGFR-mutated adenocarcinoma NSCLC patients with changed phenotype to squamous cell carcinoma after tyrosine kinase inhibitors: A pooled analysis with an additional case.
    Lung Cancer. 2019;127:12-18.
    PubMed     Abstract available


  562. HALMOS B, Tan EH, Soo RA, Cadranel J, et al
    Impact of afatinib dose modification on safety and effectiveness in patients with EGFR mutation-positive advanced NSCLC: Results from a global real-world study (RealGiDo).
    Lung Cancer. 2019;127:103-111.
    PubMed     Abstract available


    December 2018
  563. LIN YT, Chu CY
    Osimertinib-induced Stevens-Johnson syndrome in a patient with EGFR T790M mutation-positive non-small cell lung cancer.
    Lung Cancer. 2018 Dec 31. pii: S0169-5002(18)30730.
    PubMed    


  564. ONO A, Isaka M, Serizawa M, Omae K, et al
    Genetic alterations of driver genes as independent prognostic factors for disease-free survival in patients with resected non-small cell lung cancer.
    Lung Cancer. 2018 Dec 5. pii: S0169-5002(18)30691.
    PubMed     Abstract available


  565. CAPIZZI E, Ricci C, Giunchi F, Zagnoni S, et al
    Validation of the immunohistochemical expression of programmed death ligand 1 (PD-L1) on cytological smears in advanced non small cell lung cancer.
    Lung Cancer. 2018;126:9-14.
    PubMed     Abstract available


  566. UNG MH, MacKenzie TA, Onega TL, Amos CI, et al
    Statins associate with improved mortality among patients with certain histological subtypes of lung cancer.
    Lung Cancer. 2018;126:89-96.
    PubMed     Abstract available


  567. KOGA T, Kobayashi Y, Tomizawa K, Suda K, et al
    Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: An in vitro study.
    Lung Cancer. 2018;126:72-79.
    PubMed     Abstract available


  568. MOREL H, Raynard B, d'Arlhac M, Hauss PA, et al
    Prediagnosis weight loss, a stronger factor than BMI, to predict survival in patients with lung cancer.
    Lung Cancer. 2018;126:55-63.
    PubMed     Abstract available


  569. HASHEMI SADRAEI N, Feng Y, Du L, Fu P, et al
    High UDG and BRCA1 expression is associated with adverse outcome in patients with pemetrexed treated non-small cell lung Cancer.
    Lung Cancer. 2018;126:48-54.
    PubMed     Abstract available


  570. IMAI H, Kaira K, Suzuki K, Anzai M, et al
    A phase II study of afatinib treatment for elderly patients with previously untreated advanced non-small-cell lung cancer harboring EGFR mutations.
    Lung Cancer. 2018;126:41-47.
    PubMed     Abstract available


  571. MEIJER TWH, Peeters WJM, Dubois LJ, van Gisbergen MW, et al
    Targeting glucose and glutamine metabolism combined with radiation therapy in non-small cell lung cancer.
    Lung Cancer. 2018;126:32-40.
    PubMed     Abstract available


  572. UDAGAWA H, Umemura S, Murakami I, Mimaki S, et al
    Genetic profiling-based prognostic prediction of patients with advanced small-cell lung cancer in large scale analysis.
    Lung Cancer. 2018;126:182-188.
    PubMed     Abstract available


  573. SCHWYZER M, Ferraro DA, Muehlematter UJ, Curioni-Fontecedro A, et al
    Automated detection of lung cancer at ultralow dose PET/CT by deep neural networks - Initial results.
    Lung Cancer. 2018;126:170-173.
    PubMed     Abstract available


  574. ANAI S, Iwama E, Yoneshima Y, Otsubo K, et al
    Association of nephrotoxicity during platinum-etoposide doublet therapy with UGT1A1 polymorphisms in small cell lung cancer patients.
    Lung Cancer. 2018;126:156-161.
    PubMed     Abstract available


  575. JOHN T, Akamatsu H, Delmonte A, Su WC, et al
    EGFR mutation analysis for prospective patient selection in AURA3 phase III trial of osimertinib versus platinum-pemetrexed in patients with EGFR T790M-positive advanced non-small-cell lung cancer.
    Lung Cancer. 2018;126:133-138.
    PubMed     Abstract available


  576. QUIST M, Sommer MS, Vibe-Petersen J, Staerkind MB, et al
    Early initiated postoperative rehabilitation reduces fatigue in patients with operable lung cancer: A randomized trial.
    Lung Cancer. 2018;126:125-132.
    PubMed     Abstract available


  577. HINDE S, Crilly T, Balata H, Bartlett R, et al
    The cost-effectiveness of the Manchester 'lung health checks', a community-based lung cancer low-dose CT screening pilot.
    Lung Cancer. 2018;126:119-124.
    PubMed     Abstract available


  578. NG TL, Morgan RL, Patil T, Baron AE, et al
    Detection of oligoprogressive disease in oncogene-addicted non-small cell lung cancer using PET/CT versus CT in patients receiving a tyrosine kinase inhibitor.
    Lung Cancer. 2018;126:112-118.
    PubMed     Abstract available


    November 2018
  579. SATO K, Akamatsu H, Murakami E, Sasaki S, et al
    Corrigendum to "Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab" [Lung Cancer 115 (2018) 71-74].
    Lung Cancer. 2018 Nov 17. pii: S0169-5002(18)30635.
    PubMed    


  580. TANAKA I, Morise M, Kodama Y, Matsui A, et al
    Potential for afatinib as an optimal treatment for advanced non-small cell lung carcinoma in patients with uncommon EGFR mutations.
    Lung Cancer. 2018 Nov 14. pii: S0169-5002(18)30645.
    PubMed    


  581. SUN Z, Sui X, Yang F, Wang J, et al
    Effects of primary tumor resection on the survival of patients with stage IV extrathoracic metastatic non-small cell lung cancer: A population-based study.
    Lung Cancer. 2018 Nov 13. pii: S0169-5002(18)30639.
    PubMed     Abstract available


  582. ZHAO B, Zhang W
    Reply to the comments on: Erlotinib in combination with bevacizumab has potential benefit in non small cell lung cancer: A systematic review and meta-analysis of randomized clinical trials.
    Lung Cancer. 2018 Nov 12. pii: S0169-5002(18)30638.
    PubMed    


  583. HANIBUCHI M, Kakiuchi S, Atagi S, Ogushi F, et al
    A multicenter, open-label, phase II trial of S-1 plus carboplatin in advanced non-small cell lung cancer patients with interstitial lung disease.
    Lung Cancer. 2018;125:93-99.
    PubMed     Abstract available


  584. LIU SY, Dong ZY, Wu SP, Xie Z, et al
    Clinical relevance of PD-L1 expression and CD8+ T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer.
    Lung Cancer. 2018;125:86-92.
    PubMed     Abstract available


  585. CHEN K, Yu X, Zhang F, Xu Y, et al
    Applicability of the lung-molGPA index in non-small cell lung cancer patients with different gene alterations and brain metastases.
    Lung Cancer. 2018;125:8-13.
    PubMed     Abstract available


  586. COSTA GJ, de Mello MJG, Ferreira CG, Bergmann A, et al
    Increased incidence, morbidity and mortality rates for lung cancer in women in Brazil between 2000 and 2014: An analysis of three types of sources of secondary data.
    Lung Cancer. 2018;125:77-85.
    PubMed     Abstract available


  587. LUO Q, Yu XQ, Wade S, Caruana M, et al
    Lung cancer mortality in Australia: Projected outcomes to 2040.
    Lung Cancer. 2018;125:68-76.
    PubMed     Abstract available


  588. CHECK DK, Albers KB, Uppal KM, Suga JM, et al
    Examining the role of access to care: Racial/ethnic differences in receipt of resection for early-stage non-small cell lung cancer among integrated system members and non-members.
    Lung Cancer. 2018;125:51-56.
    PubMed     Abstract available


  589. SOTIROPOULOS GP, Dalamaga M, Antonakos G, Marinou I, et al
    Chemerin as a biomarker at the intersection of inflammation, chemotaxis, coagulation, fibrinolysis and metabolism in resectable non-small cell lung cancer.
    Lung Cancer. 2018;125:291-299.
    PubMed     Abstract available


  590. BALATA H, Foden P, Edwards T, Chaturvedi A, et al
    Predicting survival following surgical resection of lung cancer using clinical and pathological variables: The development and validation of the LNC-PATH score.
    Lung Cancer. 2018;125:29-34.
    PubMed     Abstract available


  591. LIN MW, Su KY, Su TJ, Chang CC, et al
    Clinicopathological and genomic comparisons between different histologic components in combined small cell lung cancer and non-small cell lung cancer.
    Lung Cancer. 2018;125:282-290.
    PubMed     Abstract available


  592. GADGEEL SM, Stevenson JP, Langer CJ, Gandhi L, et al
    Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non-small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study.
    Lung Cancer. 2018;125:273-281.
    PubMed     Abstract available


  593. ISOBE K, Kaburaki K, Kobayashi H, Sano G, et al
    New risk scoring system for predicting acute exacerbation of interstitial pneumonia after chemotherapy for lung cancer associated with interstitial pneumonia.
    Lung Cancer. 2018;125:253-257.
    PubMed     Abstract available


  594. WANG S, Zhang B, Qian J, Qiao R, et al
    Proposal on incorporating lymphovascular invasion as a T-descriptor for stage I lung cancer.
    Lung Cancer. 2018;125:245-252.
    PubMed     Abstract available


  595. JEGOU D, Dubois C, Schillemans V, Stordeur S, et al
    Use of health insurance data to identify and quantify the prevalence of main comorbidities in lung cancer patients.
    Lung Cancer. 2018;125:238-244.
    PubMed     Abstract available


  596. SAITO T, Tsuta K, Ishida M, Ryota H, et al
    Comparative study of programmed cell death ligand-1 immunohistochemistry assays using 22C3 and 28-8 antibodies for non-small cell lung cancer: Analysis of 420 surgical specimens from Japanese patients.
    Lung Cancer. 2018;125:230-237.
    PubMed     Abstract available


  597. KORT S, Tiggeloven MM, Brusse-Keizer M, Gerritsen JW, et al
    Multi-centre prospective study on diagnosing subtypes of lung cancer by exhaled-breath analysis.
    Lung Cancer. 2018;125:223-229.
    PubMed     Abstract available


  598. JIA Y, Li X, Zhao C, Jiang T, et al
    Impact of serum vascular endothelial growth factor and interleukin-6 on treatment response to epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small-cell lung cancer.
    Lung Cancer. 2018;125:22-28.
    PubMed     Abstract available


  599. YAMAGUCHI T, Shimizu J, Hasegawa T, Horio Y, et al
    Pre-existing pulmonary fibrosis is a risk factor for anti-PD-1-related pneumonitis in patients with non-small cell lung cancer: A retrospective analysis.
    Lung Cancer. 2018;125:212-217.
    PubMed     Abstract available


  600. MALHOTRA J, Rotter D, Jabbour SK, Aisner J, et al
    Receipt of recommended surveillance with imaging in elderly survivors of early stage non-small cell lung cancer.
    Lung Cancer. 2018;125:205-211.
    PubMed     Abstract available


  601. YUTAKA Y, Sonobe M, Kawaguchi A, Hamaji M, et al
    Prognostic impact of preoperative comorbidities in geriatric patients with early-stage lung cancer: Significance of sublobar resection as a compromise procedure.
    Lung Cancer. 2018;125:192-197.
    PubMed     Abstract available


  602. KARLSSON T, Kvarnbrink S, Holmlund C, Botling J, et al
    LMO7 and LIMCH1 interact with LRIG proteins in lung cancer, with prognostic implications for early-stage disease.
    Lung Cancer. 2018;125:174-184.
    PubMed     Abstract available


  603. FROST N, Tessmer A, Schmittel A, van Laak V, et al
    Local ablative treatment for synchronous single organ oligometastatic lung cancer-A propensity score analysis of 180 patients.
    Lung Cancer. 2018;125:164-173.
    PubMed     Abstract available


  604. DJUREINOVIC D, Dodig-Crnkovic T, Hellstrom C, Holgersson G, et al
    Detection of autoantibodies against cancer-testis antigens in non-small cell lung cancer.
    Lung Cancer. 2018;125:157-163.
    PubMed     Abstract available


  605. CHO JY, Kim J, Lee JS, Kim YJ, et al
    Characteristics, incidence, and risk factors of immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer.
    Lung Cancer. 2018;125:150-156.
    PubMed     Abstract available


  606. KAWANO Y, Sasaki T, Yamaguchi H, Hirano K, et al
    Phase I/II study of carboplatin plus nab-paclitaxel and concurrent radiotherapy for patients with locally advanced non-small cell lung cancer.
    Lung Cancer. 2018;125:136-141.
    PubMed     Abstract available


  607. DEJIMA H, Nakanishi H, Kuroda H, Yoshimura M, et al
    Detection of abundant megakaryocytes in pulmonary artery blood in lung cancer patients using a microfluidic platform.
    Lung Cancer. 2018;125:128-135.
    PubMed     Abstract available


  608. MOFFAT J, Hiom S, Kumar HS, Baldwin DR, et al
    Lung cancer screening - gaining consensus on next steps - proceedings of a closed workshop in the UK.
    Lung Cancer. 2018;125:121-127.
    PubMed     Abstract available


  609. REN S, Tian Q, Amar N, Yu H, et al
    The immune checkpoint, HVEM may contribute to immune escape in non-small cell lung cancer lacking PD-L1 expression.
    Lung Cancer. 2018;125:115-120.
    PubMed     Abstract available


  610. WALTER JE, Heuvelmans MA, de Bock GH, Yousaf-Khan U, et al
    Relationship between the number of new nodules and lung cancer probability in incidence screening rounds of CT lung cancer screening: The NELSON study.
    Lung Cancer. 2018;125:103-108.
    PubMed     Abstract available


  611. EZEIFE DA, Kirk V, Chew DS, Nixon NA, et al
    Economic analysis of osimertinib in previously untreated EGFR-mutant advanced non-small cell lung cancer in Canada.
    Lung Cancer. 2018;125:1-7.
    PubMed     Abstract available


    October 2018
  612. LUCCHESI C, Drogat B, Santamaria D, Cousin S, et al
    Molecular determinants of acquired resistance to BRAF inhibition in human lung cancer.
    Lung Cancer. 2018 Oct 12. pii: S0169-5002(18)30597.
    PubMed    


  613. ILIE M, Beaulande M, Hamila M, Erb G, et al
    Automated chromogenic multiplexed immunohistochemistry assay for diagnosis and predictive biomarker testing in non-small cell lung cancer.
    Lung Cancer. 2018;124:90-94.
    PubMed     Abstract available


  614. HARRIS JP, Nwachukwu C, Qian Y, Pollom E, et al
    Invasive nodal evaluation prior to stereotactic ablative radiation for non-small cell lung cancer.
    Lung Cancer. 2018;124:76-85.
    PubMed     Abstract available


  615. UCHIBORI K, Satouchi M, Sueoka-Aragane N, Urata Y, et al
    Phase II trial of gefitinib plus pemetrexed after relapse using first-line gefitinib in patients with non-small cell lung cancer harboring EGFR gene mutations.
    Lung Cancer. 2018;124:65-70.
    PubMed     Abstract available


  616. DE JONG EEC, van Elmpt W, Rizzo S, Colarieti A, et al
    Applicability of a prognostic CT-based radiomic signature model trained on stage I-III non-small cell lung cancer in stage IV non-small cell lung cancer.
    Lung Cancer. 2018;124:6-11.
    PubMed     Abstract available


  617. FERRER I, Zugazagoitia J, Herbertz S, John W, et al
    KRAS-Mutant non-small cell lung cancer: From biology to therapy.
    Lung Cancer. 2018;124:53-64.
    PubMed     Abstract available


  618. CHRISTENSEN NL, Lokke A, Dalton SO, Christensen J, et al
    Smoking, alcohol, and nutritional status in relation to one-year mortality in Danish stage I lung cancer patients.
    Lung Cancer. 2018;124:40-44.
    PubMed     Abstract available


  619. BIRCAN HA, Gurbuz N, Pataer A, Caner A, et al
    Elongation factor-2 kinase (eEF-2K) expression is associated with poor patient survival and promotes proliferation, invasion and tumor growth of lung cancer.
    Lung Cancer. 2018;124:31-39.
    PubMed     Abstract available


  620. LIM SW, Park S, Kim Y, Cho JH, et al
    Continuation of gefitinib beyond progression in patients with EGFR mutation-positive non-small-cell lung cancer: A phase II single-arm trial.
    Lung Cancer. 2018;124:293-297.
    PubMed     Abstract available


  621. HASAN S, Renz P, Turrisi A, Colonias A, et al
    Dose escalation and associated predictors of survival with consolidative thoracic radiotherapy in extensive stage small cell lung cancer (SCLC): A National Cancer Database (NCDB) propensity-matched analysis.
    Lung Cancer. 2018;124:283-290.
    PubMed     Abstract available


  622. MESSARITAKIS I, Nikolaou M, Politaki E, Koinis F, et al
    Bcl-2 expression in circulating tumor cells (CTCs) of patients with small cell lung cancer (SCLC) receiving front-line treatment.
    Lung Cancer. 2018;124:270-278.
    PubMed     Abstract available


  623. OKAMOTO T, Yano T, Shimokawa M, Takeo S, et al
    A phase II randomized trial of adjuvant chemotherapy with S-1 versus S-1 plus cisplatin for completely resected pathological stage II/IIIA non-small cell lung cancer.
    Lung Cancer. 2018;124:255-259.
    PubMed     Abstract available


  624. GEORGIEVA M, da Silveira Nogueira Lima JP, Aguiar P Jr, de Lima Lopes G Jr, et al
    Cost-effectiveness of pembrolizumab as first-line therapy for advanced non-small cell lung cancer.
    Lung Cancer. 2018;124:248-254.
    PubMed     Abstract available


  625. HASHIMOTO T, Osoegawa A, Takumi Y, Abe M, et al
    Intratumoral heterogeneity of copy number variation in lung cancer harboring L858R via immunohistochemical heterogeneous staining.
    Lung Cancer. 2018;124:241-247.
    PubMed     Abstract available


  626. JAINE R, Kvizhinadze G, Nair N, Blakely T, et al
    Cost-effectiveness of a low-dose computed tomography screening programme for lung cancer in New Zealand.
    Lung Cancer. 2018;124:233-240.
    PubMed     Abstract available


  627. NAJJAR F, Alammar M, Al-Massarani G, Almalla N, et al
    Circulating endothelial cells and microparticles as diagnostic and prognostic biomarkers in small-cell lung cancer.
    Lung Cancer. 2018;124:23-30.
    PubMed     Abstract available


  628. HSIEH MS, Lee YH, Lin MW, Chen JS, et al
    Solitary pulmonary capillary hemangioma: An under-recognized pulmonary lesion mimicking early lung cancer on computed tomography images.
    Lung Cancer. 2018;124:227-232.
    PubMed     Abstract available


  629. MERINO LARA T, Helou J, Poon I, Sahgal A, et al
    Multisite stereotactic body radiotherapy for metastatic non-small-cell lung cancer: Delaying the need to start or change systemic therapy?
    Lung Cancer. 2018;124:219-226.
    PubMed     Abstract available


  630. STONE E, Rankin N, Kerr S, Fong K, et al
    Does presentation at multidisciplinary team meetings improve lung cancer survival? Findings from a consecutive cohort study.
    Lung Cancer. 2018;124:199-204.
    PubMed     Abstract available


  631. HOFER F, Kauczor HU, Stargardt T
    Cost-utility analysis of a potential lung cancer screening program for a high-risk population in Germany: A modelling approach.
    Lung Cancer. 2018;124:189-198.
    PubMed     Abstract available


  632. SEKINE K, Kanda S, Goto Y, Horinouchi H, et al
    Change in the lymphocyte-to-monocyte ratio is an early surrogate marker of the efficacy of nivolumab monotherapy in advanced non-small-cell lung cancer.
    Lung Cancer. 2018;124:179-188.
    PubMed     Abstract available


  633. KANG HN, Choi JW, Shim HS, Kim J, et al
    Establishment of a platform of non-small-cell lung cancer patient-derived xenografts with clinical and genomic annotation.
    Lung Cancer. 2018;124:168-178.
    PubMed     Abstract available


  634. CLARK ME, Bedford LE, Young B, Robertson JFR, et al
    Lung cancer CT screening: Psychological responses in the presence and absence of pulmonary nodules.
    Lung Cancer. 2018;124:160-167.
    PubMed     Abstract available


  635. SIM WC, Loh CH, Toh GL, Lim CW, et al
    Non-invasive detection of actionable mutations in advanced non-small-cell lung cancer using targeted sequencing of circulating tumor DNA.
    Lung Cancer. 2018;124:154-159.
    PubMed     Abstract available


  636. BALATA H, Blandin Knight S, Barber P, Colligan D, et al
    Targeted lung cancer screening selects individuals at high risk of cardiovascular disease.
    Lung Cancer. 2018;124:148-153.
    PubMed     Abstract available


  637. LAFITTE C, Etienne-Mastroianni B, Fournel C, Natoli L, et al
    Implementation of optimized supportive care and hospital needs along the management of patients with advanced lung cancer.
    Lung Cancer. 2018;124:143-147.
    PubMed     Abstract available


  638. YAN SX, Qureshi MM, Suzuki K, Dyer M, et al
    Definitive treatment patterns and survival in stage II non-small cell lung cancer.
    Lung Cancer. 2018;124:135-142.
    PubMed     Abstract available


  639. DUDNIK E, Bshara E, Grubstein A, Fridel L, et al
    Rare targetable drivers (RTDs) in non-small cell lung cancer (NSCLC): Outcomes with immune check-point inhibitors (ICPi).
    Lung Cancer. 2018;124:117-124.
    PubMed     Abstract available


  640. GRANGER CL, Irving L, Antippa P, Edbrooke L, et al
    CAPACITY: A physical activity self-management program for patients undergoing surgery for lung cancer, a phase I feasibility study.
    Lung Cancer. 2018;124:102-109.
    PubMed     Abstract available


  641. MATYS T, Drury R, David S, Rassl DM, et al
    Corrigendum to "Routine preoperative brain CT in resectable non-small cell lung cancer-Ten years experience from a tertiary UK thoracic center" [Lung Cancer 122 (August) (2018) 195-199].
    Lung Cancer. 2018 Oct 1. pii: S0169-5002(18)30575.
    PubMed    


    September 2018
  642. XU R, Zhu J
    Comment on: Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients: Meta-analysis of incidence and risk factors of EGFR-TKI pneumonitis in NSCLC.
    Lung Cancer. 2018 Sep 24. pii: S0169-5002(18)30577.
    PubMed    


  643. XU R, Zhu J
    Comment on: Erlotinib in combination with bevacizumab has potential benefit in non small cell lung cancer: A systematic review and meta-analysis of randomized clinical trials.
    Lung Cancer. 2018 Sep 7. pii: S0169-5002(18)30559.
    PubMed    


  644. GARON EB, Siegfried JM, Stabile LP, Young PA, et al
    Randomized phase II study of fulvestrant and erlotinib compared with erlotinib alone in patients with advanced or metastatic non-small cell lung cancer.
    Lung Cancer. 2018;123:91-98.
    PubMed     Abstract available


  645. SCILLA KA, Zandberg DP, Bentzen SM, Mainor C, et al
    Case-control study of PD-1, PD-L1 and B7-H3 expression in lung cancer patients with and without human immunodeficiency virus (HIV) infection.
    Lung Cancer. 2018;123:87-90.
    PubMed     Abstract available


  646. VUONG HG, Ho ATN, Altibi AMA, Nakazawa T, et al
    Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer - A systematic review and meta-analysis.
    Lung Cancer. 2018;123:76-82.
    PubMed     Abstract available


  647. JIAO XD, Qin BD, You P, Cai J, et al
    The prognostic value of TP53 and its correlation with EGFR mutation in advanced non-small cell lung cancer, an analysis based on cBioPortal data base.
    Lung Cancer. 2018;123:70-75.
    PubMed     Abstract available


  648. SONG Y, Zhou Q, Zhang X, Chen GY, et al
    Factors associated with gene aberration test status and treatment decision in patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer: A multicenter survey in China (CTONG 1506).
    Lung Cancer. 2018;123:7-13.
    PubMed     Abstract available


  649. SUH CH, Park HS, Kim KW, Pyo J, et al
    Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients: Meta-analysis of incidence and risk factors of EGFR-TKI pneumonitis in NSCLC.
    Lung Cancer. 2018;123:60-69.
    PubMed     Abstract available


  650. LU S, Kong H, Hou Y, Ge D, et al
    Two plasma microRNA panels for diagnosis and subtype discrimination of lung cancer.
    Lung Cancer. 2018;123:44-51.
    PubMed     Abstract available


  651. LIU F, Liu Y, Liu X, Mao K, et al
    Inhibition of IGF1R enhances 2-deoxyglucose in the treatment of non-small cell lung cancer.
    Lung Cancer. 2018;123:36-43.
    PubMed     Abstract available


  652. TAIRA N, Atsumi E, Nakachi S, Takamatsu R, et al
    Comparison of GLUT-1, SGLT-1, and SGLT-2 expression in false-negative and true-positive lymph nodes during the (18)F-FDG PET/CT mediastinal nodal staging of non-small cell lung cancer.
    Lung Cancer. 2018;123:30-35.
    PubMed     Abstract available


  653. JAO K, Tomasini P, Kamel-Reid S, Korpanty GJ, et al
    The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer.
    Lung Cancer. 2018;123:22-29.
    PubMed     Abstract available


  654. HU X, Hay JW
    First-line pembrolizumab in PD-L1 positive non-small-cell lung cancer: A cost-effectiveness analysis from the UK health care perspective.
    Lung Cancer. 2018;123:166-171.
    PubMed     Abstract available


  655. STEWART I, Khakwani A, Hubbard RB, Beckett P, et al
    Are working practices of lung cancer nurse specialists associated with variation in peoples' receipt of anticancer therapy?
    Lung Cancer. 2018;123:160-165.
    PubMed     Abstract available


  656. CARDINALE D, Cosentino N, Moltrasio M, Sandri MT, et al
    Acute kidney injury after lung cancer surgery: Incidence and clinical relevance, predictors, and role of N-terminal pro B-type natriuretic peptide.
    Lung Cancer. 2018;123:155-159.
    PubMed     Abstract available


  657. POMPILI C, Koller M, Velikova G, Franks K, et al
    EORTC QLQ-C30 summary score reliably detects changes in QoL three months after anatomic lung resection for Non-Small Cell Lung Cancer (NSCLC).
    Lung Cancer. 2018;123:149-154.
    PubMed     Abstract available


  658. CHO BC, Dy GK, Govindan R, Kim DW, et al
    Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancer.
    Lung Cancer. 2018;123:14-21.
    PubMed     Abstract available


  659. FINKLE JH, Penney BC, Pu Y
    An updated and validated PET/CT volumetric prognostic index for non-small cell lung cancer.
    Lung Cancer. 2018;123:136-141.
    PubMed     Abstract available


  660. LI Z, Maeda D, Yoshida M, Umakoshi M, et al
    The intratumoral distribution influences the prognostic impact of CD68- and CD204-positive macrophages in non-small cell lung cancer.
    Lung Cancer. 2018;123:127-135.
    PubMed     Abstract available


  661. KOUL R, Rathod S, Dubey A, Bashir B, et al
    Comparison of 7th and 8th editions of the UICC/AJCC TNM staging for non-small cell lung cancer in a non-metastatic North American cohort undergoing primary radiation treatment.
    Lung Cancer. 2018;123:116-120.
    PubMed     Abstract available


  662. DE JONG EEC, Hendriks LEL, van Elmpt W, Gietema HA, et al
    What you see is (not) what you get: tools for a non-radiologist to evaluate image quality in lung cancer.
    Lung Cancer. 2018;123:112-115.
    PubMed     Abstract available


  663. HASHIMOTO K, Daddi N, Giuliani M, Hope A, et al
    The role of endobronchial ultrasound-guided transbronchial needle aspiration in stereotactic body radiation therapy for non-small cell lung cancer.
    Lung Cancer. 2018;123:1-6.
    PubMed     Abstract available


    August 2018
  664. DICKHOFF C, Dahele M
    In Regard to Robinson et al: Induction chemoradiotherapy versus chemotherapy alone for superior sulcus lung cancer.
    Lung Cancer. 2018 Aug 16. pii: S0169-5002(18)30527.
    PubMed    


  665. CHOUAID C, Danson S, Andreas S, Siakpere O, et al
    Adjuvant treatment patterns and outcomes in patients with stage IB-IIIA non-small cell lung cancer in France, Germany, and the United Kingdom based on the LuCaBIS burden of illness study.
    Lung Cancer. 2018 Aug 10. pii: S0169-5002(18)30503.
    PubMed     Abstract available


  666. LEE YG, Lee JH, Kim SH, Kim YJ, et al
    Comparative analysis between combination and single-agent chemotherapy for elderly patients with advanced non-small cell lung cancer: A nationwide population-based outcome study.
    Lung Cancer. 2018;122:88-93.
    PubMed     Abstract available


  667. HO JC, Leung CC
    Management of co-existent tuberculosis and lung cancer.
    Lung Cancer. 2018;122:83-87.
    PubMed     Abstract available


  668. GUIBERT N, Tsukada H, Hwang DH, Chambers E, et al
    Liquid biopsy of fine-needle aspiration supernatant for lung cancer genotyping.
    Lung Cancer. 2018;122:72-75.
    PubMed     Abstract available


  669. CHAFT JE, Dagogo-Jack I, Santini FC, Eng J, et al
    Clinical outcomes of patients with resected, early-stage ALK-positive lung cancer.
    Lung Cancer. 2018;122:67-71.
    PubMed     Abstract available


  670. DENG W, Xu T, Wang Y, Xu Y, et al
    Log odds of positive lymph nodes may predict survival benefit in patients with node-positive non-small cell lung cancer.
    Lung Cancer. 2018;122:60-66.
    PubMed     Abstract available


  671. OSUOHA CA, Callahan KE, Ponce CP, Pinheiro PS, et al
    Disparities in lung cancer survival and receipt of surgical treatment.
    Lung Cancer. 2018;122:54-59.
    PubMed     Abstract available


  672. SI X, Zhang L, Wang H, Zhang X, et al
    Quality of life results from a randomized, double-blinded, placebo-controlled, multi-center phase III trial of anlotinib in patients with advanced non-small cell lung cancer.
    Lung Cancer. 2018;122:32-37.
    PubMed     Abstract available


  673. TRIPHURIDET N, Vidhyarkorn S, Worakitsitisatorn A, Sricharunrat T, et al
    Screening values of carcinoembryonic antigen and cytokeratin 19 fragment for lung cancer in combination with low-dose computed tomography in high-risk populations: Initial and 2-year screening outcomes.
    Lung Cancer. 2018;122:243-248.
    PubMed     Abstract available


  674. LEE JS, Lee KH, Cho EK, Kim DW, et al
    Nivolumab in advanced non-small-cell lung cancer patients who failed prior platinum-based chemotherapy.
    Lung Cancer. 2018;122:234-242.
    PubMed     Abstract available


  675. ZAHEDI A, Phandthong R, Chaili A, Remark G, et al
    Epithelial-to-mesenchymal transition of A549 lung cancer cells exposed to electronic cigarettes.
    Lung Cancer. 2018;122:224-233.
    PubMed     Abstract available


  676. AHMED T, Vial MR, Ost D, Stewart J, et al
    Non-small cell lung cancer transdifferentiation into small cell lung cancer: A case series.
    Lung Cancer. 2018;122:220-223.
    PubMed     Abstract available


  677. TAKAHASHI N, Tsuji K, Tamiya H, Shinohara T, et al
    Goodpasture's disease in a patient with advanced lung cancer treated with nivolumab: An autopsy case report.
    Lung Cancer. 2018;122:22-24.
    PubMed     Abstract available


  678. GOYAL G, Kommalapati A, Bartley AC, Gunderson TM, et al
    Association between hospital volume and mortality of patients with metastatic non-small cell lung cancer.
    Lung Cancer. 2018;122:214-219.
    PubMed     Abstract available


  679. ROBINSON LA, Tanvetyanon T, Grubbs D, Antonia S, et al
    Induction chemoradiotherapy versus chemotherapy alone for superior sulcus lung cancer.
    Lung Cancer. 2018;122:206-213.
    PubMed     Abstract available


  680. IZUMI H, Yamasaki A, Takeda K, Kodani M, et al
    Acute-phase reaction induced by zoledronate and its effect on prognosis of patients with advanced non-small cell lung cancer.
    Lung Cancer. 2018;122:200-205.
    PubMed     Abstract available


  681. MATYS T, Drury R, David S, Rassl DM, et al
    Routine preoperative brain CT in resectable non-small cell lung cancer - Ten years experience from a tertiary UK thoracic center.
    Lung Cancer. 2018;122:195-199.
    PubMed     Abstract available


  682. YAP S, Goldsbury D, Yap ML, Yuill S, et al
    Patterns of care and emergency presentations for people with non-small cell lung cancer in New South Wales, Australia: A population-based study.
    Lung Cancer. 2018;122:171-179.
    PubMed     Abstract available


  683. BRUSTUGUN OT, Gronberg BH, Fjellbirkeland L, Helbekkmo N, et al
    Substantial nation-wide improvement in lung cancer relative survival in Norway from 2000 to 2016.
    Lung Cancer. 2018;122:138-145.
    PubMed     Abstract available


  684. MILLARES L, Barreiro E, Cortes R, Martinez-Romero A, et al
    Tumor-associated metabolic and inflammatory responses in early stage non-small cell lung cancer: Local patterns and prognostic significance.
    Lung Cancer. 2018;122:124-130.
    PubMed     Abstract available


  685. INOUE T, Katoh N, Ito YM, Kimura T, et al
    Stereotactic body radiotherapy to treat small lung lesions clinically diagnosed as primary lung cancer by radiological examination: A prospective observational study.
    Lung Cancer. 2018;122:107-112.
    PubMed     Abstract available


  686. SEBASTIAN M, Ryden A, Walding A, Papadimitrakopoulou V, et al
    Patient-reported symptoms possibly related to treatment with osimertinib or chemotherapy for advanced non-small cell lung cancer.
    Lung Cancer. 2018;122:100-106.
    PubMed     Abstract available


  687. ZHAO B, Zhang W, Yu D, Xu J, et al
    Erlotinib in combination with bevacizumab has potential benefit in non-small cell lung cancer: A systematic review and meta-analysis of randomized clinical trials.
    Lung Cancer. 2018;122:10-21.
    PubMed     Abstract available


  688. WANG H, Zhang L, Hu P, Zheng X, et al
    Penetration of the blood-brain barrier by avitinib and its control of intra/extra-cranial disease in non-small cell lung cancer harboring the T790M mutation.
    Lung Cancer. 2018;122:1-6.
    PubMed     Abstract available


    July 2018
  689. TENDLER S, Grozman V, Lewensohn R, Tsakonas G, et al
    Corrigendum to "Validation of the 8th TNM classification for small-cell lung cancer in a retrospective material from Sweden" [Lung Cancer 120 (June) (2018) 75-81].
    Lung Cancer. 2018 Jul 13. pii: S0169-5002(18)30468.
    PubMed    


  690. VERONESI G, Zulueta JJ, Maisonneuve P, Henschke C, et al
    At last we can go ahead with low-dose CT screening for lung cancer in Europe.
    Lung Cancer. 2018 Jul 10. pii: S0169-5002(18)30470.
    PubMed    


  691. KUIJPERS CCHJ, Hendriks LEL, Derks JL, Dingemans AC, et al
    Association of molecular status and metastatic organs at diagnosis in patients with stage IV non-squamous non-small cell lung cancer.
    Lung Cancer. 2018;121:76-81.
    PubMed     Abstract available


  692. TOMONAGA Y, Ten Haaf K, Frauenfelder T, Kohler M, et al
    Cost-effectiveness of low-dose CT screening for lung cancer in a European country with high prevalence of smoking-A modelling study.
    Lung Cancer. 2018;121:61-69.
    PubMed     Abstract available


  693. XIE F, Zhang Y, Mao X, Zheng X, et al
    Comparison of genetic profiles among primary lung tumor, metastatic lymph nodes and circulating tumor DNA in treatment-naive advanced non-squamous non-small cell lung cancer patients.
    Lung Cancer. 2018;121:54-60.
    PubMed     Abstract available


  694. NIE K, Zhang Z, Zhang C, Geng C, et al
    Osimertinib compared docetaxel-bevacizumab as third-line treatment in EGFR T790M mutated non-small-cell lung cancer.
    Lung Cancer. 2018;121:5-11.
    PubMed     Abstract available


  695. KOBAYASHI H, Naito T, Omae K, Omori S, et al
    ILD-NSCLC-GAP index scoring and staging system for patients with non-small cell lung cancer and interstitial lung disease.
    Lung Cancer. 2018;121:48-53.
    PubMed     Abstract available


  696. NISHIO M, Nakagawa K, Mitsudomi T, Yamamoto N, et al
    Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer.
    Lung Cancer. 2018;121:37-40.
    PubMed     Abstract available


  697. TOPKAN E, Selek U, Ozdemir Y, Yildirim BA, et al
    Chemoradiotherapy-induced hemoglobin nadir values and survival in patients with stage III non-small cell lung cancer.
    Lung Cancer. 2018;121:30-36.
    PubMed     Abstract available


  698. YANG M, Tong X, Xu X, Zheng E, et al
    Case Report: Osimertinib achieved remarkable and sustained disease control in an advanced non-small-cell lung cancer harboring EGFR H773L/V774M mutation complex.
    Lung Cancer. 2018;121:1-4.
    PubMed     Abstract available


    June 2018
  699. ANDREAS S, Chouaid C, Danson S, Siakpere O, et al
    Economic burden of resected (stage IB-IIIA) non-small cell lung cancer in France, Germany and the United Kingdom: A retrospective observational study (LuCaBIS).
    Lung Cancer. 2018 Jun 9. pii: S0169-5002(18)30416.
    PubMed     Abstract available


  700. KIMURA S, Harada T, Ijichi K, Tanaka K, et al
    Expression of brain-derived neurotrophic factor and its receptor TrkB is associated with poor prognosis and a malignant phenotype in small cell lung cancer.
    Lung Cancer. 2018;120:98-107.
    PubMed     Abstract available


  701. LIMWATTANANON C, Limwattananon S, Waleekhachonloet O, Rattanachotphanit T, et al
    Cost-effectiveness analysis of policy options on first-line treatments for advanced, non-small cell lung cancer in Thailand.
    Lung Cancer. 2018;120:91-97.
    PubMed     Abstract available


  702. ROBIN TP, Jones BL, Amini A, Koshy M, et al
    Radiosurgery alone is associated with favorable outcomes for brain metastases from small-cell lung cancer.
    Lung Cancer. 2018;120:88-90.
    PubMed     Abstract available


  703. TENDLER S, Grozman V, Lewensohn R, Tsakonas G, et al
    Validation of the 8th TNM classification for small-cell lung cancer in a retrospective material from Sweden.
    Lung Cancer. 2018;120:75-81.
    PubMed     Abstract available


  704. RECK M, Garassino MC, Imbimbo M, Shepherd FA, et al
    Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line setting.
    Lung Cancer. 2018;120:62-69.
    PubMed     Abstract available


  705. LEE CC, Zheng H, Soon YY, Foo LL, et al
    Association between radiation heart dosimetric parameters, myocardial infarct and overall survival in stage 3 non-small cell lung cancer treated with definitive thoracic radiotherapy.
    Lung Cancer. 2018;120:54-59.
    PubMed     Abstract available


  706. FORSTER M, Hackshaw A, De Pas T, Cobo M, et al
    A phase I study of nintedanib combined with cisplatin/gemcitabine as first-line therapy for advanced squamous non-small cell lung cancer (LUME-Lung 3).
    Lung Cancer. 2018;120:27-33.
    PubMed     Abstract available


  707. BRADBURY PA, Morris DG, Nicholas G, Tu D, et al
    Canadian Cancer Trials Group (CCTG) IND211: A randomized trial of pelareorep (Reolysin) in patients with previously treated advanced or metastatic non-small cell lung cancer receiving standard salvage therapy.
    Lung Cancer. 2018;120:142-148.
    PubMed     Abstract available


  708. MAYMANI H, Hess K, Groisberg R, Hong DS, et al
    Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials.
    Lung Cancer. 2018;120:137-141.
    PubMed     Abstract available


  709. DU M, Thompson J, Fisher H, Zhang P, et al
    Genomic alterations of plasma cell-free DNAs in small cell lung cancer and their clinical relevance.
    Lung Cancer. 2018;120:113-121.
    PubMed     Abstract available


  710. GUIBERT N, Delaunay M, Lusque A, Boubekeur N, et al
    PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab.
    Lung Cancer. 2018;120:108-112.
    PubMed     Abstract available


  711. REITER MJ, Nemesure A, Madu E, Reagan L, et al
    Frequency and distribution of incidental findings deemed appropriate for S modifier designation on low-dose CT in a lung cancer screening program.
    Lung Cancer. 2018;120:1-6.
    PubMed     Abstract available


    May 2018
  712. BRAILLON A
    Second-line therapy and advanced non-small cell lung cancer: What about smoking?
    Lung Cancer. 2018 May 21. pii: S0169-5002(18)30382.
    PubMed    


  713. HSIEH FS, Hung MH, Wang CY, Chen YL, et al
    Corrigendum to "Inhibition of protein phosphatase 5 suppresses non-small cell lung cancer through AMP-activated kinase activation" [Lung Cancer 112 (October) (2017) 81-89].
    Lung Cancer. 2018 May 3. pii: S0169-5002(18)30350.
    PubMed    


  714. D'SILVA A, Gardiner PA, Boyle T, Bebb DG, et al
    Associations of objectively assessed physical activity and sedentary time with health-related quality of life among lung cancer survivors: A quantile regression approach.
    Lung Cancer. 2018;119:78-84.
    PubMed     Abstract available


  715. RAEZ LE, Cardona AF, Santos ES, Catoe H, et al
    The burden of lung cancer in Latin-America and challenges in the access to genomic profiling, immunotherapy and targeted treatments.
    Lung Cancer. 2018;119:7-13.
    PubMed     Abstract available


  716. YANG SM, Chen LW, Wang HJ, Chen LR, et al
    Extraction of radiomic values from lung adenocarcinoma with near-pure subtypes in the International Association for the Study of Lung Cancer/the American Thoracic Society/the European Respiratory Society (IASLC/ATS/ERS) classification.
    Lung Cancer. 2018;119:56-63.
    PubMed     Abstract available


  717. CHRISTOPOULOS P, Schneider MA, Bozorgmehr F, Kuon J, et al
    Large cell neuroendocrine lung carcinoma induces peripheral T-cell repertoire alterations with predictive and prognostic significance.
    Lung Cancer. 2018;119:48-55.
    PubMed     Abstract available


  718. MODING EJ, Diehn M, Wakelee HA
    Circulating tumor DNA testing in advanced non-small cell lung cancer.
    Lung Cancer. 2018;119:42-47.
    PubMed     Abstract available


  719. FUJIMOTO D, Yoshioka H, Kataoka Y, Morimoto T, et al
    Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: A multicenter retrospective cohort study.
    Lung Cancer. 2018;119:14-20.
    PubMed     Abstract available


  720. BORGHAEI H, Yim YM, Guerin A, Pivneva I, et al
    Severe adverse events impact overall survival and costs in elderly patients with advanced non-small cell lung cancer on second-line therapy.
    Lung Cancer. 2018;119:112-119.
    PubMed     Abstract available


  721. BURUDPAKDEE C, Wong W, Seetasith A, Corvino FA, et al
    Economic impact of preventing brain metastases with alectinib in ALK-positive non-small cell lung cancer.
    Lung Cancer. 2018;119:103-111.
    PubMed     Abstract available


  722. KANG YK, Song YS, Cho S, Jheon S, et al
    Prognostic stratification model for patients with stage I non-small cell lung cancer adenocarcinoma treated with surgical resection without adjuvant therapies using metabolic features measured on F-18 FDG PET and postoperative pathologic factors.
    Lung Cancer. 2018;119:1-6.
    PubMed     Abstract available


    April 2018
  723. TSAO MS, Yoon JY
    The eighth TNM classification for lung cancer-What is next?
    Lung Cancer. 2018 Apr 25. pii: S0169-5002(18)30346.
    PubMed    


  724. YEN CC, Su HC, Chu CY, Lai SJ, et al
    Excellent treatment response with pembrolizumab in a lung cancer patient who developed immune-mediated acute motor/sensory axonal polyneuropathy.
    Lung Cancer. 2018 Apr 17. pii: S0169-5002(18)30342.
    PubMed    


  725. LIAO WY, Ho CC, Tsai TH, Chen KY, et al
    Combined effect of ERCC1 and ERCC2 polymorphisms on overall survival in non-squamous non-small-cell lung cancer patients treated with first-line pemetrexed/platinum.
    Lung Cancer. 2018;118:90-96.
    PubMed     Abstract available


  726. HAINSWORTH JD, Waterhouse DM, Shih KC, Boccia RV, et al
    Phase II trial of preoperative pemetrexed plus carboplatin in patients with stage IB-III nonsquamous non-small cell lung cancer (NSCLC).
    Lung Cancer. 2018;118:6-12.
    PubMed     Abstract available


  727. SONG Z, Cheng G, Xu C, Wang W, et al
    Clinicopathological characteristics of POLE mutation in patients with non-small-cell lung cancer.
    Lung Cancer. 2018;118:57-61.
    PubMed     Abstract available


  728. LEE JW, Choi JS, Lyu J, Lee SM, et al
    Prognostic significance of (18)F-fluorodeoxyglucose uptake of bone marrow measured on positron emission tomography in patients with small cell lung cancer.
    Lung Cancer. 2018;118:41-47.
    PubMed     Abstract available


  729. BAINE MJ, Verma V, Schonewolf CA, Lin C, et al
    Histology significantly affects recurrence and survival following SBRT for early stage non-small cell lung cancer.
    Lung Cancer. 2018;118:20-26.
    PubMed     Abstract available


  730. HELFRICH BA, Gao D, Bunn PA Jr
    Eribulin inhibits the growth of small cell lung cancer cell lines alone and with radiotherapy.
    Lung Cancer. 2018;118:148-154.
    PubMed     Abstract available


  731. HUDSON A, Chan C, Woolf D, McWilliam A, et al
    Is heterogeneity in stage 3 non-small cell lung cancer obscuring the potential benefits of dose-escalated concurrent chemo-radiotherapy in clinical trials?
    Lung Cancer. 2018;118:139-147.
    PubMed     Abstract available


  732. SAKAKURA N, Mizuno T, Kuroda H, Arimura T, et al
    The eighth TNM classification system for lung cancer: A consideration based on the degree of pleural invasion and involved neighboring structures.
    Lung Cancer. 2018;118:134-138.
    PubMed     Abstract available


  733. IMAI S, Kobayashi M, Takasaki C, Ishibashi H, et al
    High expression of P-cadherin is significantly associated with poor prognosis in patients with non-small-cell lung cancer.
    Lung Cancer. 2018;118:13-19.
    PubMed     Abstract available


  734. COUNAGO F, Rodriguez de Dios N, Montemuino S, Jove-Teixido J, et al
    Neoadjuvant treatment followed by surgery versus definitive chemoradiation in stage IIIA-N2 non-small-cell lung cancer: A multi-institutional study by the oncologic group for the study of lung cancer (Spanish Radiation Oncology Society).
    Lung Cancer. 2018;118:119-127.
    PubMed     Abstract available


  735. FILIPSKA M, Skrzypski M, Czetyrbok K, Stokowy T, et al
    MiR-192 and miR-662 enhance chemoresistance and invasiveness of squamous cell lung carcinoma.
    Lung Cancer. 2018;118:111-118.
    PubMed     Abstract available


  736. LIU Y, Li Y, Ou Q, Wu X, et al
    Acquired EGFR L718V mutation mediates resistance to osimertinib in non-small cell lung cancer but retains sensitivity to afatinib.
    Lung Cancer. 2018;118:1-5.
    PubMed     Abstract available


    March 2018
  737. HSIEH FS, Hung MH, Wang CY, Chen YL, et al
    Corrigendum to "Inhibition of protein phosphatase 5 suppresses non-small cell lung cancer through AMP-activated kinase activation" [Lung Cancer 112, (October) (2017) 81-89].
    Lung Cancer. 2018 Mar 19. pii: S0169-5002(18)30301.
    PubMed    


  738. LI J, Wang Z, Groen HJM, Zhao J, et al
    Uncommon EGFR G724S mutations arise in non-small-cell lung cancer patients with acquired resistance to first-generation EGFR-TKIs.
    Lung Cancer. 2018 Mar 1. pii: S0169-5002(18)30273.
    PubMed    


  739. GERBER DE, Socinski MA, Neal JW, Wakelee HA, et al
    Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer.
    Lung Cancer. 2018;117:44-49.
    PubMed     Abstract available


  740. SPIGEL DR, Hainsworth JD, Shipley DL, Mekhail TM, et al
    Amrubicin and carboplatin with pegfilgrastim in patients with extensive stage small cell lung cancer: A phase II trial of the Sarah Cannon Oncology Research Consortium.
    Lung Cancer. 2018;117:38-43.
    PubMed     Abstract available


  741. SCULIER JP, Lafitte JJ, Berghmans T, Meert AP, et al
    A phase III randomised study comparing concomitant radiochemotherapy with cisplatin and docetaxel as induction versus consolidation treatment in patients with locally advanced unresectable non-small cell lung cancer.
    Lung Cancer. 2018;117:32-37.
    PubMed     Abstract available


  742. ZHANG B, Xu J, Zhang X, Gu P, et al
    Coexistence of sensitive and resistant epidermal growth factor receptor (EGFR) mutations in pretreatment non-small cell lung cancer (NSCLC) patients: First or third generation tyrosine kinase inhibitors (TKIs)?
    Lung Cancer. 2018;117:27-31.
    PubMed     Abstract available


  743. YANG W, Qian F, Teng J, Wang H, et al
    Community-based lung cancer screening with low-dose CT in China: Results of the baseline screening.
    Lung Cancer. 2018;117:20-26.
    PubMed     Abstract available


  744. OKAMOTO I, Morita S, Tashiro N, Imamura F, et al
    Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort.
    Lung Cancer. 2018;117:14-19.
    PubMed     Abstract available


  745. ARIYASU R, Nishikawa S, Uchibori K, Oh-Hara T, et al
    High ratio of T790M to EGFR activating mutations correlate with the osimertinib response in non-small-cell lung cancer.
    Lung Cancer. 2018;117:1-6.
    PubMed     Abstract available


  746. PARK BJ, Cho JH, Lee JH, Shin S, et al
    Temporal and regional distribution of initial recurrence site in completely resected N1-stage II lung adenocarcinoma: The effect of postoperative adjuvant chemotherapy.
    Lung Cancer. 2018;117:7-13.
    PubMed     Abstract available


    February 2018
  747. ODA K, Kato K, Nakamura M, Jotatsu T, et al
    Surface marker profiles on lung lymphocytes may predict the mechanism of immune-mediated pneumonitis triggered by tumor-infiltrating lymphocytes in lung cancer patients treated with pembrolizumab.
    Lung Cancer. 2018 Feb 21. pii: S0169-5002(18)30269.
    PubMed    


  748. BARUA S, Fang P, Sharma A, Fujimoto J, et al
    Spatial interaction of tumor cells and regulatory T cells correlates with survival in non-small cell lung cancer.
    Lung Cancer. 2018 Feb 3. pii: S0169-5002(18)30236.
    PubMed     Abstract available


  749. VANDERLAAN PA, Rangachari D, Majid A, Parikh MS, et al
    Tumor biomarker testing in non-small-cell lung cancer: A decade of change.
    Lung Cancer. 2018;116:90-95.
    PubMed     Abstract available


  750. CHENG CC, Chou KF, Wu CW, Su NW, et al
    EGFR-mediated interleukin enhancer-binding factor 3 contributes to formation and survival of cancer stem-like tumorspheres as a therapeutic target against EGFR-positive non-small cell lung cancer.
    Lung Cancer. 2018;116:80-89.
    PubMed     Abstract available


  751. ARAN V, Masson Domingues P, Carvalho de Macedo F, Moreira de Sousa CA, et al
    A cross-sectional study examining the expression of splice variants K-RAS4A and K-RAS4B in advanced non-small-cell lung cancer patients.
    Lung Cancer. 2018;116:7-14.
    PubMed     Abstract available


  752. GAUVAIN C, Vauleon E, Chouaid C, Lerhun E, et al
    Intracerebral efficacy and tolerance of nivolumab in non-small-cell lung cancer patients with brain metastases.
    Lung Cancer. 2018;116:62-66.
    PubMed     Abstract available


  753. DRIESSEN EJM, Schulkes KJG, Dingemans AC, van Loon JGM, et al
    Patterns of treatment and survival among older patients with stage III non-small cell lung cancer.
    Lung Cancer. 2018;116:55-61.
    PubMed     Abstract available


  754. CUI S, Cheng Z, Qin W, Jiang L, et al
    Exosomes as a liquid biopsy for lung cancer.
    Lung Cancer. 2018;116:46-54.
    PubMed     Abstract available


  755. PARK KS, Moon YW, Raffeld M, Lee DH, et al
    High cripto-1 and low miR-205 expression levels as prognostic markers in early stage non-small cell lung cancer.
    Lung Cancer. 2018;116:38-45.
    PubMed     Abstract available


  756. ARNEY J, Helm A, Crook T, Braun UK, et al
    Utilization of genomic testing in advanced non-small cell lung cancer among oncologists in the Veterans Health Administration.
    Lung Cancer. 2018;116:25-29.
    PubMed     Abstract available


  757. MCLEER-FLORIN A, Duruisseaux M, Pinsolle J, Dubourd S, et al
    ALK fusion variants detection by targeted RNA-next generation sequencing and clinical responses to crizotinib in ALK-positive non-small cell lung cancer.
    Lung Cancer. 2018;116:15-24.
    PubMed     Abstract available


  758. REMON J, Pardo N, Martinez-Marti A, Cedres S, et al
    Corrigendum to "Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: Current status and future approaches" [Lung Cancer 106 (2017) 70-75].
    Lung Cancer. 2018 Feb 1. pii: S0169-5002(17)30564.
    PubMed    


  759. PAAJANEN J, Laaksonen S, Ilonen I, Wolff H, et al
    Computed tomography in the evaluation of malignant pleural mesothelioma-Association of tumor size to a sarcomatoid histology, a more advanced TNM stage and poor survival.
    Lung Cancer. 2018;116:73-79.
    PubMed     Abstract available


  760. QIN BD, Jiao XD, Zang YS
    Primary pulmonary leiomyosarcoma: A population-based study.
    Lung Cancer. 2018;116:67-72.
    PubMed     Abstract available


  761. ZHOU F, Hou L, Ding T, Song Q, et al
    Distinct clinicopathologic features, genomic characteristics and survival of central and peripheral pulmonary large cell neuroendocrine carcinoma: From different origin cells?
    Lung Cancer. 2018;116:30-37.
    PubMed     Abstract available


  762. TAKADA K, Toyokawa G, Tagawa T, Kohashi K, et al
    PD-L1 expression according to the EGFR status in primary lung adenocarcinoma.
    Lung Cancer. 2018;116:1-6.
    PubMed     Abstract available


  763. CHEN Y, Chen B, Zhu X, Zhong J, et al
    A patient with malignant pleural mesothelioma carrying BRAF V600E mutation responding to vemurafenib.
    Lung Cancer. 2018;116:96-98.
    PubMed    


    January 2018
  764. GOROSPE L, Arrieta P, Ajuria-Illarramendi O, Barbolla-Diaz I, et al
    Pulmonary aspergilloma mimicking synchronous lung cancer on PET/CT in a patient with head and neck cancer.
    Lung Cancer. 2018 Jan 17. pii: S0169-5002(18)30018.
    PubMed    


  765. KHAN SA, Pruitt SL, Xuan L, Makris U, et al
    How does autoimmune disease impact treatment and outcomes among patients with lung cancer? A national SEER-Medicare analysis.
    Lung Cancer. 2018;115:97-102.
    PubMed     Abstract available


  766. LEE J, Kim HK, Park BJ, Cho JH, et al
    Recurrence dynamics after trimodality therapy (Neoadjuvant concurrent chemoradiotherapy and surgery) in patients with stage IIIA (N2) lung cancer.
    Lung Cancer. 2018;115:89-96.
    PubMed     Abstract available


  767. TAN PS, Aguiar P Jr, Haaland B, Lopes G, et al
    Comparative effectiveness of immune-checkpoint inhibitors for previously treated advanced non-small cell lung cancer - A systematic review and network meta-analysis of 3024 participants.
    Lung Cancer. 2018;115:84-88.
    PubMed     Abstract available


  768. YANG CJ, Gu L, Shah SA, Yerokun BA, et al
    Long-term outcomes of surgical resection for stage IV non-small-cell lung cancer: A national analysis.
    Lung Cancer. 2018;115:75-83.
    PubMed     Abstract available


  769. SATO K, Akamatsu H, Murakami E, Sasaki S, et al
    Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab.
    Lung Cancer. 2018;115:71-74.
    PubMed     Abstract available


  770. HUANG HC, Su WJ, Chiang CL, Feng JY, et al
    The predictive value of the interferon-gamma release assay for chemotherapy responses in patients with advanced non-small-cell lung cancer.
    Lung Cancer. 2018;115:64-70.
    PubMed     Abstract available


  771. TOURNOY KG, Thomeer M, Germonpre P, Derijcke S, et al
    Does nivolumab for progressed metastatic lung cancer fulfill its promises? An efficacy and safety analysis in 20 general hospitals.
    Lung Cancer. 2018;115:49-55.
    PubMed     Abstract available


  772. THAWANI R, McLane M, Beig N, Ghose S, et al
    Radiomics and radiogenomics in lung cancer: A review for the clinician.
    Lung Cancer. 2018;115:34-41.
    PubMed     Abstract available


  773. ISAKA M, Kojima H, Takahashi S, Omae K, et al
    Risk factors for local recurrence after lobectomy and lymph node dissection in patients with non-small cell lung cancer: Implications for adjuvant therapy.
    Lung Cancer. 2018;115:28-33.
    PubMed     Abstract available


  774. EVISON M, Edwards T, Balata H, Tempowski A, et al
    Prevalence of nodal metastases in lymph node stations 8 & 9 in a large UK lung cancer surgical centre without routine pre-operative EUS nodal staging.
    Lung Cancer. 2018;115:127-130.
    PubMed     Abstract available


  775. SOO RA, Lim SM, Syn NL, Teng R, et al
    Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions.
    Lung Cancer. 2018;115:12-20.
    PubMed     Abstract available


  776. TANAKA K, Isse K, Fujihira T, Takenoyama M, et al
    Prevalence of Delta-like protein 3 expression in patients with small cell lung cancer.
    Lung Cancer. 2018;115:116-120.
    PubMed     Abstract available


  777. LIU X, Jiang T, Li W, Li X, et al
    Characterization of never-smoking and its association with clinical outcomes in Chinese patients with small-cell lung cancer.
    Lung Cancer. 2018;115:109-115.
    PubMed     Abstract available


  778. NINOMIYA T, Nogami N, Kozuki T, Harada D, et al
    A phase I trial of afatinib and bevacizumab in chemo-naive patients with advanced non-small-cell lung cancer harboring EGFR mutations: Okayama Lung Cancer Study Group Trial 1404.
    Lung Cancer. 2018;115:103-108.
    PubMed     Abstract available


  779. NAKAMURA H, Ichikawa T, Nakasone S, Miyoshi T, et al
    Abundant tumor promoting stromal cells in lung adenocarcinoma with hypoxic regions.
    Lung Cancer. 2018;115:56-63.
    PubMed     Abstract available


  780. JIANG J, Wu X, Tong X, Wei W, et al
    GCC2-ALK as a targetable fusion in lung adenocarcinoma and its enduring clinical responses to ALK inhibitors.
    Lung Cancer. 2018;115:5-11.
    PubMed     Abstract available


  781. MIURA Y, Kaira K, Sakurai R, Sunaga N, et al
    High expression of topoisomerase-II predicts favorable clinical outcomes in patients with relapsed small cell lung cancers receiving amrubicin.
    Lung Cancer. 2018;115:42-48.
    PubMed     Abstract available


  782. MINARI R, Bordi P, Del Re M, Facchinetti F, et al
    Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy.
    Lung Cancer. 2018;115:21-27.
    PubMed     Abstract available


  783. GALLI G, Corrao G, Imbimbo M, Proto C, et al
    Uncommon mutations in epidermal growth factor receptor and response to first and second generation tyrosine kinase inhibitors: A case series and literature review.
    Lung Cancer. 2018;115:135-142.
    PubMed     Abstract available


  784. ZHU YC, Wang WX, Xu CW, Song ZB, et al
    EGFR-RAD51 fusion variant in lung adenocarcinoma and response to erlotinib: A case report.
    Lung Cancer. 2018;115:131-134.
    PubMed     Abstract available


  785. ZHANG L, Belani CP, Zhang PH, Wang X, et al
    Dynamic change of fatigue of pemetrexed maintenance treatment in the JMEN trial.
    Lung Cancer. 2018;115:121-126.
    PubMed     Abstract available


  786. HORNE ZD, Richman AH, Dohopolski MJ, Clump DA, et al
    Stereotactic body radiation therapy for isolated hilar and mediastinal non-small cell lung cancers.
    Lung Cancer. 2018;115:1-4.
    PubMed     Abstract available


    December 2017
  787. LIU E, Guha A, Jia K, Ayers AM, et al
    Corrigendum to "Cardiogenic shock in a patient being treated with Atezolizumab for metastatic non-small cell lung cancer" [Lung Cancer, 114, (December) (2017) 106-107].
    Lung Cancer. 2017 Dec 29. pii: S0169-5002(17)30621.
    PubMed    


  788. VYFHUIS MAL, Bhooshan N, Molitoris J, Bentzen SM, et al
    Corrigendum to "Clinical outcomes of black vs. non-black patients with locally advanced non-small cell lung cancer" [Lung Cancer 114, (December 2017) 44-49].
    Lung Cancer. 2017 Dec 27. pii: S0169-5002(17)30618.
    PubMed    


  789. GROSSI F, Genova C, Rijavec E, Barletta G, et al
    Prognostic role of the VeriStrat test in first line patients with non-small cell lung cancer treated with platinum-based chemotherapy.
    Lung Cancer. 2017 Dec 13. pii: S0169-5002(17)30614.
    PubMed     Abstract available


  790. TU HY, Ke EE, Yang JJ, Sun YL, et al
    A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer.
    Lung Cancer. 2017;114:96-102.
    PubMed     Abstract available


  791. TIAN HX, Zhang XC, Yang JJ, Guo WB, et al
    Clinical characteristics and sequence complexity of anaplastic lymphoma kinase gene fusions in Chinese lung cancer patients.
    Lung Cancer. 2017;114:90-95.
    PubMed     Abstract available


  792. SHEN J, Ye Y, Chang DW, Huang M, et al
    Circulating metabolite profiles to predict overall survival in advanced non-small cell lung cancer patients receiving first-line chemotherapy.
    Lung Cancer. 2017;114:70-78.
    PubMed     Abstract available


  793. CHALMERS A, Jensen L, Akerley W
    Durable response to osimertinib in EGFR mutated T790M wildtype non-small cell lung cancer with leptomeningeal metastases: A case report.
    Lung Cancer. 2017;114:68-69.
    PubMed     Abstract available


  794. ZHU Y, Li T, Chen G, Yan G, et al
    Identification of a serum microRNA expression signature for detection of lung cancer, involving miR-23b, miR-221, miR-148b and miR-423-3p.
    Lung Cancer. 2017;114:6-11.
    PubMed     Abstract available


  795. KEUSTERS WR, de Weger VA, Hovels A, Schellens JHM, et al
    Changing costs of metastatic non small cell lung cancer in the Netherlands.
    Lung Cancer. 2017;114:56-61.
    PubMed     Abstract available


  796. VYFHUIS MAL, Bhooshan N, Molitoris J, Bentzen SM, et al
    Clinical outcomes of black vs. non-black patients with locally advanced non-small cell lung cancer.
    Lung Cancer. 2017;114:44-49.
    PubMed     Abstract available


  797. WANG X, Leader JK, Wang R, Wilson D, et al
    Vasculature surrounding a nodule: A novel lung cancer biomarker.
    Lung Cancer. 2017;114:38-43.
    PubMed     Abstract available


  798. ZANON M, Pacini GS, de Souza VVS, Marchiori E, et al
    Early detection of lung cancer using ultra-low-dose computed tomography in coronary CT angiography scans among patients with suspected coronary heart disease.
    Lung Cancer. 2017;114:1-5.
    PubMed     Abstract available


  799. HAN L, Lee CK, Pang H, Chan HT, et al
    Genetic predisposition to lung adenocarcinoma among never-smoking Chinese with different epidermal growth factor receptor mutation status.
    Lung Cancer. 2017;114:79-89.
    PubMed     Abstract available


  800. YAMAUCHI Y, Safi S, Muley T, Warth A, et al
    C-reactive protein-albumin ratio is an independent prognostic predictor of tumor recurrence in stage IIIA-N2 lung adenocarcinoma patients.
    Lung Cancer. 2017;114:62-67.
    PubMed     Abstract available


  801. KUIJVENHOVEN JC, Crombag L, Breen DP, van den Berk I, et al
    Esophageal ultrasound (EUS) assessment of T4 status in NSCLC patients.
    Lung Cancer. 2017;114:50-55.
    PubMed     Abstract available


  802. WANG L, Guo Q, Yu W, Qiao L, et al
    Quantification of plasma EGFR mutations in patients with lung cancers: Comparison of the performance of ARMS-Plus and droplet digital PCR.
    Lung Cancer. 2017;114:31-37.
    PubMed     Abstract available


  803. MATSUMURA Y, Suzuki H, Ohira T, Shiono S, et al
    Matched-pair analysis of a multi-institutional cohort reveals that epidermal growth factor receptor mutation is not a risk factor for postoperative recurrence of lung adenocarcinoma.
    Lung Cancer. 2017;114:23-30.
    PubMed     Abstract available


  804. FOY V, Schenk MW, Baker K, Gomes F, et al
    Targeting DNA damage in SCLC.
    Lung Cancer. 2017;114:12-22.
    PubMed     Abstract available


    November 2017
  805. DUDNIK E, Moskovitz M, Daher S, Shamai S, et al
    Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: The real-life data.
    Lung Cancer. 2017 Nov 23. pii: S0169-5002(17)30582.
    PubMed     Abstract available


  806. SCHOUTEN RD, Muller M, de Gooijer CJ, Baas P, et al
    Real life experience with nivolumab for the treatment of non-small cell lung carcinoma: Data from the expanded access program and routine clinical care in a tertiary cancer centre-The Netherlands Cancer Institute.
    Lung Cancer. 2017 Nov 17. pii: S0169-5002(17)30569.
    PubMed    


  807. GOROSPE L, Garcia-Latorre R, Ajuria-Illarramendi O, Arrieta P, et al
    Lipoid pneumonia mimicking multifocal lung cancer in a patient with a remote laryngectomy and a recently diagnosed lung cancer: PET/CT findings.
    Lung Cancer. 2017 Nov 7. pii: S0169-5002(17)30560.
    PubMed    


  808. GOROSPE L, Sanchez-Monforte JC, Cabanas-Montero J, Arrieta P, et al
    Incidental retroperitoneal malignant solitary fibrous tumor detected at lung cancer screening with low-dose thoracic CT.
    Lung Cancer. 2017 Nov 6. pii: S0169-5002(17)30561.
    PubMed    


  809. AHMED Z, Grover P, Kennedy KF, Masood A, et al
    Predictors for chemotherapy in early stage small cell lung carcinoma (SCLC): A National Cancer Database (NCDB) analysis.
    Lung Cancer. 2017;113:85-87.
    PubMed    


  810. SPIGEL DR, Rubin MS, Gian VG, Shipley DL, et al
    Sorafenib and continued erlotinib or sorafenib alone in patients with advanced non-small cell lung cancer progressing on erlotinib: A randomized phase II study of the Sarah Cannon Research Institute (SCRI).
    Lung Cancer. 2017;113:79-84.
    PubMed     Abstract available


  811. KAWANO Y, Iwama E, Tsuchihashi K, Shibahara D, et al
    CD44 variant-dependent regulation of redox balance in EGFR mutation-positive non-small cell lung cancer: A target for treatment.
    Lung Cancer. 2017;113:72-78.
    PubMed     Abstract available


  812. KATO T, Jin CS, Ujiie H, Lee D, et al
    Nanoparticle targeted folate receptor 1-enhanced photodynamic therapy for lung cancer.
    Lung Cancer. 2017;113:59-68.
    PubMed     Abstract available


  813. HORN L, Gettinger S, Camidge DR, Smit EF, et al
    Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib.
    Lung Cancer. 2017;113:51-58.
    PubMed     Abstract available


  814. HEUVELMANS MA, Walter JE, Peters RB, Bock GH, et al
    Relationship between nodule count and lung cancer probability in baseline CT lung cancer screening: The NELSON study.
    Lung Cancer. 2017;113:45-50.
    PubMed     Abstract available


  815. HOCHMAIR MJ, Schwab S, Burghuber OC, Krenbek D, et al
    Symptomatic pseudo-progression followed by significant treatment response in two lung cancer patients treated with immunotherapy.
    Lung Cancer. 2017;113:4-6.
    PubMed     Abstract available


  816. CORRALES-RODRIGUEZ L, Arrieta O, Mas L, Baez-Saldana R, et al
    An international epidemiological analysis of young patients with non-small cell lung cancer (AduJov-CLICaP).
    Lung Cancer. 2017;113:30-36.
    PubMed     Abstract available


  817. LIU C, Cui H, Gu D, Zhang M, et al
    Genetic polymorphisms and lung cancer risk: Evidence from meta-analyses and genome-wide association studies.
    Lung Cancer. 2017;113:18-29.
    PubMed     Abstract available


  818. BOUAZZA YB, Chiairi I, El Kharbouchi O, De Backer L, et al
    Patient-reported outcome measures (PROMs) in the management of lung cancer: A systematic review.
    Lung Cancer. 2017;113:140-151.
    PubMed     Abstract available


  819. SANTONI-RUGIU E, Grauslund M, Melchior LC, Costa JC, et al
    Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3-mutation, localized transformation to EGFR-mutated SCLC, and acquired T790M EGFR-mutation.
    Lung Cancer. 2017;113:14-17.
    PubMed     Abstract available


  820. ICHIKAWA T, Saruwatari K, Mimaki S, Sugano M, et al
    Immunohistochemical and genetic characteristics of lung cancer mimicking organizing pneumonia.
    Lung Cancer. 2017;113:134-139.
    PubMed     Abstract available


  821. SCHMIDT LH, Stucke-Ring J, Brand C, Schliemann C, et al
    CD13 as target for tissue factor induced tumor vascular infarction in small cell lung cancer.
    Lung Cancer. 2017;113:121-127.
    PubMed     Abstract available


  822. TALBOT T, Dangoor A, Shah R, Naik J, et al
    The burden of neutropenic sepsis in patients with advanced non-small cell lung cancer treated with single-agent docetaxel: A retrospective study.
    Lung Cancer. 2017;113:115-120.
    PubMed     Abstract available


  823. LEE CK, Kim S, Lee JS, Lee JE, et al
    Next-generation sequencing reveals novel resistance mechanisms and molecular heterogeneity in EGFR-mutant non-small cell lung cancer with acquired resistance to EGFR-TKIs.
    Lung Cancer. 2017;113:106-114.
    PubMed     Abstract available


  824. HASSAN A, Latif MT, Soo CI, Faisal AH, et al
    Short communication: Diagnosis of lung cancer increases during the annual southeast Asian haze periods.
    Lung Cancer. 2017;113:1-3.
    PubMed     Abstract available


    October 2017
  825. SAWA K, Koh Y, Kawaguchi T, Kambayashi S, et al
    PIK3CA mutation as a distinctive genetic feature of non-small cell lung cancer with chronic obstructive pulmonary disease: A comprehensive mutational analysis from a multi-institutional cohort.
    Lung Cancer. 2017;112:96-101.
    PubMed     Abstract available


  826. SCHVARTSMAN G, Peng SA, Bis G, Lee JJ, et al
    Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer.
    Lung Cancer. 2017;112:90-95.
    PubMed     Abstract available


  827. HSIEH FS, Hung MH, Wang CY, Chen YL, et al
    Inhibition of protein phosphatase 5 suppresses non-small cell lung cancer through AMP-activated kinase activation.
    Lung Cancer. 2017;112:81-89.
    PubMed     Abstract available


  828. HE Y, Rozeboom L, Rivard CJ, Ellison K, et al
    MHC class II expression in lung cancer.
    Lung Cancer. 2017;112:75-80.
    PubMed     Abstract available


  829. ROS-MAZURCZYK M, Jelonek K, Marczyk M, Binczyk F, et al
    Serum lipid profile discriminates patients with early lung cancer from healthy controls.
    Lung Cancer. 2017;112:69-74.
    PubMed     Abstract available


  830. FACCHINETTI F, Bluthgen MV, Tergemina-Clain G, Faivre L, et al
    LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value.
    Lung Cancer. 2017;112:62-68.
    PubMed     Abstract available


  831. TOMIZAWA K, Shimizu S, Ohara S, Fujino T, et al
    Clinical significance of tumor cavitation in surgically resected early-stage primary lung cancer.
    Lung Cancer. 2017;112:57-61.
    PubMed     Abstract available


  832. LEFRESNE S, Olson R, Cashman R, Kostuik P, et al
    Prospective analysis of patient reported symptoms and quality of life in patients with incurable lung cancer treated in a rapid access clinic.
    Lung Cancer. 2017;112:35-40.
    PubMed     Abstract available


  833. NISHIE K, Yamamoto S, Nagata C, Koizumi T, et al
    Anamorelin for advanced non-small-cell lung cancer with cachexia: Systematic review and meta-analysis.
    Lung Cancer. 2017;112:25-34.
    PubMed     Abstract available


  834. KUYAMA S, Ochi N, Bessho A, Hotta K, et al
    A phase II trial of carboplatin plus S-1 for elderly patients with advanced non-small-cell lung cancer with wild-type epidermal growth factor receptor: The Okayama Lung Cancer Study Group Trial 1202.
    Lung Cancer. 2017;112:188-194.
    PubMed     Abstract available


  835. RECK M, Paz-Ares L, Bidoli P, Cappuzzo F, et al
    Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer.
    Lung Cancer. 2017;112:181-187.
    PubMed     Abstract available


  836. QIN N, Wang C, Zhu M, Lu Q, et al
    Fine-mapping the MHC region in Asian populations identified novel variants modifying susceptibility to lung cancer.
    Lung Cancer. 2017;112:169-175.
    PubMed     Abstract available


  837. LARA JD, Brunson A, Riess JW, Kelly K, et al
    Clinical predictors of survival in young patients with small cell lung cancer: Results from the California Cancer Registry.
    Lung Cancer. 2017;112:165-168.
    PubMed     Abstract available


  838. VINOD SK, Chandra A, Berthelsen A, Descallar J, et al
    Does timeliness of care in Non-Small Cell Lung Cancer impact on survival?
    Lung Cancer. 2017;112:16-24.
    PubMed     Abstract available


  839. JACOBSEN MM, Silverstein SC, Quinn M, Waterston LB, et al
    Timeliness of access to lung cancer diagnosis and treatment: A scoping literature review.
    Lung Cancer. 2017;112:156-164.
    PubMed     Abstract available


  840. EL ZOGHBI M, Salameh P, Stucker I, Paris C, et al
    Phenotypes of lung cancer and statistical interactions between tobacco smoking and occupational exposure to asbestos and crystalline silica from a large case-only study: The CaProMat study.
    Lung Cancer. 2017;112:140-155.
    PubMed     Abstract available


  841. KWINT M, Walraven I, Burgers S, Hartemink K, et al
    Outcome of radical local treatment of non-small cell lung cancer patients with synchronous oligometastases.
    Lung Cancer. 2017;112:134-139.
    PubMed     Abstract available


  842. PAZ-ARES LG, Perol M, Ciuleanu TE, Kowalyszyn RD, et al
    Treatment outcomes by histology in REVEL: A randomized phase III trial of Ramucirumab plus docetaxel for advanced non-small cell lung cancer.
    Lung Cancer. 2017;112:126-133.
    PubMed     Abstract available


  843. AGGARWAL C, Wang X, Ranganathan A, Torigian D, et al
    Circulating tumor cells as a predictive biomarker in patients with small cell lung cancer undergoing chemotherapy.
    Lung Cancer. 2017;112:118-125.
    PubMed     Abstract available


  844. SNOECKX A, Dendooven A, Carp L, Desbuquoit D, et al
    Wolf in Sheep's Clothing: Primary Lung Cancer Mimicking Benign Entities.
    Lung Cancer. 2017;112:109-117.
    PubMed     Abstract available


  845. MEZQUITA L, Charrier M, Faivre L, Dupraz L, et al
    Prognostic value of HLA-A2 status in advanced non-small cell lung cancer patients.
    Lung Cancer. 2017;112:10-15.
    PubMed     Abstract available


    September 2017
  846. ROUSSEAU-GAZANIOL C, Fraboulet S, Couderc LJ, Kreis H, et al
    Lung cancer in renal transplant recipients: A case-control study.
    Lung Cancer. 2017;111:96-100.
    PubMed     Abstract available


  847. MIURA K, Hamanaka K, Koizumi T, Kitaguchi Y, et al
    Clinical significance of preoperative serum albumin level for prognosis in surgically resected patients with non-small cell lung cancer: Comparative study of normal lung, emphysema, and pulmonary fibrosis.
    Lung Cancer. 2017;111:88-95.
    PubMed     Abstract available


  848. LIM SM, Chang H, Cha YJ, Liang S, et al
    Validation of ALK/ROS1 Dual Break Apart FISH Probe probe in non-small-cell lung cancer.
    Lung Cancer. 2017;111:79-83.
    PubMed     Abstract available


  849. MOON SM, Lee DG, Hwang NY, Ahn S, et al
    Ipsilateral pleural recurrence after diagnostic transthoracic needle biopsy in pathological stage I lung cancer patients who underwent curative resection.
    Lung Cancer. 2017;111:69-74.
    PubMed     Abstract available


  850. TOKACA N, Wotherspoon A, Nicholson AG, Fotiadis N, et al
    Lack of response to nivolumab in a patient with EGFR-mutant non-small cell lung cancer adenocarcinoma sub-type transformed to small cell lung cancer.
    Lung Cancer. 2017;111:65-68.
    PubMed     Abstract available


  851. CAPELAN M, Roda D, Geuna E, Rihawi K, et al
    Phase I clinical trials in patients with advanced non-small cell lung cancer treated within a Drug Development Unit: What have we learnt?
    Lung Cancer. 2017;111:6-11.
    PubMed     Abstract available


  852. CALIFANO R, Greystoke A, Lal R, Thompson J, et al
    Management of ceritinib therapy and adverse events in patients with ALK-rearranged non-small cell lung cancer.
    Lung Cancer. 2017;111:51-58.
    PubMed     Abstract available


  853. SHEN L, Niu X, Jian H, Xu Y, et al
    Assessment of interfering factors and clinical risk associated with discontinuation of pemetrexed maintenance therapy in advanced non-squamous non-small cell lung cancer.
    Lung Cancer. 2017;111:43-50.
    PubMed     Abstract available


  854. MORIKAWA N, Inoue A, Sugawara S, Maemondo M, et al
    Randomized phase II study of carboplatin plus irinotecan versus carboplatin plus amrubicin in patients with chemo-naive extensive-stage small-cell lung cancer: North Japan Lung Cancer Study Group (NJLCG) 0901.
    Lung Cancer. 2017;111:38-42.
    PubMed     Abstract available


  855. GOBBINI E, Galetta D, Tiseo M, Graziano P, et al
    Molecular profiling in Italian patients with advanced non-small-cell lung cancer: An observational prospective study.
    Lung Cancer. 2017;111:30-37.
    PubMed     Abstract available


  856. LABBE C, Cabanero M, Korpanty GJ, Tomasini P, et al
    Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC).
    Lung Cancer. 2017;111:23-29.
    PubMed     Abstract available


  857. HATA A, Katakami N, Nanjo S, Okuda C, et al
    Programmed death-ligand 1 expression and T790M status in EGFR-mutant non-small cell lung cancer.
    Lung Cancer. 2017;111:182-189.
    PubMed     Abstract available


  858. DIEM S, Schmid S, Krapf M, Flatz L, et al
    Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
    Lung Cancer. 2017;111:176-181.
    PubMed     Abstract available


  859. SCULIER C, Bentea G, Ruelle L, Grigoriu B, et al
    Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature: Part 5: Neurological auto-antibodies, discussion, flow chart, conclusions.
    Lung Cancer. 2017;111:164-175.
    PubMed     Abstract available


  860. RUELLE L, Bentea G, Sideris S, El Koulali M, et al
    Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature Part 4: Neurological paraneoplastic syndromes, involving the peripheral nervous system and the neuromuscular junction and muscles.
    Lung Cancer. 2017;111:150-163.
    PubMed     Abstract available


  861. WOHLKOENIG C, Leithner K, Olschewski A, Olschewski H, et al
    TR3 is involved in hypoxia-induced apoptosis resistance in lung cancer cells downstream of HIF-1alpha.
    Lung Cancer. 2017;111:15-22.
    PubMed     Abstract available


  862. YOUSAF-KHAN AU, van der Aalst CM, Aerts JGJV, den Bakker MA, et al
    Uniform and blinded cause of death verification of the NELSON lung cancer screening participants.
    Lung Cancer. 2017;111:131-134.
    PubMed     Abstract available


  863. GAGLIASSO M, Migliaretti G, Ardissone F
    Assessing the prognostic impact of the International Association for the Study of Lung Cancer proposed definitions of complete, uncertain, and incomplete resection in non-small cell lung cancer surgery.
    Lung Cancer. 2017;111:124-130.
    PubMed     Abstract available


  864. TAGHIZADEH N, Taylor KL, MacEachern P, Koetzler R, et al
    Tobacco use and motivation to stop smoking among long-term smokers who are ineligible for lung cancer screening.
    Lung Cancer. 2017;111:101-107.
    PubMed     Abstract available


  865. FUJIMOTO D, Morimoto T, Ito J, Sato Y, et al
    A pilot trial of nivolumab treatment for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia.
    Lung Cancer. 2017;111:1-5.
    PubMed     Abstract available


    August 2017
  866. VON VERSCHUER U, Schnell R, Tessen HW, Eggert J, et al
    Treatment, outcome and quality of life of 1239 patients with advanced non-small cell lung cancer - final results from the prospective German TLK cohort study.
    Lung Cancer. 2017 Aug 22. pii: S0169-5002(17)30419.
    PubMed     Abstract available


  867. CHENG YW, Chiou HL, Chen JT, Chou MC, et al
    Corrigendum to: 'Gender difference in human papillomarvirus infection for non-small cell lung cancer in Taiwan' [Lung Cancer 46 (November(2)) (2004) 165-170].
    Lung Cancer. 2017 Aug 18. pii: S0169-5002(17)30486.
    PubMed    


  868. LIAO BC, Lin CC, Lee JH, Yang JC, et al
    Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy.
    Lung Cancer. 2017;110:7-13.
    PubMed     Abstract available


  869. KIM EY, Kim A, Kim SK, Chang YS, et al
    MYC expression correlates with PD-L1 expression in non-small cell lung cancer.
    Lung Cancer. 2017;110:63-67.
    PubMed     Abstract available


  870. KIM SH, Hyun JW, Kim HJ, Gwak HS, et al
    De novo cystic brain lesions mimicking neurocysticercosis in ALK-positive lung cancer.
    Lung Cancer. 2017;110:53-55.
    PubMed     Abstract available


  871. TAO MH, Dai Q, Chen S, Freudenheim JL, et al
    Calcium plus vitamin D supplementation and lung cancer incidence among postmenopausal women in the Women's Health Initiative.
    Lung Cancer. 2017;110:42-47.
    PubMed     Abstract available


  872. KOBAYASHI-WATANABE N, Sato A, Watanabe T, Abe T, et al
    Functional analysis of Discoidin domain receptor 2 mutation and expression in squamous cell lung cancer.
    Lung Cancer. 2017;110:35-41.
    PubMed     Abstract available


  873. SANDS J, Li Q, Hornberger J
    Urine circulating-tumor DNA (ctDNA) detection of acquired EGFR T790M mutation in non-small-cell lung cancer: An outcomes and total cost-of-care analysis.
    Lung Cancer. 2017;110:19-25.
    PubMed     Abstract available


  874. DICKHOFF C, Dahele M, Smit EF, Paul MA, et al
    Patterns of care and outcomes for stage IIIB non-small cell lung cancer in the TNM-7 era: Results from the Netherlands Cancer Registry.
    Lung Cancer. 2017;110:14-18.
    PubMed     Abstract available


    July 2017
  875. LIU E, Guha A, Bertino E, Franco V, et al
    Cardiogenic shock in a patient being treated with atezolizumab for metastatic non-small cell lung cancer.
    Lung Cancer. 2017 Jul 29. pii: S0169-5002(17)30416.
    PubMed    


  876. SCHONEWOLF CA, Verma V, Post CM, Berman AT, et al
    Outcomes of invasive mediastinal nodal staging versus positron emission tomography staging alone for early-stage non-small cell lung cancer treated with stereotactic body radiation therapy.
    Lung Cancer. 2017 Jul 14. pii: S0169-5002(17)30384.
    PubMed     Abstract available


  877. TAMURA T, Takagi Y, Okubo H, Yamaguchi S, et al
    Plasma concentration of osimertinib in a non-small cell lung cancer patient with chronic renal failure undergoing hemodialysis.
    Lung Cancer. 2017 Jul 8. pii: S0169-5002(17)30386.
    PubMed    


  878. YOSHIDA T, Kuroda H, Oya Y, Shimizu J, et al
    Clinical outcomes of platinum-based chemotherapy according to T790M mutation status in EGFR-positive non-small cell lung cancer patients after initial EGFR-TKI failure.
    Lung Cancer. 2017;109:89-91.
    PubMed     Abstract available


  879. WAKEAM E, Acuna SA, Leighl NB, Giuliani ME, et al
    Surgery Versus Chemotherapy and Radiotherapy For Early and Locally Advanced Small Cell Lung Cancer: A Propensity-Matched Analysis of Survival.
    Lung Cancer. 2017;109:78-88.
    PubMed     Abstract available


  880. LOPEZ-PASTORINI A, Riedel R, Koryllos A, Beckers F, et al
    The impact of preoperative elevated serum C-reactive protein on postoperative morbidity and mortality after anatomic resection for lung cancer.
    Lung Cancer. 2017;109:68-73.
    PubMed     Abstract available


  881. ERIGUCHI T, Takeda A, Sanuki N, Tsurugai Y, et al
    Stereotactic body radiotherapy for operable early-stage non-small cell lung cancer.
    Lung Cancer. 2017;109:62-67.
    PubMed     Abstract available


  882. FUJISHITA T, Okamoto T, Akamine T, Takamori S, et al
    Association of MTH1 expression with the tumor malignant potential and poor prognosis in patients with resected lung cancer.
    Lung Cancer. 2017;109:52-57.
    PubMed     Abstract available


  883. GAO SJ, Kim AW, Puchalski JT, Bramley K, et al
    Indications for invasive mediastinal staging in patients with early non-small cell lung cancer staged with PET-CT.
    Lung Cancer. 2017;109:36-41.
    PubMed     Abstract available


  884. ZIEMKE M, Patil T, Nolan K, Tippimanchai D, et al
    Reduced Smad4 expression and DNA topoisomerase inhibitor chemosensitivity in non-small cell lung cancer.
    Lung Cancer. 2017;109:28-35.
    PubMed     Abstract available


  885. O'KANE GM, Bradbury PA, Feld R, Leighl NB, et al
    Uncommon EGFR mutations in advanced non-small cell lung cancer.
    Lung Cancer. 2017;109:137-144.
    PubMed     Abstract available


  886. WAKEAM E, Varghese TK Jr, Leighl NB, Giuliani M, et al
    Trends, practice patterns and underuse of surgery in the treatment of early stage small cell lung cancer.
    Lung Cancer. 2017;109:117-123.
    PubMed     Abstract available


  887. SUDA K, Rozeboom L, Rivard CJ, Yu H, et al
    Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells.
    Lung Cancer. 2017;109:1-8.
    PubMed     Abstract available


  888. DURUISSEAUX M, Antoine M, Rabbe N, Rodenas A, et al
    Lepidic predominant adenocarcinoma and invasive mucinous adenocarcinoma of the lung exhibit specific mucin expression in relation with oncogenic drivers.
    Lung Cancer. 2017;109:92-100.
    PubMed     Abstract available


  889. DEARDEN S, Brown H, Jenkins S, Thress KS, et al
    EGFR T790M mutation testing within the osimertinib AURA Phase I study.
    Lung Cancer. 2017;109:9-13.
    PubMed     Abstract available


  890. RASKIN J, Masrori P, Cant A, Snoeckx A, et al
    Recurrent dysphasia due to nivolumab-induced encephalopathy with presence of Hu autoantibody.
    Lung Cancer. 2017;109:74-77.
    PubMed     Abstract available


  891. ITO J, Fujimoto D, Nakamura A, Nagano T, et al
    Aprepitant for refractory nivolumab-induced pruritus.
    Lung Cancer. 2017;109:58-61.
    PubMed     Abstract available


  892. YOTSUKURA M, Yasuda H, Shigenobu T, Kaseda K, et al
    Clinical and pathological characteristics of EGFR mutation in operable early-stage lung adenocarcinoma.
    Lung Cancer. 2017;109:45-51.
    PubMed     Abstract available


  893. UENAMI T, Hosono Y, Ishijima M, Kanazu M, et al
    Vitiligo in a patient with lung adenocarcinoma treated with nivolumab: A case report.
    Lung Cancer. 2017;109:42-44.
    PubMed     Abstract available


  894. ZHANG L, Li S, Choi YL, Lee J, et al
    Systematic identification of cancer-related long noncoding RNAs and aberrant alternative splicing of quintuple-negative lung adenocarcinoma through RNA-Seq.
    Lung Cancer. 2017;109:21-27.
    PubMed     Abstract available


  895. BOLAND JM, Wampfler JA, Yang P, Yi ES, et al
    Growth pattern-based grading of pulmonary adenocarcinoma-Analysis of 534 cases with comparison between observers and survival analysis.
    Lung Cancer. 2017;109:14-20.
    PubMed     Abstract available


  896. HERRERA-MARTINEZ AD, Gahete MD, Sanchez-Sanchez R, Salas RO, et al
    The components of somatostatin and ghrelin systems are altered in neuroendocrine lung carcinoids and associated to clinical-histological features.
    Lung Cancer. 2017;109:128-136.
    PubMed     Abstract available


  897. ZHU YJ, Zhang HB, Liu YH, Zhang FL, et al
    Quantitative cell-free circulating EGFR mutation concentration is correlated with tumor burden in advanced NSCLC patients.
    Lung Cancer. 2017;109:124-127.
    PubMed     Abstract available


  898. ZHANG L, Li J, Hu J, Li D, et al
    Cigarette smoke extract induces EGFR-TKI resistance via promoting EGFR signaling pathway and ROS generation in NSCLC cell lines.
    Lung Cancer. 2017;109:109-116.
    PubMed     Abstract available


  899. GADGEEL S, Goss G, Soria JC, Felip E, et al
    Evaluation of the VeriStrat((R)) serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study.
    Lung Cancer. 2017;109:101-108.
    PubMed     Abstract available


    June 2017
  900. GOROSPE L, Rioja-Martin ME, Santos-Carreno AL, Pacios-Blanco RE, et al
    Supraclavicular schwannoma mimicking a lymphadenopathy in a lung cancer patient: PET/CT findings.
    Lung Cancer. 2017 Jun 8. pii: S0169-5002(17)30354.
    PubMed    


  901. ZHAO J, Guerrero A, Kelnar K, Peltier HJ, et al
    Synergy between next generation EGFR tyrosine kinase inhibitors and miR-34a in the inhibition of non-small cell lung cancer.
    Lung Cancer. 2017;108:96-102.
    PubMed     Abstract available


  902. GREENBERG V, Lazarev I, Frank Y, Dudnik J, et al
    Semi-automatic volumetric measurement of response to chemotherapy in lung cancer patients: How wrong are we using RECIST?
    Lung Cancer. 2017;108:90-95.
    PubMed     Abstract available


  903. IMPERATORI A, Sahnane N, Rotolo N, Franzi F, et al
    LINE-1 hypomethylation is associated to specific clinico-pathological features in Stage I non-small cell lung cancer.
    Lung Cancer. 2017;108:83-89.
    PubMed     Abstract available


  904. HIDAKA N, Iwama E, Kubo N, Harada T, et al
    Most T790M mutations are present on the same EGFR allele as activating mutations in patients with non-small cell lung cancer.
    Lung Cancer. 2017;108:75-82.
    PubMed     Abstract available


  905. GION M, Remon J, Caramella C, Soria JC, et al
    Symptomatic leptomeningeal metastasis improvement with nivolumab in advanced non-small cell lung cancer patient.
    Lung Cancer. 2017;108:72-74.
    PubMed     Abstract available


  906. NIHO S, Ohe Y, Ohmatsu H, Umemura S, et al
    Switch maintenance chemotherapy using S-1 with or without bevacizumab in patients with advanced non-small cell lung cancer: a phase II study.
    Lung Cancer. 2017;108:66-71.
    PubMed     Abstract available


  907. MCEVOY SH, Halpenny DF, Viteri-Jusue A, Hayes SA, et al
    Investigation of patterns of nodal metastases in BRAF mutant lung cancer.
    Lung Cancer. 2017;108:62-65.
    PubMed     Abstract available


  908. YU XQ, Luo Q, Kahn C, Grogan P, et al
    Contrasting temporal trends in lung cancer incidence by socioeconomic status among women in New South Wales, Australia, 1985-2009.
    Lung Cancer. 2017;108:55-61.
    PubMed     Abstract available


  909. CROMBAG LMMJ, Szlubowski A, Stigt JA, Schuurbiers O, et al
    EUS-B-FNA vs conventional EUS-FNA for left adrenal gland analysis in lung cancer patients.
    Lung Cancer. 2017;108:38-44.
    PubMed     Abstract available


  910. SEKINE I, Harada H, Yamamoto N, Wakabayashi M, et al
    Randomized phase II trial of weekly dose-intensive chemotherapy or amrubicin plus cisplatin chemotherapy following induction chemoradiotherapy for limited-disease small cell lung cancer (JCOG1011).
    Lung Cancer. 2017;108:232-237.
    PubMed     Abstract available


  911. KOSHY M, Malik R, Spiotto M, Mahmood U, et al
    Association between intensity modulated radiotherapy and survival in patients with stage III non-small cell lung cancer treated with chemoradiotherapy.
    Lung Cancer. 2017;108:222-227.
    PubMed     Abstract available


  912. RUIZ-BANOBRE J, Perez-Pampin E, Garcia-Gonzalez J, Gomez-Caamano A, et al
    Development of psoriatic arthritis during nivolumab therapy for metastatic non-small cell lung cancer, clinical outcome analysis and review of the literature.
    Lung Cancer. 2017;108:217-221.
    PubMed     Abstract available


  913. WEHLER T, Thomas M, Schumann C, Bosch-Barrera J, et al
    A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non-small cell lung cancer.
    Lung Cancer. 2017;108:212-216.
    PubMed     Abstract available


  914. DRIESSEN EJ, Aarts MJ, Bootsma GP, van Loon JG, et al
    Trends in treatment and relative survival among Non-Small Cell Lung Cancer patients in the Netherlands (1990-2014): Disparities between younger and older patients.
    Lung Cancer. 2017;108:198-204.
    PubMed     Abstract available


  915. YANG SC, Lai WW, Lin CC, Su WC, et al
    Cost-effectiveness of implementing computed tomography screening for lung cancer in Taiwan.
    Lung Cancer. 2017;108:183-191.
    PubMed     Abstract available


  916. HARRIS JP, Patel MI, Loo BW, Wakelee HA, et al
    A population-based comparative effectiveness study of chemoradiation regimens and sequences in stage III non-small cell lung cancer.
    Lung Cancer. 2017;108:173-182.
    PubMed     Abstract available


  917. MORAN T, Palmero R, Provencio M, Insa A, et al
    A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib.
    Lung Cancer. 2017;108:154-160.
    PubMed     Abstract available


  918. MORABITO A, Daniele G, Costanzo R, Favaretto AG, et al
    A multicenter, randomized, phase 3 trial comparing fixed dose versus toxicity-adjusted dose of cisplatin + etoposide in extensive small-cell lung cancer (SCLC) patients: The Small-cell-lung cancer Toxicity Adjusted Dosing (STAD-1) trial.
    Lung Cancer. 2017;108:15-21.
    PubMed     Abstract available


  919. PATEL MI, McKinley M, Cheng I, Haile R, et al
    Lung cancer incidence trends in California by race/ethnicity, histology, sex, and neighborhood socioeconomic status: An analysis spanning 28 years.
    Lung Cancer. 2017;108:140-149.
    PubMed     Abstract available


  920. KRON F, Kostenko A, Scheffler M, Muller D, et al
    Economic burden of clinical trials in lung cancer in a German Comprehensive Cancer Center.
    Lung Cancer. 2017;108:134-139.
    PubMed     Abstract available


  921. KANAJI N, Sakai K, Ueda Y, Miyawaki H, et al
    Peripheral-type small cell lung cancer is associated with better survival and higher frequency of interstitial lung disease.
    Lung Cancer. 2017;108:126-133.
    PubMed     Abstract available


  922. PATEL SH, Rimner A, Foster A, Zhang Z, et al
    Patterns of initial and intracranial failure in metastatic EGFR-mutant non-small cell lung cancer treated with erlotinib.
    Lung Cancer. 2017;108:109-114.
    PubMed     Abstract available


  923. MIKUBO M, Nakashima H, Naito M, Matsui Y, et al
    Prognostic impact of uncertain parietal pleural invasion at adhesion sites in non-small cell lung cancer patients.
    Lung Cancer. 2017;108:103-108.
    PubMed     Abstract available


    April 2017
  924. SIMMONS CP, Koinis F, Fallon MT, Fearon KC, et al
    Corrigendum to "Prognosis in advanced lung cancer - A prospective study examining key clinicopathological factors" [Lung Cancer 88 (2015) 304-309].
    Lung Cancer. 2017 Apr 27. pii: S0169-5002(17)30302.
    PubMed    


  925. TANAKA N, Toyooka S, Soh J, Kubo T, et al
    Erratum to "Frequent methylation and oncogenic role of microRNA-34b/c in small-cell lung cancer" [Lung Cancer 76 (1) (2012) 32-38].
    Lung Cancer. 2017 Apr 27. pii: S0169-5002(16)30299.
    PubMed    


  926. EDWARDS T, Balata H, Foden P, Crosbie P, et al
    Research letter: Evaluating the future pathological N descriptors for lung cancer staging in a UK population.
    Lung Cancer. 2017 Apr 15. pii: S0169-5002(17)30295.
    PubMed    


  927. METRO G, Tazza M, Matocci R, Chiari R, et al
    Optimal management of ALK-positive NSCLC progressing on crizotinib.
    Lung Cancer. 2017;106:58-66.
    PubMed     Abstract available


  928. BASLER L, Kroeze SG, Guckenberger M
    SBRT for oligoprogressive oncogene addicted NSCLC.
    Lung Cancer. 2017;106:50-57.
    PubMed     Abstract available


  929. VANDERLAAN PA, Rangachari D, Mockus SM, Spotlow V, et al
    Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes.
    Lung Cancer. 2017;106:17-21.
    PubMed     Abstract available


  930. KWON D, Koh J, Kim S, Go H, et al
    MET exon 14 skipping mutation in triple-negative pulmonary adenocarcinomas and pleomorphic carcinomas: An analysis of intratumoral MET status heterogeneity and clinicopathological characteristics.
    Lung Cancer. 2017;106:131-137.
    PubMed     Abstract available


  931. HONG SW, Park NS, Noh MH, Shim JA, et al
    Combination treatment with erlotinib and ampelopsin overcomes erlotinib resistance in NSCLC cells via the Nox2-ROS-Bim pathway.
    Lung Cancer. 2017;106:115-124.
    PubMed     Abstract available


    March 2017
  932. LI H, Yang T, Ning Q, Shang D, et al
    MicroRNA-505 modulates cancer proliferation and migration in human non-small cell lung cancer through inverse regulation of FZD4.
    Lung Cancer. 2017 Mar 31. pii: S0169-5002(17)30270.
    PubMed     Abstract available


  933. CAPELLETTO E, Mariniello A, Novello S
    Targeted therapy in small cell lung cancer: A new era?
    Lung Cancer. 2017 Mar 12. pii: S0169-5002(17)30258.
    PubMed    


    February 2017
  934. HIDA T, Hamasaki M, Matsumoto S, Sato A, et al
    Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis: Comparison with 9p21 FISH and BAP1 immunohistochemistry.
    Lung Cancer. 2017;104:98-105.
    PubMed     Abstract available


  935. SAKAGUCHI H, Ishida H, Nitanda H, Yamazaki N, et al
    Pharmacokinetic evaluation of intrapleural perfusion with hyperthermic chemotherapy using cisplatin in patients with malignant pleural effusion.
    Lung Cancer. 2017;104:70-74.
    PubMed     Abstract available


  936. TAKADA K, Okamoto T, Toyokawa G, Kozuma Y, et al
    The expression of PD-L1 protein as a prognostic factor in lung squamous cell carcinoma.
    Lung Cancer. 2017;104:7-15.
    PubMed     Abstract available


  937. LAURIE SA, Hao D, Leighl NB, Goffin J, et al
    A phase II trial of dovitinib in previously-treated advanced pleural mesothelioma: The Ontario Clinical Oncology Group.
    Lung Cancer. 2017;104:65-69.
    PubMed     Abstract available


  938. WU YL, Saijo N, Thongprasert S, Yang JC, et al
    Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC.
    Lung Cancer. 2017;104:119-125.
    PubMed     Abstract available


    January 2017
  939. TO KK, Tong WS, Fu LW
    Reversal of platinum drug resistance by the histone deacetylase inhibitor belinostat.
    Lung Cancer. 2017;103:58-65.
    PubMed     Abstract available


  940. TSIM S, Stobo DB, Alexander L, Kelly C, et al
    The diagnostic performance of routinely acquired and reported computed tomography imaging in patients presenting with suspected pleural malignancy.
    Lung Cancer. 2017;103:38-43.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: